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Abstract 
Advancements in cancer immunotherapy have revealed the importance of targeting 
neoantigens. Neoantigens are tumor specific antigens that prompt a strong antitumor 
response escaping from the central T tolerance. Our laboratory has previously shown that 
infection of murine tumor cell lines with Salmonella elicits the transfer of antigens 
between adjacent cells through hemichannels (Saccheri et al. 2010). Now we demonstrate 
that Salmonella not only leads to the transfer of immunogenic antigens between adjacent 
cells, but also to the release of peptides in the extracellular milieu. A first ATP assay 
showed that infection of murine cell lines with Salmonella induces ATP release, and its 
accumulation is hemichannel dependent, thus proving that Salmonella induces 
hemichannel opening. We also demonstrate that dendritic cells loaded with peptides 
derived from Salmonella-infected murine melanoma B16-OVA cells, induced the 
activation of OT1-CD8a+ cells. Moreover, mass spectrometry (MS) analysis of B16 OVA-
derived peptides revealed the presence of the ovalbumin-derived peptide (SIINFEKL). 
These peptides when tested as components of a vaccine formulation to prevent tumor 
progression in a murine model of melanoma, shown to be immunogenic.  
Furthermore, we also attested that human melanoma cell lines release peptides upon 
Salmonella infection. T2 binding assays performed on two different human melanoma cell 
lines suggested that also in this case, the high peptide release is mediated by hemichannels. 
Specifically, we demonstrated that peptides released by a human melanoma cell line 
induced the expansion of anti-tumor CD8-T cells from healthy-donor peripheral blood 
mononuclear cells. An MS analysis of proteins and peptides released by infected murine 
and human melanoma cells revealed that among them there are novel tumor epitopes. 
Through an innovative MS-approach, that combined the analysis of classical database 
searching engine with the analysis of the features at MS1-level, we gained knowledge of 
peptides that otherwise would not be accessible (neoantigens, spliced tumor antigens, post 
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translational modified peptides). De novo sequencing procedures will allow us to identify 
their sequence in the future. Encouraging preliminary results, that also proved the 
feasibility and safety of the approach have been shown in the treatment of both canine 
osteosarcoma and canine high grade sarcoma. Specifically, the therapeutic vaccine 
treatment of animals using peptides derived from their own Salmonella-infected tumor 
cells appeared to be extremely successful. 
Hence, we propose to treat patients-derived tumor cells with Salmonella in order to obtain 
neoantigens that could be applied in clinical studies as a vaccine formulation. 
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1. INTRODUCTION 
1.1 Cancer immunosurveillance and cancer immunoediting 
The role played by the immune system in body-surveillance against cancer progression 
was first hypothesized in 1943 by Gross and colleagues. They reported that mice 
undergoing a primary tumor resection were protected by a subsequent re-exposure. 
Furthermore, they observed that tumor development was also avoided by a preventive 
exposure of mice to lethally irradiated tumor cells (Gross 1943). Since then, the 
development of mouse tumor models with defined immune-deficiencies and the production 
of highly specific blocking monoclonal antibodies able to target particular immune cells 
led to the description and immune characterization of the so called “cancer 
immunosurveillance” hypothesis. In the late 1980 Boon and colleagues were the first ones 
to describe that the antitumor immune surveillance was due to lymphocytes recognition of 
aberrant derived by tumor-derived peptides, later defined tumor antigens (De Plaen et al. 
1988). The hypothesis of the immune surveillance cannot explain why cancers can evolve 
in the presence of a competent immune system. Increasing knowledge about the 
contribution of the immune system to cancer development has led to describe immune 
system as a dynamic process that can protect the host against tumor development but also 
promote tumor growth by selecting for more aggressive tumors (Dunn et al. 2004a).  
This process referred as “cancer immunoediting” comprises of three phases: elimination, 
equilibrium and escape (Dunn et al. 2004b). During the elimination phase the activation of 
the innate and adaptive immune system leads to an efficacious cancer immune surveillance 
preventing tumor development. In order to elicit an effective antitumor immune response a 
number of stepwise events must be initiated. First, tumor antigens need to be taken up by 
dendritic cells (DCs) at the tumor site and presented to their MHC class I and II. Then, pro-
inflammatory signals have to enable DCs to properly mature and migrate to the lymph 
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nodes to prime and activate T cells. At this point T cell expansion occurs if the DC-
presented antigen has broken both central and peripheral immunological tolerance whose 
aim is to prevent autoimmunity (Träger et al. 2012). The antigen needs to be different from 
all the self-antigens presented at thymus level during T cell development thus avoiding the 
negative selection of antigen-specific-T cell. Moreover, at lymph nodes level, DC-
presented antigens need to be recognized with high affinity by the TCR of antigen-specific 
T cell (Redmond & Sherman 2005). As last step, activated T lymphocytes infiltrate the 
tumor site and kill their target cells upon tumor antigen recognition. However, some tumor 
cells may avoid the elimination phase and keep coexisting with immune cells transitioning 
to a period of latency called equilibrium phase. During this phase, tumor cells with reduced 
immunogenicity are selected and these cells are more capable of surviving in an 
immunocompetent host. The ability of cancer to evade the specifically activated antitumor 
response became eventually recognized as cancer hallmark: “Immune destruction evasion” 
(Hanahan & Weinberg 2011). This property that was only ultimately described as cancer 
hallmark is possibly the most critical aspect of cancer. There are many mechanisms 
through which tumor cells can evade the immune system. Tumor cells can acquire lesions 
in antigen processing and presentation pathway (Seliger et al. 2001) that facilitate evasion 
from adaptive immune recognition; or they can express ligands for inhibitory receptors, 
such as, the programmed cell death protein ligand 1 (PDL1) leading  PD-1-expressing 
tumor-specific lymphocytes to anergy  (Taube et al. 2012). Tumor cells can also promote 
the escape phase by directly acting on the tumor microenvironment through the secretion 
of cytokines and chemokines that inhibit the protective functions of the immune system, 
such as the transforming growth factor β (TGF-β) or the interleukin-10 (IL-10). Recent 
studies have documented that tumors may also facilitate the generation, activation, or 
function of immunosuppressive T cell populations such as interleukin-13 (IL-13)-
producing NKT cells (Terabe et al. 2000) or CD4+CD25+ regulatory T cells (T reg) 
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(Shimizu et al. 1999). The latter play an important role in inhibiting naturally occurring 
and therapeutically induced protective immune responses against tumors (Shimizu et al. 
1999).  
1.2 Tumor antigens 
Nucleated cells have the capacity to present peptides derived from endogenous proteins 
on their MHC class I molecules. This property is needed for the activation of CD8+ 
cytotoxic T lymphocytes (CTLs) that are able to recognize only the antigenic peptides 
associated with MHC class I molecules (Leone et al. 2013). Four different classes of 
tumor antigens have been described until now: tumor associated antigens (TAA), that are 
peptides encoded by the normal genome but aberrantly expressed by tumor cells (i.e. 
overexpressed, (Menard et al. 2000)); cancer testis antigens (CTAs), that are peptides 
belonging to developmental protein (hence not present during adulthood) whose expression 
is re-stored by cancer cells (van der Bruggen et al. 1991); neoantigens, that are mutated 
peptides generated by non-synonymous mutation or other genetic alteration (Heemskerk et 
al. 2012); and the recently identified spliced antigens that arise from post translational 
splicing (Vigneron 2004; Vigneron & Van den Eynde 2014; Liepe et al. 2016). The 
stronger and more efficient immune response is directed against antigens that are highly 
tumor specific. First, T cell responses that are elicited against such antigens in cancer 
patients ought to leave normal tissues completely unharmed. Second, our natural tolerance 
mechanisms should not prevent or repress these responses (Coulie et al. 2014). 
Neoantigens and spliced tumor antigens, having a different sequence from all the self-
peptides, can be considered as the best-choice target for an effective antitumor response. 
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Figure 1-1. Tumor antigens specificity. A High specific tumor antigens arise from single 
non synonymous mutation: an epitope different in sequence from the parental peptide is 
associates to the MHC molecules (neoantigens), or the presentation of a peptide that 
normally do not bind MHC molecule is promoted (germ-line tumor antigens). B Low 
tumor specificity antigens are instead antigens that usually have a tissue-specific 
expression (like melanoma associated antigens, gp100) but also antigens that are 
recognized because overexpressed.  Adapted from Boon et al Nature 2014 
1.2.1 Antigen presentation and immunoediting 
Endogenous proteins are processed in an ubiquitin-proteasome-dependent manner at the 
level of the cytosol; proteasome-derived peptides, either spliced peptides or 
conventional peptides, are translocated into the endoplasmic reticulum by TAP (ATP-
dependent peptide transporter associated with antigen processing) where can be further 
trimmed by ER-amino-terminal peptidases (ERAP) to properly fit into the groove of the 
MHC class I molecule. Peptide binding on class I heavy chain and ß2-microglobulin and 
the stabilization of the trimeric complex occurs by the assistance of four chaperones: 
calreticulin, calnexin, ERp57 and tapasin. Then the complex is transported via the trans-
Golgi apparatus to the cell surface.  
18 
 
 
Figure 1-2. Class I antigens presentation. Endogenous proteins are processed in an 
ubiquitin-proteasome-dependent manner at the level of the cytosol; proteasome-derived 
peptides, either spliced peptides or conventional peptides, are translocated into the 
endoplasmic reticulum by TAP where can be further trimmed by ERAP to properly fit into 
the groove of the MHC class I molecule  Adapted from Mishto M and Liepe J. Trends in 
Immunology 2017 
 
Immunoediting pressure can lead tumor cells to accumulate defects in MHC class I 
proteins expression (Ferrone & Marincola 1995) or other components of the antigen 
processing machinery (APM) (Restifo et al. 1993), leading to a reduced MHC molecules 
expression (Durgeau et al. 2011). By these alterations tumors lower the chance to be 
recognized by immune cells avoiding their activation. Aberrations in MHC class I 
expression can be sometimes reversed targeting gene expression regulators; for example 
treatment with IFN-γ agonist or with histone deacetylase inhibitors enable to re-establish a 
correct MHC class I expression (Khan et al. 2008). In most of the cases APM-defective 
tumors are not responsive to any treatment that targets gene expression. Strategy to 
counteract these tumors have been recently proposed thanks to the discovery that APM-
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defective tumor cells express on the residual MHC class I molecules a unique class of 
CD8+ T cell epitopes that is associated with impaired peptides processing (TEIPP)(Seidel 
et al. 2012). TEIPP are mainly derived by non-mutated sequences of housekeeping genes 
(Lampen et al. 2010) but, since they fail to be presented by cells that have a functional 
APM, central tolerance is not a concern thus becoming an attractive target for tumor 
specific-CTL (van Hall et al. 2006). In a preclinical study, therapeutic vaccination with 
TAP-inhibited DCs induced TEIPPs-specific CTLs that successfully avoided APM-
defective tumor growth (Chambers et al. 2007). 
1.2.2 Antigen presentation by antigen presenting cells: cross-presentation and 
immunoproteasome 
Antigen presenting cells (APC) are responsible for the activation of naïve CD8+ T cells 
toward effector antigen-specific CTL, enabling them to recognize and kill infected cells 
and tumor cells. If the APCs are not directly infected (hence they cannot process 
pathogen antigens by the standard ubiquitin proteasome pathway), they need to acquire 
exogenous antigens from the infectious agent (or from cancer cells) and present them on 
MHC class I molecules, by a mechanism known as cross-presentation (Joffre et al. 
2012). This property is uniquely shared by APC cells. Exogenous proteins are taken up by 
endocytosis or by autophagy and delivered to the endosomes. From here proteins can 
follow two different pathways, either a vesicular pathway or a cytosolic pathway (Joffre et 
al. 2012). By the former pathway, endosomes can fuse with lysosomes where lysosomal 
peptidases process the exogenous protein and the derived peptides are loaded on MHC 
class I molecules. Proteasome and TAP are not involved in antigen loading, in this 
pathway. Alternatively, following the cytosolic pathway, proteins can be exported from the 
endosomes to the cytosol and being processed into peptides at this level in a proteasome-
dependent manner or by proteases like insulin-degrading enzyme, nardilysin and thimet 
oligopeptidase. Cytosol-generated peptides are then loaded on MHC class I molecules 
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following the classical MHC class I-mediated antigen presentation pathway, in a TAP-
dependent manner. MHC class I molecules loaded with the antigens are eventually 
transported via the trans-Golgi apparatus to the cell surface for presentation to CTLs 
(Joffre et al. 2012). 
It is known that mature APCs express almost a uniquely variant of proteasome, the 
immunoproteasome (Vigneron & Van den Eynde 2014), that differs in structure and for 
cleavage quality from the standard proteasome expressed by all body cells. Both in vitro 
(Toes et al. 2001) and in vivo (Kincaid et al. 2012) studies have shown that 
immunoproteasome and standard proteasome give rise to antigens that only partially 
overlap; hence DCs could prime T cells towards antigens that eventually are not exposed 
by tumor cells (Morel et al. 2000).  
1.2.3 Gap junction  
Exogenous peptides can enter the cross-presentation pathway also via gap junctions (GJ) 
(Saccheri et al. 2010; Neijssen et al. 2005). GJ are formed by the docking of the plasma-
membrane hemichannels of two adjacent cells that create an overall 3D structure that 
resembles a channel through which substances with a molecular weight up to 1KDa are 
transferred. Small peptides up to 2KDa (or about 16 amino acids) can also diffuse over gap 
junctions (Neijssen et al. 2005); indeed the lack of secondary structure of such small 
peptides enable them to be transferred through adjacent cells (Neijssen et al. 2005). A 
single functional hemichannel is composed by six connexin molecules (Unger et al. 1999) 
and every connexin molecule is formed by four membrane spanning domains, two 
extracellular domains and a large cytoplasmic C-terminal tail, which is important in the 
gating of the channel. Connexin isoforms are expressed in a strictly tissue-specific manner 
with the exception of Cx43 isotype that is expressed ubiquitously (Oyamada et al. 2005). 
Connexons formed by different connexin isotypes can still combine to form a gap junction. 
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Two adjacent cells have an homotypic interaction if both cells express the same 
connexons, heterotypic interaction if cells express different connexons (Weber et al. 2004).  
 
Figure 1-3. Hemichannels and gap junction. A single functional plasma membrane 
hemichannel is composed by six connexin molecules (Unger et al. 1999) and every 
connexin molecule is formed by four membrane spanning domains, two extracellular 
domains and a large cytoplasmic C-terminal tail which is important to regulate the opening 
of the channel. The hemichannels of two adjacent cells can either combine to form gap 
junctions or simply stand as unopposed hemichannels. Adapted from Orellana et al 
Journal of Neuroscienc 2011. 
In the skin, GJ-mediated intercellular communication is likely to be involved in the 
regulation of keratinocyte growth, differentiation, migration and in keratinocyte-
melanocyte interaction. Alterations of the physiological GJ-mediated communication also 
play a role both in carcinogenesis and in cancer progression of different tumors (Mesnil et 
al. 2005). GJ downregulation or their complete loss, allows tumor cells to be isolated from 
the surrounding cells prompting their expansion. Several factors, such as tumor-promoting 
agents, oncogenes, and growth factors, can be responsible for the reduced GJ level. Among 
the genetic alteration that have been identified, some involve the connexin genes and are 
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responsible for their low transcription; others instead induce an aberrant trafficking thus 
avoiding a proper connexin proteins transport to the membrane (Oyamada et al. 2005). 
Several different connexin isoforms are expressed in skin, including Cx26, Cx30, Cx31, 
and Cx43. Both mouse skin carcinomas and human skin cancer cell lines have shown to 
express low levels of these connexins (Mesnil et al. 2005).  
Cx proteins are also expressed by cells of the immune system and GJ are commonly used 
by immune cells to receive and send biochemical information with the surrounding cells. 
Multiple studies have demonstrated that GJ-intercellular communication contributes to the 
activation of a functional antitumor response, and that a GJ-mediated communication 
between DCs is required for their own effective maturation and activation (Matsue et al. 
2005). At the level of lymphoid germinal center, Cx43-GJ functionally couples follicular 
DCs to each other and to B lymphocytes allowing delivering of signals (Krenacs T et al. 
1997). Moreover, in the intestine the transfer of fed antigens via GJ from CX3CR1+ 
macrophages to CD103+ DCs has been shown to enable the establishment of oral tolerance 
(Mazzini et al. 2014). Connexin proteins are also recruited to the immunological synapse 
during T cell priming as both GJs and stand-alone hemichannels (Mendoza-Naranjo et al. 
2011); intercellular communication between DCs and T cells is bidirectional and the 
silencing of Cx43 impairs the crosstalk necessary for T cells activation (Elgueta et al. 
2009). In addition, GJs allow melanoma antigen transfer between tumor and DCs that can 
activate melanoma-specific CTLs (Mendoza-Naranjo et al. 2007). The involvement of GJs 
and particularly Cx43 in this process was demonstrated by the inhibition of Ag acquisition 
after the addition of either a Cx-mimetic peptide or GJ blockers (Mendoza-Naranjo et al. 
2007). Accordingly, cross-presentation via GJs from tumor cells to immune cells can be 
targeted to improve immunotherapy protocols. By GJs-mediated antigen transfer, DCs can 
present not only tumor antigens that have been processed by DC-immunoproteasome, but 
also by tumor antigens that have been pre-processed by tumor-proteasome (Matsue et al. 
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2005). GJs-mediated intercellular methods of communication have been largely exploited 
by our laboratory identifying a promising immunotherapy approach based on the peptides 
that are specifically transferred through GJs, following Salmonella infection (Saccheri et 
al. 2010). We have shown that infection of human and mouse melanoma cells with 
Salmonella induces the up-regulation of connexin 43, the most abundant and ubiquitous 
component of hemichannels. Furthermore, we have demonstrated that bacteria-treated 
melanoma cells establish GJs with DCs, thus allowing the transfer of pre-processed 
antigens from the tumor cells to the DCs (bypassing the DC-immuneproteasome function), 
ultimately leading to the activation of potent antitumor cytotoxic responses (Saccheri et al. 
2010). The possibility that Salmonella could also induce immunogenic peptides release 
through the unopposed connexin hemichannels is still to be elucidated 
1.2.4 Mass spectrometry approaches to detect tumor antigens 
Identification of tumor antigens is pivotal to design efficient immunotherapy strategies. 
The first and successful approach was based on DNA-cloning technology and was  
proposed by Boon and colleagues (Van der Bruggen et al. 1991). They created a genomic 
library of a patient’s derived tumor, and targeted each library component with patients 
PBMCs sensitized to tumor cells in vitro. The DNA clones form the genomic libraries 
responsible for lymphocyte stimulation were then identified. The discovery that tumor 
antigens were expressed on HLA molecules lead to the development of mass spectrometry 
(MS) strategies to identify the whole collection of antigens presented by tumor cells, the 
immunopeptidome (Caron et al. 2015). Data obtained by the analysis of immunopeptidome 
were mainly derived applying an MS data acquisition method called discovery-based 
method or data dependent analysis (DDA). By this method the most abundant precursor 
ions detected by the mass spectrometer in a survey scan per millisecond (MS1) are selected 
for fragmentation (MS2). MS identification was performed after isolation of MHC class I 
peptides from tumor cells by immunoaffinity columns coupled with antibody against HLA 
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molecules. Isolated peptides were then identified by MS after liquid chromatography 
separation (Berlin et al. 2015; Walter et al. 2012; Kumari et al. 2014). The discovery of 
neoantigens and the compelling evidence that they are the best candidates to induce a 
clinically efficient antitumor response have boosted the development of new MS 
approaches for their identification. Neoantigens are mutated peptides generated by non-
synonymous mutation or other genetic alteration, hence their identification cannot be 
achieved without taking into consideration their sequence differences. To overcome this 
challenge the database search has been performed on customized databases of peptides 
usually derived by exome sequencing data. The integration of exome sequencing data 
(followed by a plethora of in silico analysis to prioritize neoantigens list) with MS 
approaches allowed to unravel neoantigens (Kalaora et al. 2016; Yadav et al. 2014; Castle 
et al. 2012; Lu et al. 2014) and spliced tumor antigens that could be exploited for 
immunotherapy purposes (Liepe et al. 2016). Although the important achievements, this 
approach has some drawbacks; it is time consuming, still costly considering that it should 
be applied to each single patient. 
1.3 Immunotherapy of cancer 
Immunotherapy is an anticancer approach aimed at promoting or enhancing antitumor 
immune responses. This concept dates back to the late nineteenth century, when William 
B. Coley observed tumor shrinkage and eventually complete regression following injection 
of bacterial products in and around tumors (Coley 1891). Following this revolutionary 
approach, several immunotherapeutic strategies were developed, consisting of both passive 
and active immunotherapy (Salem et al. 2007). Passive strategies include the use of 
immunomodulators such as cytokines, adoptive cells transfer (ACT) and antibodies. On the 
contrary, active immunotherapy strategies rely on cancer vaccines and oncolytic viruses, 
seeking the generation within the patients of long-lasting antitumor responses able to 
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protect in case of relapse (Mellman et al. 2011). The immunotherapeutic approaches 
proposed till now aim to promote or enhance the anticancer response at different levels 
(Chen & Mellman 2013): promoting immunogenic tumor-cell death, instructing immune 
cells towards tumor antigens and counteracting the immune suppressive mechanisms 
imposed by the tumor cells. Considering the complexity of tumor development and the 
negative regulation of the immune responses exerted by tumor cells, the more promising 
approach to treat cancer is by far the one that combines more immunotherapeutic 
strategies. 
1.3.1 Cytokines 
Cytokines are having a limited clinical application due to the opposite effect they can exert 
on the immune system; they can increase or decrease various aspects of the immune 
response. The two cytokines whose administration in patients has been exploited are IFN-α 
and IL-2. Both cytokines often showed low overall response rate, drug’s low tolerability 
and potentially life-threatening side effects (Rosenberg et al. 1985).  
1.3.2 Adoptive cell transfer  
Adoptive cell transfer (ACT) is the transfer of patient’s T lymphocytes that show reactivity 
toward tumor antigens. They are reintroduced into the patient after ex vivo expansion with 
cytokines and/or transduction with tumor-specific T-cell receptor (TCR) (McGranahan et 
al. 2016). Lymphocytes can be isolated from peripheral blood (PB) or from tumor 
specimens (tumor infiltrating lymphocytes, TILs). While TILs isolation is not always 
feasible for each patient, the use of PB-derived T cells showed encouraging results. 
Nevertheless, the main drawback of ACT therapy still remains the toxicity due to 
lymphodepletion induced by high dose chemotherapy or radiotherapy, and by 
administration of high doses of IL-2. Moreover, the identification of the right antigens to 
be used for this approach represents a limitation. A recently developed antitumor strategy 
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relies on T cells genetically engineered to express chimeric antigen receptors, CARs. 
CARs are synthetic receptors that have an extracellular antigen specific target binding 
domain (derived from scFv), a hinge and transmembrane segment (derived from CD8α or 
IgG4) as well as an intracellular domain (Schmitt 2017). The advantages of CAR T cells 
rely on the capability of these cells to specifically recognize target antigens in an HLA-
independent manner, and to exerted T cell cytotoxicity activity, without the need to recruit 
other effector immune cells. Although CAR T cells can be envisioned as a possible 
treatment of several cancers, this possibility has thus far been severely limited by the lack 
of suitable tumor antigens that would avoid toxicity from off-target immune activation 
(Maude et al. 2014). Advancement in neoantigens identification may pave the path of 
successful CAR T cells against solid tumor sas it was recently shown in a preclinical 
model of adenocarcinoma (Posey et al. 2016).  
1.3.3 Monoclonal antibodies 
Monoclonal antibody (mAb) can be used to harness the host defense mechanisms, either 
targeting immune cell receptors to boost their activation or by the binding of tumor cell 
receptors to directly inhibit tumor growth. Several effects can be prompted upon the 
recognition of the targets on tumor cells. Some antibodies can directly exert an 
antiproliferative or apoptotic eﬀect, while others can induce complement system activation 
or an antibody-dependent cellular cytotoxicity. A category of monoclonal antibodies that is 
providing significant benefits to cancer patients is represented by immunocheckpoint 
inhibitors. It has been clearly demonstrated that antibodies against either programmed cell 
death 1 receptor (PD-1) and its ligand (PDL-1), or the CD28/cytotoxic T-lymphocyte 
antigen 4 (CTLA-4) release the breaks by which antitumor-lymphocytes are constrained by 
tumor cells.  
Although immunocheckpoint inhibitors have different targets, their effect is not tumor-type 
specific but is exerted on T cells level within the tumor microenviroment, hence their 
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success relies on the existing T cell repertoire (Gros et al. 2014). This explains why the 
combinatorial use of anti PD-1 and anti CTLA-4 antibodies showed improvement in 
clinical response only on a subset of patients (Wolchok et al. 2013; Larkin et al. 2015) with 
a high mutational burden (Rizvi et al. 2015; Le et al. 2015). Specifically, it was observed 
that higher mutational load (that correlates with a higher number of neoantigens presented 
on their HLA) was associated with improved patient survival (Zaretsky et al. 2016) (Hugo 
et al. 2017). All these observations suggest that immunocheckpoint inhibitors are 
successful only in those patients that, having tumors with high number of mutations, are 
prone to induce an antitumor response mediated towards neoantigens. Hence, combining 
checkpoint blockade with therapies that provide the necessary neoantigen-specificity to the 
antitumor response could be clinically successful, for patients that have an immunogenic 
tumor but do not develop a neoantigen antitumor, and for patients suffering of a poorly 
immunogenic tumor (Ott et al. 2017). Cancer vaccines, discussed below, can be a valuable 
option for combinatorial strategies. 
1.3.4 Oncolytic viruses 
Advancement in viral biology, tumor immunology and in molecular genetics techniques 
allowed researchers to investigate oncolytic viruses as novel anticancer therapeutic agents. 
Although oncolytic viruses can enter both normal and cancer cells, genetic alteration in 
cancer cells provides a selective advantage for viral replication. Virus replication within 
tumor cells eventually provokes cell lysis and the subsequent antigen release causes viral 
propagation to other tumor cells. Released tumor antigens can be taken up by DCs 
prompting a systemic anti-tumor response (Kaufman et al. 2015). Once injected at the 
tumor level, viruses exert an adjuvant function per se, due to their pathogenicity. They 
provide stimulatory signals both to favor immune cell recruitment at the tumor site and to 
promote immune cell activation (Kaufman et al. 2015). Another advantage of oncolytic 
viruses is that their genetic content can be modified to produce cytokines or specific 
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proteins upon infection that could be subsequently released by tumor cell’ lysis. This 
possibility has been recently exploited to generate the talimogene laherparepvec (T-VEC) 
oncovirus, a modified herpes simplex virus type 1, encoding granulocyte–macrophage 
colony-stimulating factor (GM-CSF) (Andtbacka et al. 2015). Nevertheless, oncolytic virus 
adoption as cancer therapy needs to be accurately evaluated since not every accessible 
tumor is suitable for oncolytic viruses treatment. Challenges to the development of 
oncolytic viruses as therapeutic strategies include validated pharmaco-dynamic and 
pharmacokinetic assays due to the fact that viruses are not eliminated as a result of cell 
metabolism, but need to be eradicated by patient immune system; biosafety issues need 
also to be taken into consideration (Chiocca & Rabkin 2015). 
1.4 Anti-cancer vaccines 
Anti-cancer vaccines can be potentially applied to overcome primary resistance to 
checkpoint blockade of tumors with low mutational load and increasing response rate of 
highly mutated tumors (Gross et al. 2017). The challenges that avoid the initiation of the 
stepwise events necessary to prompt a proper antitumor response need to be taken into 
account at the moment of designing a novel anti-cancer vaccine; the choice of a tumor-
specific antigen able to overcome peripheral tolerance; the choice of an adjuvant capable to 
properly boost the immune response; and the development of a cancer vaccine that can 
overcome the immunesuppression of tumor-specific CTL and elicit a long lasting 
antitumor response. 
Anti-cancer vaccines can be divided into two major groups: DC-dependent and DC–
independent vaccines. Numerous studies have evaluated the efficacy of DCs pulsed with 
tumor-derived proteins or peptides in cancer immunotherapy (Nair et al. 1997; P Paglia et 
al 1996; Fong et al. 2001). From an immunologic standpoint, DCs-based immunotherapy 
carries the highest potential of inducing effective anticancer immune responses since DCs 
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are key players in the activation of T cells. In order to induce powerful and specific CTL 
responses, the best option has been to load DCs with tumor-associated antigens either 
derived from tumor MHC molecules, (Berlin et al. 2015; Stronen et al. 2016), or newly 
predicted through exon sequencing data (Kalaora et al. 2016; Lu et al. 2014). Specific 
tumor antigen prediction was then evaluated on their ability to bind MHC class I by in 
silico tools or cell-based approaches (Carreno 2015; Bassani-Sternberg & Coukos 2016). 
When high affinity neoantigens identified by patients-derived melanoma cells were loaded 
on DCs and used for autologous vaccinations, not only was observed an increased T cell 
immunity directed at naturally occurring neoantigens, but also an expanded breadth of the 
antitumor response by revealing subdominal neoantigens (Carreno 2015). Recently, the 
result of twelve-year survival of non-resectable metastatic melanoma patients vaccinated 
over two years with monocytes-derived DCs matured in vitro was reported to be similar to 
the one observed in Ipilimumab-treated patients without any major toxicity 
(>2grade)(Gross et al. 2017) suggesting that the combinatorial treatment with therapies that 
target the immunesuppression can provide unprecedented benefits to melanoma patients. 
Unfortunately, one major drawback of DC-based approaches is that they are specific for 
each patient and require leukapheresis, processing and culturing of PBMCs, therefore 
allowing a limited number of vaccinations.  
Immunization strategies that overcome these limitations are DC-free vaccines. Tumor-
specific neoantigens are selected as described above but instead of being loaded on DCs, 
they are conjugated with adjuvant and used as vaccine formulation (Castle et al. 2012; 
Yadav et al. 2014). These peptide-based vaccines are well tolerated, are not patient-
specific and can potentially induce a multi-target and strong immune response when 
several antigens are included in the vaccine formulation thus targeting tumor heterogeneity 
as well as minimizing the chance of tumor escape by loss of antigens. In vaccine 
formulations, either peptides of the exact length that directly bind to MHC molecules or 
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15-35 amminoacid-long peptides (synthetic long peptides, SLP) that span the MHC-
binding-epitope, can be included. SLPs have been shown to activate a broader and long 
lasting T cell response than peptides that precisely fit into MHC class I molecule 
independently from adjuvant choice (Bijker et al. 2007). Moreover dendritic cells process 
synthetic long peptides better than whole proteins, improving antigen presentation and T-
cell activation (Rosalia et al. 2013). SLP constant inclusion in designing novel strategies 
could prompt the development of high immunogenic and durable cancer vaccines. 
Recently, the results of a trial involving 6 melanoma patients that were vaccinated with 
patients-specific neoantigens combined with a TLR3 agonist (poly:IC synthetic analog of 
double-stranded RNA), showed that four patients had no tumor recurrence at 25 months 
after vaccination, while 2 patients with recurrent disease were treated with anti PD-1 
antibody and had complete tumor regression (Ott et al. 2017). This latter result highlighted 
the success of multi-targets approaches for cancer treatment. In this setting, patient-specific 
neoantigens used for the immunization were SLPs and together with the chosen adjuvant 
not only expanded pre-existing neoantigen-specific T cell populations but also induced a 
broader repertoire of new T cell-specificities. Compelling evidence demonstrated the 
feasibility and safety of neoantigens-based cancer vaccines and furthermore their ability to 
elicit an antitumor T cell response. All together these reports have eventually provided a 
strong rational for cancer vaccine development either as monotherapy or in combination 
with other cancer treatments that target tumor-escape strategies. 
1.4.1 Salmonella’s biology and Salmonella-based cancer immunotherapy 
Salmonella enterica serovars are Gram-negative facultative intracellular bacteria that, 
depending on the serovar, can cause local gastroenteritis or systemic disease called typhoid 
fever through food and water intake. Indeed, human infections by Salmonella enterica 
serovar Typhi (hereafter referred to as S. typhi) causes typhoid fever, while Salmonella 
enterica serovar Typhimurium (referred to as S. typhimurium) induces only locally 
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restricted infection. On the contrary, mice are susceptible to oral infection with S. 
typhimurium, but not S.typhi, resembling the human systemic disease (Voedisch et al. 
2009). Therefore S. typhimurium oral infection in mice is widely used as model of human 
systemic infection.  
Salmonella, is able to cross the membranes and get inside the cytosol of infected cells 
through the expression of effector proteins belonging to the type III secretion system 
(TTSS) (Sukhan et al. 2001). These translocated effectors, encoded by chromosomal 
regions are called Salmonella’s pathogenicity island 1 and 2 (SP-1, SP-2), and are able to 
alter host-cell functions such as signal transduction, cytoskeletal architecture, membrane 
trafficking, and cytokine gene expression. These modifications create an intracellular 
compartment distinct from a classical phagosome that is permissive for bacterial growth 
(Sukhan et al. 2001). Genes of the SPI-1 TTSS are activated at the early stage of cell 
infection and are required for translocating effectors across the host cell plasma membrane 
(Sukhan et al. 2001). The SPI-2 encoded proteins have been associated to the ability of 
Salmonella to survive in the host cell and to spread systemically (Ochman et al., 1996). 
Salmonella, as other bacteria including Listeria, Clostridium, Bacillus Calmette-Gu (BCG) 
has been extensively studied as anticancer agent, both as immunostimulatory agent and as 
vaccine vector (Paterson et al. 2015). The advantage of using bacteria instead of viruses is 
that bacteria can be readily and irreversibly attenuates, their infection can be curtailed by 
antibiotics and can be produced at lower costs. Pathogens can induce a strong pro-
inflammatory innate immune response through the action of pathogen associated molecular 
pattern (PAMPs) and potently activate DCs mainly through engagement of their toll-like 
receptors (TLRs) (Van Duin et al. 2006), representing the most powerful natural adjuvants. 
These properties have been exploited to overcome the tolerance associated with tumors.  
Salmonella can infect both phagocytic cells and non-phagocytic cells, via the expression of 
a type-three secretion system (TTSS); moreover, if systemically injected, Salmonella is 
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also able to colonize preferentially tumor areas. This ability, shared also by the Gram+ 
bacteria Listeria, has been exploited following the development of attenuated and non-
pathogenic bacteria strains, and through DNA manipulation tailored to regulate specific 
gene expression (Vendrell et al. 2011; Sun et al. 2009; Singh et al. 2014). Preclinical 
studies have shown the feasibility of tumor antigens delivery as well as cytotoxic proteins 
by Salmonella and Listeria. Recently a non-virulent Salmonella was engineered to secrete 
heterologous flagellin (TLR5 agonist) which showed the capability to suppress tumor 
development (Zheng et al. 2017).  
Salmonella as an immunotherapy agent that can also be directly injected inside the tumor 
mass. It has been shown that Salmonella injection  in melanoma-B16 tumor mass, resulted 
in the regression of even bulky tumor masses, and had also impacts on the growth of 
distant untreated lesions (Avogadri et al. 2008). Three main mechanisms are responsible 
for its antitumor effect. First, infected tumor cells  express Salmonella antigens on their 
HLA and become target of Salmonella-specific CTLs (Avogadri et al. 2005). Second, both 
innate and adaptive immune cells are recruited at the infection site, overcoming the tumor 
suppressive environment (Yoon et al. 2017; Hong et al. 2013). Third, infection with 
Salmonella promotes cross-presentation of tumor antigens and establishment of systemic 
antitumor response (Saccheri et al. 2010). The transfer of antigens occurs mainly through 
gap junctions (Mendoza-Naranjo et al. 2007). This last event has been extensively 
investigated in our laboratory (Saccheri et al. 2010) and is the fundamental basis of the 
presented study. 
1.5 Melanoma 
Melanoma is a malignant tumor that arises from melanocytic cells and primarily involves 
the skin; according to an updated epidemiologic report, in Europe the incidence rate is 
<10-25 new melanoma cases per 100.000 inhabitants (Whiteman 2016 Jinvet Dermat). 
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While melanomas are usually heavily pigmented, they can also be amelanotic. Melanoma 
has the tendency to develop metastasis and become resistant to therapy: these aggressive 
features make it one of the deadliest forms of cancer. Although it accounts roughly for 4% 
of all skin cancers, it is responsible for 90% of skin cancer deaths (Dummer et al. 2015).  
The anatomical classification of melanoma is based on the thickness of the tumor and 
whether cancer has spread to lymph nodes or other parts of the body. This classification, 
reported below in figure 1.4, includes four stages of disease progression and was proposed 
in 2009 by the American Joint Committee on Cancer; it is still the cornerstone for 
classifying melanomas (Balch et al. 2009).  
 
Figure 1-4. Staging of melanoma. Melanoma includes four stages of disease progression. 
This classification was proposed in 2009 by the American Joint Committee on Cancer   
Adapted from C. Garbe et al., European Journal of Cancer 2016 
Staging of melanoma inversely correlates with survival. Melanoma that are diagnosed as 
primary tumor without evidence of metastasis are associated with 75-85% of 10-year 
survival (Stage I and stage II). Stage III melanoma patients have a different life expectancy 
according to the type of diagnosed metastasis: 
• satellite metastases: up to 2 cm distant from primary tumor; the 10-year survival is 
30-50%. 
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• in-transit metastases: located in the skin, distant more than 2 cm from the primary 
tumor; the 10-year survival is 30-50% 
• micrometastases: located in the regional lymph nodes, diagnosed by sentinel lymph 
node biopsy; the 10-year survival is 30-70% 
• macrometastases: located in the regional lymph nodes; palpation or imaging 
techniques are sufficient for diagnosis; the 10-year survival is 20-40% 
Stage IV melanoma patients with distant metastases have a grim prognosis with a median 
survival in untreated patients being only of 6-9 months, although there is considerable 
variation depending on aggressiveness of the individual tumor (Garbe et al. 2016).  
Although melanoma is a highly heterogeneous disease, deep molecular analyses have 
revealed consistent genetic patterns among different melanoma subtypes that can be 
considered ‘driver mutations’. The BRAF, NRAS and NF-1 mutations can be considered 
driver mutations that then lead to the accumulation of several other genetic alterations. The 
mutational load of melanoma is high; a median of 171 mutations are found in melanoma 
while an average of 80 mutations are found in colon cancer as well as breast tumor 
(Greenman et al. 2007). Most of the mutations are not necessary for the survival of the 
tumor but increase the number of potential neoantigens, thus leading to an increased 
immunogenicity and a higher opportunity for immune system recognition. Melanoma 
antigens and neoantigens can be divided in four categories: 
1. germ cells/cancer testis antigens, peptides belonging to proteins expressed during 
the development but not in adult stage: NY-ESO/MAGE/BAGE/GAGE 
2. differentiation antigens, peptides belonging to protein expressed only by 
melanocytes: Tyrp1, gp100, MelanA 
3. overexpressed antigens: beta catenin/Cyclin dependent kinase  
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4. sequestered antigens, peptides usually hidden from immune detection: TEIPP 
peptides 
1.5.1 Melanoma therapies 
The first line of melanoma therapy is surgical resection with safety margins. Evaluation of 
the draining lymph nodes by palpation or by sonography is required and, if metastases are 
diagnosed, lymph nodes are radically dissected. The surgical removal of metastases 
detected at skin level is considered a curative practice in stage III patients. In addition to 
surgery, other conventional therapies can be adopted like laser therapy and cryosurgery; 
immunotherapy strategies (e.g. IL-2 administration, TLR 9 agonist (imiquimod), and 
oncolytic viruses-based therapies (as T-VEC). Radiotherapy is indicated in case  surgical 
resection is not complete and when regional lymph nodes are not operable (Garbe et al. 
2016). 
Mutational test is mandatory for patients with advanced disease (high risk resected 
melanoma stage IIc, stage III and stage IV) in order to apply a therapy that specifically 
targets the identified mutation. Vemurafenib and Dabrafenib, drugs that specifically inhibit 
the kinase activity of mutated BRAF gene, were shown to successful prolong the overall 
survival of melanoma patients BRAF-mutated (Chapman et al. 2011). The discovery of 
melanoma antigens and neoantigens has also led to the development of immunotherapy 
strategies. DC-mediated cancer vaccines, in which monocyte-derived DCs matured in vitro 
and loaded with 4 HLA class I and 6 HLA class II-restricted tumor peptides were used to 
treat nonresectable metastatic melanoma patients reporting an overall survival of 20% of 
the patients (Gross et al. 2017). Neoantigens and tumor antigens have also been exploited 
directly as synthetic peptides in cancer vaccine formulation; successful results of high risk 
melanoma patients immunization with synthetic long peptides have been recently reported 
(Ott et al. 2017). Immunotherapies approved for melanoma comprise monoclonal 
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antibodies against immunocheckpoint, both CTLA-4 (Ipilimumab) (Smith et al. 2011) and 
PD-1 (Nivolumab and Pembrolizumab) (Postow et al. 2015). It has been shown that 
melanoma patients treated with the combination of Nivolumab and Ipilimumab had longer 
overall survival than patients treated with a single antibody (Wolchok et al. 2013; Larkin et 
al. 2015). Chemotherapy at the moment is considered the second or third line of approach 
in patients with resistance to immunotherapy and targeted therapy (Garbe et al. 2016). 
1.6 Model of human osteo/sarcoma: dog affected by spontaneous 
osteosarcoma and high-grade sarcoma. 
In humans, the most commonly diagnosed primary malignant tumor of the bone is 
osteosarcoma (OSA). The term OSA is synonymous with osteogenic sarcoma, meaning 
that these tumors are characterized by the formation of osteoid bone matrix material. It is 
the third most frequent cause of cancer in adolescents and represents over 56% of all bone 
tumors (Rowell et al. 2011). Importantly, for OSA-human patients the main cause of death 
is lung metastasis; only 20% patients survive after 5 years post-diagnosis. To facilitate the 
introduction of novel therapeutic approaches that had positive results in murine models 
into human clinical practice, dogs are often considered a testbed. That is because dogs are 
a valuable model of naturally occurring cancers like osteosarcoma and sarcoma (Rowell et 
al. 2011). Dogs develop OSA at similar sites as humans and both have similar histology 
and response to treatment (Rowell et al. 2011). Dogs first participated in clinical trials 
pioneering limb salvage techniques that are now used in humans.  
OSA is the most common primary bone tumor in dogs, comprising 85% of all reported 
bone neoplasia (Mirabello et al. 2009). On the basis of the quantity of matrix produced and 
cell arrangement, canine osteosarcoma can be classified as osteoblastic, chondroblastic, 
fibroblastic, and undifferentiated OSA. Most OSA patients already have microscopic and 
not visible metastatic disease at the time of diagnosis of the primary tumor (Mirabello et al. 
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2009). Like in humans, metastases mainly develop at the level of the lung (60%) but also at 
other bones (5%) or both sites (4,6%) and become the principal cause of death (Spodnick 
GJ 1992). Median survival times approach 4–5 months with amputation alone (Mirabello 
et al. 2009), and adjuvant chemotherapy improves median survival times to 8–12 months 
(Selmic et al. 2014). Recently with the aim to avoid metastasis development, in a multi 
institutional study conducted in United States, toceranib (multi tyrosin receptor inhibitor) 
was added to metronomic piroxicam/cyclophosphamide therapy following amputation and 
carboplatin chemotherapy but the results did not show any improvement of the patients’ 
survival rate  (London et al. 2015). Despite the use of various chemotherapy protocols and 
novel treatment approaches, clinically meaningful improvements in survival have not been 
achieved, and 90% of dogs die of metastatic disease within 2 years after treatment 
(Wycislo & Fan 2015).  
Soft tissue sarcomas (STSs) are an uncommon and diverse group of malignancies that due 
to their mesenchymal origin can virtually arise from every tissue of the body; on the basis 
of their localization 50 different STSs have been described but they are usually classified 
together because of their similar biological behavior. STSs are more prevalent in childhood 
and adolescence, where they account for 20% of cancer-related deaths (Young et al. 2014). 
Most of sarcomas are resistant to both chemotherapy and radiotherapy. Human patients 
with primary STS, surgery with or without radiotherapy can offer a cure, but nearly half of 
patients recur and eventually die, with an estimated median survival of 12 to 15 months 
(Dancsok et al. 2017).  
Dogs are an excellent model of STS because they have similar tumor genetic complexity to 
humans (Rowell et al. 2011). Dog STSs represent between 9 and 15% of all cutaneous or 
subcutaneous tumors (Liptak & Forrest 2013). There is no apparent breed disposition for 
STS, but middle to-large dogs are more commonly affected (Mayer & Larue 2005). In 
dogs, STSs develop most frequently in a subcutaneous location and can arise from several 
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anatomical sites (e.g. example lymphatic vessels, tendons, joint capsule, ligaments, ascia 
and nerves) (Liptak & Forrest 2013). Histological criteria are used to define the grade of 
the tumor. Low (grade I), intermediate (grade II), or high (grade III). For low and 
intermediate STSs surgery alone remains the most effective strategy in the management of 
STS (Bray 2016). Local recurrence following surgical  resection is the usual reason for 
treatment failure in the management of STS and may occur in between 7 and 75% of 
patients, with recurrence consistently associated with reduced overall survival for the dog 
(Bray et al. 2014). Recurrence is mainly influenced by the size of the excision margins. An 
inappropriate conservative treatment will adversely affect outcomes for patients with more 
aggressive disease (Liptak & Forrest 2013). Higher tumor grade is associated with more 
aggressive biologic behavior and higher rates of local recurrence, distant metastasis and 
shorter disease free. High grade sarcoma patient’s life expectancy is between 3 and 6 
months from diagnosis (Frezza et al. 2017).  
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2. AIM OF THE STUDY 
Advancements in cancer immunotherapy have revealed the importance of targeting 
neoantigens. Neoantigens are tumor specific antigens that prompt a strong antitumor 
response escaping from the central T tolerance. We have previously shown that infection 
of mouse melanoma cells with Salmonella induces the up-regulation plasma-membrane 
hemichannels. Furthermore, we have demonstrated that bacteria-treated melanoma cells 
establish gap junctions with dendritic cells (DCs), thus allowing the transfer of pre-
processed antigens from the tumor cells to the DCs, ultimately leading to the activation of 
potent antitumor cytotoxic responses (Saccheri et al. 2010). We hypothesized that infection 
of tumor cells with Salmonella may also lead to the extracellular release of immunogenic 
peptides, neoantigens, that could be potentially used as anticancer vaccines. Using both 
mouse and human melanoma cells, we have addressed the following specific points: 
1) Assess if Salmonella infection of murine melanoma cells leads to hemichannels 
opening and to a subsequent release of peptides able to induce an antitumor 
response as prophylactic vaccine.  
2) Assess if human melanoma cells release immunogenic peptides upon Salmonella 
infection able to expand tumor specific T lymphocytes.  
3) Address the feasibility and safety of the immunotherapy strategy based on the use 
of the peptides released from Salmonella-infected tumor cells.  
4) Investigate whether among the released peptides, known tumor antigen and novel 
tumor epitopes are found.  
5) Optimize a mass spectrometry-based pipeline to identify neoantigens, tumor 
spliced-peptides and post-translational modified tumor antigens. 
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3. MATHERIAL AND METHODS 
3.1 Mice 
6 weeks old WT C57BL/6J mice were purchased from Charles River. For some experiment 
OTI mice (C57BL/6-Tg(TcraTcrb)1100Mjb/Crl) were also used. These homozygous mice 
contain transgenic inserts for mouse Tcra-V2 and Tcrb-V5 genes; the transgenic T cell 
receptor was designed to recognize OVA257-264 in the context of H2Kb. All experiments 
were performed in accordance with the guidelines established in the Principles of 
Laboratory Animal Care (directive 86 /609 /EEC). 
3.2 Cell lines and bacterial strain 
The murine melanoma B16-F10, B16F10-OVA (called throughout the manuscript B16 and 
B16-OVA, respectively (Overwijk & Restifo 2001) and T2 cells (HLA-A0201 hybrid 
human cell line lacking TAP-2 (Hosken & Bevan 1990)  were cultured in RPMI 1640 
medium supplemented with 10% fetal bovine serum (FBS-South American), 2 mM 
glutamine, penicillin (100 U/ml), streptomycin (100 mg/ml), and 50 mM β-
mercaptoethanol (complete RPMI). Human melanoma cell lines 624.38 (HLA-2A 
proficient) and 624.28 (HLA-2A deficient) were cultured in RPMI 1640 medium 
supplemented with 10% of FBS (North American), 2 mM glutamine, penicillin (100 
U/ml), streptomycin (100 mg/ml), 1% non-essential amminoacids (NeAA). The immature 
DC line D1 (Winzler et al. 1997) was cultured in Iscove’s modified Dulbecco’s medium 
supplemented with 30% NIH-3T3 supernatant containing 10 to 20 ng/ml mouse 
granulocyte-macrophage CSF. PBMCs for the expansion of antigen specific CD8+ T cells 
were cultured in RPMI supplemented with 5% human serum, 2mM L-Glutamine, 100 
U/ml penicillin, 100 mg/mL Streptomycin, 10 µg/mL βmercaptoethanol and 1% NeAA. 
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S. typhimurium SL3261AT is an aroA metabolically defective strain on SL1344 background 
and is grown at 37°C in Luria broth (LB). 
Vivofit® (Thyphoid vaccine live oral Ty21a) is a vaccine containing the attenuated strain 
of Salmonella enterica serovar Typhi Ty21a and is grown at 37 °C in Luria broth. 
3.3 In vitro infection with bacteria 
Single bacterial colonies were grown overnight and restarted the next day to reach an 
absorbance at 600 nm of 0.6 corresponding to 0.6 × 109 colony-forming units (CFUs)/ml. 
Murine and human melanoma cells were incubated with bacteria for 90 minutes, at a cell-
to-bacteria ratio of 1:50, in the appropriate medium added with L-Glutamine without 
antibiotics. Cells were washed with medium and incubated in medium supplemented with 
gentamicin (50 mg/ml) for 18 hours to kill extracellular bacteria. At the end of the 
incubation cells were harvested and then lysed for protein analysis while supernatant was 
collected and filtered through 0,22µm filter to get rid of potentially still alive bacteria.  
3.4 T2 binding assay 
To assess peptides enrichment inside tumor cells’ supernatant following Salmonella 
treatment T2 cells (Hosken & Bevan 1990) were incubated overnight at 37 °C at 2x105 
cells/ well in serum-free RPMI medium either with 100 µL of supernatant or with MART-
1 peptide (1 µM and 10 µM) as a positive control. After overnight incubation, cells were 
blocked with mouse FcR block (1:100 BD), stained with BB7.2, an HLA-A0201 
conformation-specific mouse antibody (BD). The cells were washed twice and fixed in 
paraformaldehyde for later acquisition by Accuri C6 Flow Cytometer (BD). 
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3.5 Adenosine5’-triphosfate bioluminescent assay 
Adenosine 5’- triphosphate (ATP) Biolumescent Assay (Cell-Titer-Glo Luminescent cell 
viability Assay, Promega) allows to measure the quantity of ATP inside a sample. Firefly 
luciferase catalyzes the oxidation of D-luciferin giving rise to a colorimetric reaction; light 
emission is proportional to ATP content thus it can be quantified. Briefly, 100 µL aliquots 
of each supernatant to include in the test were distributed in a 96-well plates; they were 
then rapidly mixed with an equivalent volume of MIX-assay solution. Light emission was 
detected and quantified by a luminometer. ATP standard curve was included every test; 
higher concentration: 1 µM ATP. 
3.6 OTI-CD8a+ activation assay 
With the purpose to assess the presence of OVA (SIINFEKL) peptide inside the medium of 
B16 OVA cells infected with Salmonella (as described in Chapter 3.2)), OTI-CD8a+ 
activation assay was performed. Samples were prepared as follow. Supernatants were 
enriched of peptides by a TCA-protein precipitation; TCA was added at final concentration 
13% and samples were incubated overnight at 4°C. Following high speed centrifugation 
the supernatant was loaded on chromabond SPE C18 devices (Macherey-Nagel) and 
peptides were eluted with different percentages of Acetonitrile solution. Fractions were 
dried with a speed vacuum and peptides were directly solved in IMDM. The assay was 
performed as follow. Murine dendritic cells (D1), were incubated for 4 hours at 2x104 
cells/well in a 96wells/plate with fractions of supernatants derived by Salmonella-treated 
B16/B16-OVA cells. Cells were then washed twice and incubated for 72 hours with 2x105 
CD8a+ cells isolated from the spleen of OTI mice. CD8a+ cells were obtained owing to 
magnetic column separator device (MACS). IFN-γ production was assessed by ELISA 
(BD).   
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3.7 Bone marrow derived dendritic cells derivation 
To obtain bone marrow derived dendritic cells (BMDCs), total bone marrow cells derived 
by C57BL/6 mice were plated in RPMI1640 containing 10% FCS, 0,5mM  2-
ßmercaptoethanol, 2mM glutamine, 0,1mM NEAA, 20 µg/ml gentamycin, 30% murine 
GM-CSF. 2x106cells in 10cm2 Petri dish (Corning) with 10ml of medium. After 3 days, 10 
ml of fresh complete medium was added to the plates and on day 6, all the medium was 
replaced with a fresh one. At day 10 non-adherent and loosely adherent cells were 
harvested and DC markers expression (CD11c+ CD11b GR1 I-A I-E CD86) was assessed 
by FACS before using BMDCs for in vitro experiments. 
3.8 iNKT activation assay 
In order to assess whether supernatant derived from B16 cells upon Salmonella infection 
contained lipids that activate iNKT cells in vitro, BMDCs were plated in a flat bottom 
96wells plate (5x104 per well) in ratio 1:1 with mouse hybridoma Vα14i NKT, FF13 
(Schümann et al. 2007). Cells were stimulated either with B16 supernatant or with 
increasing concentration of sonicated α-Galactosylceramide (Cd1-ligand, Alexis 
Corporation, Lausen, Switzerland) (higher concentration= 200 ng/ml) or left untreated 
(BMDc+FF13) up to a final volume of 200ul per well. The co-culture lasted for 48 hours, 
then ELISA for IL-2 production was performed. 
3.9 PBMCs isolation 
Peripheral blood was obtained from HLA-A2+ normal donors, and PBMC were obtained 
by Ficoll (Ficoll/Hypaque density of 1,077 ± 0001) density gradient centrifugation. The 
blood was layered over the ficoll (Figure 3-1), substance which creates a density gradient 
if subjected to a centrifugation of 300g for 30 minutes at room temperature without brake. 
The blood cells are stratified according to different densities: the erythrocytes with higher 
44 
 
density than Ficoll settle on the bottom, granulocytes are layered to form a thin whitish 
above the red blood cells, while PBMC that are less dense than Ficoll are collected at the 
interface between Ficoll and plasma. To optimize this procedure  buffy coats were diluted 
with PBS to a total volume of 35 mL (to prevent sedimentation of groups of cells) and 15 
mL of Ficoll were added, slowly and at the same speed, under diluted buffy coat.  
 
Figure 3-1. PBMCs isolation. PBMC were obtained by Ficoll density gradient 
centrifugation. The erythrocytes with higher density than Ficoll settle on the bottom, 
granulocytes are layered to form a thin whitish above the red blood cells, while PBMC that 
are less dense than Ficoll are collected at the interface between Ficoll and plasma. Adapted 
from Zhonghua Lin Nature Protocols 2014 
Samples were centrifuged at 300 g for 30 minutes at room temperature (set up acceler on 
slow and deceler on off). The PBMC ring was recovered with a pasteur pipette and was 
transferred to a 50 mL tube PBMC were washed (at 4°C) once with PBS by centrifugation 
at 300 g for 10 minutes and twice by centrifugation at 160 g for 10 minutes to remove any 
platelets. PMBC were resuspended in isolation buffer (MACS buffer: PBS, 2mM EDTA, 
0,5 % BSA) in case of a subsequent immunomagnetic separation. 
3.10 Antigen specific-CD8+ T cells expansion from healthy donor 
PBMCs 
Total PBMCs isolated by healthy HLA-A2+ donor were plated in 24-well plates (2 x 106      
cells per well) and incubated either with supernatant derived by 2x106 62438 cells treated 
with Salmonella or 30uM Mart-1 in a final volume of 2 ml. From day 3 the recombinant 
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IL-2 (proleukin, Novartis) was added at the final concentration of 20 U/mL. Cells were fed 
every 2-3 days with 20 U/mL IL-2 and restimulated every 10 day.  At every restimulation, 
expanded lymphocytes were enriched in CD8+ T cells by magnetic column separation 
(Miltenyi). 2x106 of the isolated CD8+ T cells were plated with 4x105 irradiated (10 Gy) 
HLA-A2+ PBMCs that were pulsed either with Mart-1 or with supernatant of 62438 cells 
infected with Salmonella. To pulse PBMC they were incubated for 90 minutes at 37°C in 
RPMI supplemented with the selected stimulus (Mart-1/cells’ supernatant). After 
incubation, cells were washed twice and irradiated (10 Gy) before mixing with the CD8+ T 
cells. 
3.11 moDCs derivation 
CD14+ cells were obtained  in accord to Miltenyi biotec protocols. PBMC were labeled 
with anti-CD14 microbeads to isolate monocytes. The cell suspensions were loaded onto a 
MACS Column, which were placed in the magnetic field of a MACS Separator. The 
magnetically labelled CD14+ cells were retained within the column from the magnetic field 
and these positive cells have been eluted as the positively selected cell fraction. Isolated 
CD14+ cells were used to produce dendritic cells. Monocytes were plated in 6-well plate 
(1x106 /mL) in RPMI 1640 medium. After  1 hour of incubation at 37°C the non-adherent 
cells were removed by washing with medium. The remaining (adherent) cells were 
incubated in complete medium plus 10 ng/mL of granulocyte macrophage colony-
stimulating factor (BD) and 10 ng/mL of IL-4 (BD). At the 6 day of culture monocyte-
derived dendritic cells (MoDCs) were used for in vitro tests. 
3.12 Mice immunization 
For preventive vaccination, C57BL/6J mice were injected at their left flank with 
supernatant derived from B16 cells that were infected with Salmonella or left untreated. 
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According to the in vivo test, supernatants were differently prepared. The supernatant was 
either lyophilized or concentrated by chromabond SPE C18 devices (Macherey-Nagel). 
Preventive vaccination was performed at day 0, 4, 11. 105 B16 cells were injected 
subcutaneously in the right flank of the mice, at day 40. Tumor growth was monitored by 
measuring the two visible dimensions with a caliper every 2 days. Blood withdraw was 
performed at different time points: day 0, 18, 35 and at the moment of sacrifice. 
Supernatants used for each vaccination were combined with different type of adjuvants. 
IFA+Aldara: Aldara cream (Imiquimod, MEDA) was applied at the immunization site until 
dried; supernatant emulsified with Incomplete Freud’s Adjuvant (IFA, Sigma) at ratio 1:1, 
was then injected subcutaneously at final volume of 100 µl. 
CpG: 10 µg of ODN1826 (Invivogen) were combined with the supernatant derived by 
2x106 cells and inoculated into the flank of mice at final volume of 100 µl. 
DCs: D1 cells were incubated for 2 hours with LPS (1µg/ml) at 37°C and then for other 2 
hours either with the supernatant derived by 2x106 B16 cells or with a mix of Trp2180-188 
and gp10025-33 (1 mg/ml each). 3.5x105 D1 cells in a final volume of 100 µl were 
eventually injected subcutaneously at the flank of the mice. 
3.13 Immunomonitoring 
3.13.1 CD107a mobilization assay 
CD107a mobilization assay enable to assess degranulation of effector cells such as CD8+ T 
cells upon stimulation with a target cells. CD107 (or LAMP-1) is expressed on granules-
membrane hence it is a suitable marker of degranulation. Effector and target cells are 
incubated together in addition with a CD107 antibody and golgi inhibitors that prevent 
granules release in the extracellular space thus allowing a proper evaluation of cytotoxic 
response.  
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Effector cells included in the test were either peripheral blood mononucleated cells 
(PBMC) of dog patients or ex vivo expanded CD8+ T cells from human healthy donor 
PBMCs. Target cells were either dog patient’s tumor cells or 62438 cells. Effector cells 
and target cells were incubated in a tube in complete medium in ratio of 1:1 and 2:1. Anti-
CD107a monoclonal antibody conjugated with APC (1:100, BD), brefeldin A 10 µg/ml 
(BD) and GolgiStop containing monensin (1:1000, BD) were added to the culture for a 
final volume of 500ul and incubated for 5 h at 37 °C. Cells were then blocked with mouse 
FcR block (1:100, BD), stained with anti-CD3a, anti CD8 anti CD4 (1:200, BD) and then 
fixed in 4% PFA. Intracellular staining for IFNg (1:100, BD) production was also 
performed in order to further assess T cell activation. Stained cells were acquired by 
FACSCantoII (BD Biosciences). 
3.13.2 Delfia 
Cell-mediated cytotoxicity of effector cells was measured performing Delfia test. Target 
cells are colored with Delfia-BATDA and killing ability of effector cells is proportional to 
Delfia-BATDA release. In detail, target cells (tumor cell lines) were collected, washed 
once and solved at concentration of 1x106 cells/ml. 2ml of cells were loaded with 3µl of 
Delfia-BATDA (DELFIA, Perkin Elmer) reagent, at 37°C for 30 min. Following 4 washes 
with PBS and 1 wash with medium w/o serum, 5000 cells were seeded in a v-bottom plate 
and incubated with effector PBMCs for 90 min in a humidified 5% CO2 atmosphere at 
37°C. The controls included in the experiment were: background (media without cells), 
spontaneous release (target cells without effector cells) and maximum release (lysed target 
cells). After incubation cells were centrifuged for 5 minutes at 500 g and 20 µL of the 
supernatant was transferred to a flat-bottom plate and 180 µL of Europio solution were 
added.  After 15 minutes of incubation at room temperature the fluorescence was measured 
in the time-resolved fluorometer. The percentage of specific release is calculated as 
follows:  
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𝐸𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙	𝑟𝑒𝑙𝑒𝑎𝑠𝑒 − 𝑆𝑝𝑜𝑛𝑡𝑎𝑛𝑒𝑜𝑢𝑠	𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑀𝑎𝑥𝑖𝑚𝑢𝑚	𝑟𝑒𝑙𝑒𝑎𝑠𝑒 − 𝑆𝑝𝑜𝑛𝑡𝑎𝑛𝑒𝑜𝑢𝑠	𝑟𝑒𝑙𝑒𝑎𝑠𝑒 ×100 
3.13.3 Humoral response assessment 
To assess tumor specific antibodies inside patients’ blood, tumor cells were lysed by freeze 
and thaw and the lysate corresponding to 10000 tumor cells was used to coat single wells 
of PVC microtiter plates (final volume of 50 µl). The coating was an overnight incubation 
at 37°C. Then, plates were blocked with 100 µl 5% BSA in PBS per well for 1 hr at 37°C. 
After removing blocking buffer, cells were probed with serum samples. 50 µl of patient’s 
sera diluted in PBS with 1% BSA was added in each well and incubate for 2 hr at 37°C. 
Typical dilutions used are 1:10, 1:50, 1:250, 1:1250, 1:6250, and 1:31,250. Wells were 
then washed three times with 1% BSA in PBS at room temperature and the incubation with 
HRP-conjugated anti-dog antisera (1:4000) in 1% BSA in PBS for 1 hr at 4°C was 
performed. Following a last wash step of three washes with 1% BSA in PBS signals was 
developed with OPD (50 µl) as substrate. Reaction was stopped by adding 50 µl 4M H2SO4 
per well. Plates were read at 492 nm in an ELISA reader. 
3.14.1 nLC-ESI-MS for biochemical characterization of cells supernatants 
3.14.1.1 Sample preparation 
Supernatants derived from 40x106cells (Salmonella treated or left untreated) were 
concentrated through the use of chromabond SPE C18 devices (Macherey-Nagel). Once 
eluted with 80% CH3CN in 0.1% Formic Acid (FA) solution, samples were dried by speed 
vacuum, solved in water and sonicated with Bioruptor 30’’ ON + 30’’ OFF (2 cycles). Low 
and high molecular weight peptides were separated with a 10KDa centrifugation filter 
(Filter aided sample preparation, FASP) (Millipore) and differently analysed. Low 
molecular weight (LMW) fraction was concentrated in a centrifuge vacuum concentrator 
and soon acquired by nano-scale liquid chromatographic mass spectrometry (nLC-ESI-
MS) on a Q-Exactive HF (as described in the following paragraph), while high molecular 
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weight fraction, containing mainly proteins, underwent enzymatic treatment before 
acquisition. Proteins were overnight digested by secret 3D method that enables a more 
efficient protein digestion (Matafora et.al manuscript in preparation) after reduction and 
alkylation with 10mM TCEP and 55mM Chloroacetamide added simoultanously. Peptides 
derived by digestion of proteins (HMW) were desalted and dried in a centrifuge vacuum, 
resuspended in 10 µL of solvent A (2 % ACN, 0.1% formic acid) and quantified with 
NanoDrop Spectrophotometer (Thermo Scientific). 
3.14.1.2 Mass spectrometry 
4µl of each sample were loaded at max pressure of 900 bar on a QExactive-HF mass 
spectrometer (Thermo Fisher Scientific) coupled with an UHPLC Easy-nLC 1000 (Thermo 
Scientific) with a 25 cm fused-silica emitter of 75 µm inner diameter. Columns were 
packed in-house with ReproSil-Pur C18-AQ 1.9 µm beads (Dr Maisch Gmbh, 
Ammerbuch, Germany) using a high-pressure bomb loader (Proxeon, Odense, Denmark). 
Peptides separation was achieved on a linear gradient from 95% solvent A (2% ACN, 0.1% 
formic acid) to 50% solvent B (80% acetonitrile, 0.1% formic acid) over 33 min and from 
50 to 100% solvent B in 2 min at a constant flow rate of 0.25 µl/min. MS data were 
acquired using a data-dependent top 15 method for HCD fragmentation. Survey full scan 
MS spectra (300–1650 Th) were acquired in the Orbitrap with 60000 resolution, AGC 
target 3e6, IT 20ms. For HCD spectra, resolution was set to 15000 at m/z 200, AGC target 
1e5, IT 80ms; Normalized Collision energy 28% and isolation with 1.2 m/z. Technical 
replicates were conducted on the LC–MS-MS part of the analysis. 
3.14.1.3 Database Searching 
Data acquisition was controlled by Xcalibur 3.1. Mass spectra were analyzed using 
MaxQuant software (version 1.5.2.8). Search parameters were set to an initial precursor ion 
tolerance of 10 ppm and MS/MS tolerance at 20 ppm. For LMW enzyme specificity was 
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set to unspecific and methionine oxidation was set as variable modification. For HMW  
enzyme specificity was set to Trypsin, maximum missed cleavage 2, fixed modification 
carbamidomethylation, variable modification oxidation, and protein N-terminal 
acetylation. The spectra were searched by the Andromeda search engine in MaxQuant 
against the Uniprot_CP_Mouse_2016 or the Uniprot_CP_Human_2017 or Uniprot_Canis-
lupus-familiaris_CP_2017 sequence database. Label-free analysis was carried out, 
including a ‘match between runs’ option imposing the following parameters: quantification 
based on extracted ion chromatograms with minimum ratio count of 1 for LMW or of 2 for 
HMW, peptide and protein false discovery rates (FDRs) were set to 0.01 and the minimum 
required peptide length was set to 7 amino acids for LMW and to 6 ammino acids for 
HMW. The reversed sequences of the target database were used as decoy database. 
Comparative analyses were performed using the Perseus software (version 1.5.1.6). 
Missing values were replaced by random numbers drawn from a normal distribution by the 
function ‘imputation’ (width 0.3, down shift 1.8, separately for each column).For all the 
statistical analysis a t-test analysis was performed imposing a p-value of 0.05.  
LMW peptides were also analyzed by Proteome Discover (version 1.4.0.288, Thermo 
Fisher Scientific). MS2 spectra were searched with Mascot ver. 2.3.02 engine against 
uniprot_CP_Mouse database or the Uniprot_CP_Human_2017 or Uniprot_Canis-lupus-
familiaris_CP_2017 sequence database. Enzyme specificity was set to unspecific and 
methionine oxidation was set as variable modification. Peptide tolerance 10 ppm, MS/MS 
tolerance 20 mmu. Peptide Spectral Matches (PSM) were filtered using percolator 
imposing the following parameters peptide score > 20, peptide length > 7 ammino acids. 
3.14.1.4 XCMS  
XCMS Online applies a specific algorithm to filter and identify peaks from the MS1 scan 
and to match peaks across samples then it performs a two-group comparisons to match the 
independent dataset, “control” versus “disease” experimental design. Data derived by 
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Orbitrap QExactive-HF mass spectrometer (Thermo Fisher Scientific) were converted into 
mzXML format and loaded for two group comparison into two data-sets Salmonella and 
untreated. For features detection by CentWave Method, the parameters were set as follow: 
ppm=10; minimum peak width=5; maximum peak width=20. Retention time correction 
was performed by obiwarp methodology. Statistics applied was unpaired parametric t-test 
(Welch t-test) and features were selected imposing the following parameters: pvalue<0.01 
fold change>3 Intensity precursor>2x106. 
1.14.2 MALDI-TOF Mass spectrometry 
Matrix-assisted laser desorption ionization (MALDI) mass spectra were acquired on 4800 
MALDI-TOF/ TOF mass spectrometer (Applied Biosystems, Foster City, CA) equipped 
with a nitrogen laser operated at 336nm laser, averaging 2500 laser shots in a random, 
uniform pattern. Ions were accelerated with a 20 kV pulse, with a delayed extraction period 
of 170 ns. Spectra were generated by averaging between 200 and 400 laser pulses. Laser 
intensity was set to optimize the signal-to-noise ratio and the resolution of mass peaks of 
the analyte. Acquisition was in positive reflector mode in the mass range m/z 700-4000 
when samples were crystalized on alpha-ciano-hydroxycinnamic acid matrix while it was 
in the mass range of m/z 2000-21000 when samples were crystalized on sinapinic acid 
matrix. All spectra were internally calibrated and processed via the Data Explorer (version 
4.9) software. 
3.14.3 SACI-ESI_MS 
A liquid chromatography Surface-Activated Chemical Ionization/Electrospray Ionization 
(LC-SACI-ESI) was employed to overall characterize the composition of supernatants 
derived from murine melanoma cells treated with Salmonella or left untreated. Instrument 
analysis was performed using an Orbitrap mass spectrometer (ThermoFisher) coupled with 
a SACI/ESI source (Albini et al. 2015). Full-scan spectra were acquired in the wide range 
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of 40–3500 m/z for non-targeted metabolomics to detect all analyte and calibration m/z 
signals. Ion source parameters used were as follows: ESI capillary voltage 1500 V, SACI 
surface voltage 47 V, drying gas: 2 L/min, nebulizer gas: 80 psi and temperature: 40°C. 
 
3.15  Clinical protocol for the treatment of dogs affected by spontaneous 
osteosarcoma or by high grade sarcoma with peptides released from tumor cells upon 
Salmonella infection. 
3.15.1 Primary canine osteosarcoma cells derivation  
Primary canine osteosarcoma cells were obtained from dissociation of dog’s osteosarcoma 
specimens. Tissues were minced with a scalpel in a cell strainer. Cells were washed with 
DMEM (supplemented with 10% FBS, 2 mM L-Glutamine, 100 U/ml Penicillin, 100 
mg/ml Streptomycin) and filtered with a cell strainer (100 µM). Cells were counted and 
cultured at high concentration in complete medium. As soon as cells grew, they were 
expanded and infected with Ty21a as described above (Chapter 3.3). Supernatants derived 
from untreated tumor cells (ON) and from Salmonella-treated tumor cells (Ty21a ON) 
were then lyophilized. Each vaccination dose consist of supernatant derived from 2x106 
cells. 
3.15.2 Dog-patients vaccination procedure 
Patients undergo standard chemotherapy treatment consisting of 4 cycles of Carboplatin 
(every 3 weeks). Following the second carboplatin cycle, vaccine is administered for a 
total of 6 injections: 2 NONE and 4 Ty21a. Only for the first and the second immunization, 
lyophilized vaccine is solved in Nobivac (used as adjuvant) and given intradermically 
following Aldara cream administration at the vaccine-injection site. At different time 
points blood withdraws and DTH test are performed. Description and scheme of the 
protocol is reported below: 
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Figure 3-2 Schedule of the clinical trial. OSA and SA patients enrolled in the clinical 
trial underwent standard chemotherapy cycles (Carboplatin) and were additionally 
vaccinated as described in the figure. 7-months treatments include vaccinations, DTH test, 
and blood withdraw for PBMCs isolation and sera analysis. 
  
Months
Weeks 1 2 3 4 5 6 7 8 9 10 11 12
Carboplatin 1
Carboplatin 2
Carboplatin 3
Carboplatin 4
Vax-a 1a 2a+1b
Vax-a+-b Blood8T0 Blood8T1
Months
Weeks 13 14 15 16 17 18 19 20 21 22 23 24
Vax-b 2b 3b 4b
Blood8T2
DTH
Months
Weeks 25 26
Vax-b 5b
Blood8T3
Note
Vax-a)
Vax-b)
Blood
DTH
2 3
4 5 6
Nobivac?Lepto
SN8OSA8cells8ON
SN8OSA8cell8TY21a8ON
Nobivac?Lepto8+8SN8OSA8cells8ON
SN8OSA8cell8TY21a8ON
Prelievo8(PBMC8+8Siero)
Scheda8Trattamento8Canine8OSA8888888888888
Vax8ciclo81)82x8ogni83w888888888888888888888888
Vax8ciclo82)84x8ogni84w
Vax-ciclo-1
Vax-ciclo-2
Vax-ciclo-2
Water
7
1
54 
 
4.  RESULTS 
4.1 Murine melanoma B16 cells upon Salmonella infection release 
peptides that if combined as prophylactic vaccine induce a strong 
antitumor response 
4.1.1 Murine melanoma cells infected with Salmonella activate membrane 
hemichannels 
Salmonella infection of murine tumor cells leads to the overexpression of Cx43 (Saccheri 
et al. 2010), the most abundant and ubiquitous component of plasma membrane 
hemichannel (Neijssen et al. 2005; Mendoza-Naranjo et al. 2007). Bacteria-treated tumor 
cells have been shown to establish gap junctions (GJ) with dendritic cells (DCs) by the 
docking of two plasma membrane hemichannels, allowing the transfer of pre-processed 
antigens from the tumor cells to the DCs (Saccheri et al. 2010). It is known that Salmonella 
up-regulates hemichannels expression on tumor cells, hence, we hypothesized that 
infection of tumor cells with this bacterium may lead to extracellular release of peptides 
that could be used as anticancer vaccine.  
A necessary condition for peptides release through hemichannels is hemichannel activation 
(Weber et al. 2004); it has been previously shown that if hemichannels get activated, an 
hemichannel-dependent ATP release occurs (Kang et al. 2008). Hence to verify whether 
Salmonella infection of tumor cells leads to hemichannels opening we infected the mouse 
melanoma B16 cell line, a melanocytic and non-immunogenic melanoma cell line 
(Overwijk & Restifo 2001), and we monitored ATP release. B16 cells were treated with 
Salmonella Thiphimurium SL3216AT for 90 min; the infection was stopped by the 
addiction of gentamycin and after 4 hours we analysed the extracellular ATP content. 
Conditioned media from Salmonella-infected melanoma cells (B16 AT, Figure 4-1) was 
characterized by a higher amount of ATP compared to medium of untreated cells. 
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Importantly, the pre-treatment of B16 cells with the hemichannel inhibitor heptanol 
reduced ATP release to baseline levels. This data suggests that ATP was specifically 
released through hemichannels. The same findings were obtained treating with Salmonella 
the murine B16-OVA melanoma cell line, a melanoma cell line that expresses the 
exogenous protein Ovalbumin. Both results demonstrate that Salmonella treatment of 
murine tumor cells leads to hemichannel activation suggesting that peptide release might 
occur as well. 
 
Figure 4-1. Bacteria-treated murine tumor cells functionally open hemichannels. 
Functional hemichannels opening was assessed performing an ATP assay. Both mouse 
melanoma cell line B16 and B16-OVA were treated with Salmonella Thiphimurium 
SL3216AT (AT) in presence or absence of the hemichannel blocker heptanol (Hept.). The 
derived supernatants were analysed for ATP content. **p<0.05 1-way-ANOVA test 
Bonferroni post test, (n=3). 
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4.1.2 Murine melanoma cells infected with Salmonella release potentially 
immunogenic peptides 
Tumor antigens expressed by tumor cells on their MHC molecules are small peptides (7-13 
amminoacids) that mainly derive from the intracellular processing of large proteins by 
proteasome enzymes (Leone et al. 2013). Only peptides that fit into the spatial constrain of 
MHC pocket can bind to it and only some of these peptides activate an immune response. 
To assess whether Salmonella infection could lead to the extracellular release of 
immunogenic peptides, we used murine B16-OVA cell line, a cell line that expresses 
Ovalbumin protein intracellularly. Ovalbumin processing by cell proteasome induces the 
release of peptides that can be exposed on the cell surface combined with MHC class I and 
II molecules. Hence, we wanted to address whether following Salmonella infection release 
of OVA-derived peptides could be found in the conditioned media. In order to do so we 
decided to follow two different strategies. First, we decided to test the ability of B16-OVA 
supernatants to activate CD8a+ lymphocytes derived from OTI mice. OTI are transgenic 
mice whose CD8a+ cells are restricted for the recognition of OVA257-264 the 
immunodominant class I peptide derived from the proteasome cleavage of Ovalbumin 
(Ben-Shahar et al. 1999). Second, knowing the OVA sequence, we wanted to detect OVA-
derived peptides by a mass spectrometry approach. 
B16-OVA cells were treated with Salmonella (as described in Chapter 3.3). Briefly, cells 
were deprived of serum and antibiotics and treated with Salmonella for 90 min. Infection 
was stopped incubating cells with fresh medium added with gentamycin; the lack of serum 
was maintained for the entire experiment to avoid serum-derived proteins inside cells’ 
supernatants that could interfere during the following analysis. After the overnight 
incubation, supernatant of Salmonella-treated and untreated cells were collected, peptides 
were enriched following an optimized TCA-based protocol and fractionated by Sep-pak 
C18 device, a silica-based bonded phase with strong hydrophobicity (as explained in: 
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Annex 4.5.1). The different fractions were obtained using as elution buffer, increasing 
percentages of Acetonitrile-based solution, ranging from 5% to 80%. Dendritic cells 
loaded with Salmonella-derived-supernatant-fractions for 4 hours specifically induced 
IFN-γ production by OTI-CD8a+ lymphocytes (Figure 4-2). The specific OTI-CD8a+ cell 
activation highlighted in the supernatant the presence of the OVA257-264, the most 
immunogenic class I peptide derived from the proteasome cleavage of Ovalbumin. This 
suggests that Salmonella induces the release of potentially immunogenic peptides from 
tumor cells.  
 
Figure 4-2. B16-OVA cells infected with Salmonella release peptides leading to the 
activation of CD8a+-OTI cells in vitro. Murine dendritic cells (D1) were loaded for 4 
hours with fractions of supernatants derived from untreated (NONE) or Salmonella-
infected B16-OVA cells (AT). Following 72 hours of co-culture, OTI-CD8+ cells 
activation was assessed measuring IFN-y release by ELISA. B16 derived supernatants 
were assessed as negative control. Results of one representative experiment out of four are 
shown. 
 
The stress induced by 18 hours of starvation of the protocol used could have promoted the 
release of peptides in the extracellular space even from untreated cells. The percentage of 
dead cells both in untreated and in Salmonella infected cells was detected by FACS using 
Annexin+PI+ staining. The percentage of late apoptotic cells after 18 hours was around 
58 
 
20%; thus, indicating that the presence of OVA257-264 in the supernatant of Salmonella-
infected B16-OVA cells was not due to an augmented cell mortality (Figure 4-3).  The 
release of OVA257-264 was further confirmed by nano-scale liquid chromatographic tandem 
mass spectrometry  combined with electrospray ionization (nLC-ESI-MS/MS , Figure 4-
4). OVA-peptide was detected as double charge (m/z=482,28) inside all the fractions that 
activated OTI-CD8a+ cells. nLC-ESI-MS/MS spectrum of (m/z 482.28, z = +2) confirmed 
OVA257-264 identity (sequence: SIINFEKL). 
 
Figure 4-3Salmonella treatment of B16-OVA cells do not alter cell vitality. 
Representative Annexin staining performed to check mortality of cells at the end of 
protocol used to induce peptides release by tumor cells: thus after 18 hours from 
Salmonella infection, during which cells are maintained in starvation. Vital cells are 
showed as Annexin-PI- cells, cells undergoing apoptosis mark as Annexin+PI- while 
necrotic cells stain as Annexin+PI+. 
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Figure 4-4. B16-OVA cells infected with Salmonella release peptides among which the 
immunogenic OVA-derived peptide SIINFEKL. Full nLC-ESI spectrum [300-1650 Da] 
at 53.3 min of B16-OVA-derived supernatant. OVA257-264 (sequence: SIINFEKL) is mostly 
detected as double charge m/z=482.28 z=2. nLC-ESI-MS/MS spectrum of (m/z 482.28, z = 
+2) confirmed OVA257-264identity.  
 
4.1.3 Dendritic cells loaded with peptides released by Salmonella-infected tumor 
cells boost an immune response in vivo 
Immunogenicity is the ability of an antigen to boost an immune response tailored against 
cells that expose that specific antigen. To assess whether the peptides released by tumor 
cells following Salmonella infection are immunogenic, we tested their ability to induce an 
antitumor response in vivo. From an immunologic standpoint, DCs-based immunotherapy 
carries the highest potential of inducing effective anticancer immune responses since DCs 
are key players in the activation of T cells (Steinman & Banchereau 2007). Notably DCs 
process antigens through the immune-proteasome, that differs in structure and function 
from the proteasome of tumor cells; hence, antigens derived from DCs are not necessarily 
the same as the ones produced by the tumor cells (Morel et al. 2000). However besides 
picking up and processing antigens themselves, DCs are also able to acquire exogenous 
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antigens and to induce T cell activation via cross-presentation (Joffre et al. 2012). Antigens 
derived from the treatment of B16 cells with Salmonella were directly processed by tumor-
proteasome therefore they have a high probability to match the ones exposed by tumor 
cells on their own MHC molecules. Simulating the antigen uptake by DCs that happens in 
vivo, we loaded DCs with the peptides derived from the treatment of tumor cells with 
Salmonella and we used them to immunize mice. 
Two different methodologies to concentrate peptides were compared. In the first 
methodology, supernatant derived from the equivalent of 2x106 Salmonella-infected cells 
was concentrated and desalted using a Sep-Pak-C18 device and the derived peptides were 
used for each immunization (Vax). In the second methodology, the supernatant derived 
from the equivalent of 2x106 Salmonella-infected cells was simply lyophilized and the 
derived peptides were dissolved in water and used for each immunization (Lyoph). 
We preventively vaccinated 6 weeks old mice (C57J/BL6) three times, specifically at day 
0, 4 and 11. Four weeks later, we challenged mice with 105 B16 cells (Figure 4-5A). Mice 
immunized with DCs loaded with peptides derived from B16 cells infected with 
Salmonella (DCs Vax and DCs lyoph) showed a trend of delayed tumor growth and a 
longer overall survival (Figure 4-5B-D) compared to the mice vaccinated with DCs alone. 
The delayed tumor growth was evident particularly in the late phase of growth (Figure 4-
5B) suggesting that the recall of the immune response induced by the vaccination was not 
immediate. This might be due to the fact that immunization were performed 4 weeks 
before tumor cells injection; the antitumor effect became visible in terms of tumor growth 
delay but eventually the tumor escaped control. No major differences in term of survival 
were observed between vaccination based on peptides released by tumor cells treated with 
Salmonella that were enriched by lyophilization (DC-lyoph) or by the use of Sep-Pak C18 
device (DCs-Vax); thus, both methods are suitable to concentrate peptides. Interestingly 
vaccination with DCs loaded with two well-known melanoma antigens Trp2180-188 gp10025-
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33 induced only a mild tumor growth delay (Figure 4-5B) mirrored by a little amelioration 
in term of survival (Figure 4-5E). 
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Figure 4-5 Dendritic cells loaded with peptides released by Salmonella-treated B16 
cells induce an antitumor response in vivo. (A) Scheme of the schedule used to assess 
peptides immunogenicity in vivo. Immunization with dendritic cells loaded with peptides 
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were performed at day 0, 4 and 11. 105 B16 cells were injected subcutaneously at day 40. 
(B) Tumor volume growth of C57J/BL6 mice that underwent to different immunization 
protocol. Mice were immunized with dendritic cells alone (DCs), dendritic cells loaded 
with murine melanoma antigens Trp2180-188 gp10025-33 (DC Trp2 gp100), dendritic cells 
loaded with peptides released by of Salmonella-treated B16 cells that were lyophilized to 
be concentrated (DC lyoph), dendritic cells loaded with peptides released by of 
Salmonella-treated B16 cells that were processed on Sep-pak C18 to be concentrated (DC 
Vax); a group of mice was not immunized (untreated)  (C-E) Growth Kaplan–Meier 
survival curves of C57J/BL6 mice (n=6-12 animals per group) differently vaccinated. 
Tumor growth was monitored every two days and mice were sacrificed once tumor volume 
reached cm3. (Log-rank Mantel-Cox test was performed to assess differences among 
survival curves. Two way ANOVA followed by Bonferroni post-test *p<0,05 **p<0,01 
***p<0,001) 
4.1.4 Peptides release by tumor cells following Salmonella infection do not exert an 
adjuvant effect per se 
Peptides released by tumor cells following Salmonella infection might have a direct effect 
on dendritic cells altering their activation status. In order to evaluate the possible adjuvant 
effect exerted by peptides on DCs, we loaded on a murine dendritic cell line (D1) the 
supernatant derived from Salmonella infected B16 cells and we analyzed the expression of 
surface activation markers (CD40 and CD86). Activation of D1 was not detectable neither 
following incubation with supernatant derived from Salmonella infection of B16 cells (B16 
Vax NS) nor following the incubation with the same supernatant but processed by Sep-Pak 
C18 (B16 Vax Sep-pak), step that we usually perform to concentrate peptides (Figure 4-
6A). The same very low percentages of CD40+ or CD86+ cells were detected incubating 
DCs with supernatant derived from untreated B16 cells (B16 None NS, B16 None Sep-
Pak). Consistently we found that peptides released by tumor cells following Salmonella 
infection or by untreated tumor cells do not have any adjuvant effect on human primary 
dendritic cells: monocyte derived dendritic cells (MoDCs) (Figure 4-6B). No significant 
changes in the percentage of activated MoDCs (HLA-DR+CD86+CD206-) were observed. 
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In all the tests LPS treatment was performed as positive control to induce DCs activation 
(Figure 4-6A-B). 
 
Figure 4-6. Cells supernatants derived from Salmonella-treated tumor cells do not activate 
dendritic cells. Supernatants derived from Salmonella-treated melanoma tumor cells (B16 
Vax) and untreated cells (B16 None) were collected. Half of their volume was stored 
untouched (NS- not separated) and the second half was loaded on Sep-Pak C18 membrane 
(Sep-pak). After washing with 0.01%Formic Acid solution to remove salts, protein and 
peptides were eluted with 80%Acetonitrile solution. Samples were dried by speed-vacuum 
and solved in an appropriate volume of dendritic cells (DCs) medium. (A) Both TQ and 
Sep-pak-derived supernatants were loaded on an established murine dendritic cell line 
(D1); its activation state was evaluated by the expression of CD40 and CD80 markers. (B) 
B16/B16 Vax-derived supernatants were also incubated with primary human DCs: 
monocytes-derived DCs (moDCs); their activation state was determined by the expression 
of HLADR+CD86+CD206-.   
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4.1.5 Salmonella induces tumor cells to release peptides that boost an immune 
response in vivo 
A pivotal role in modulating the antitumor effect of immunogenic peptides is exerted by 
adjuvants since they can tailor the immune response by recruiting immune cells at the 
immunization site and inducing their activation (Christian Bode 2011; Aucouturier et al. 
2002). We tested the amplitude of the antitumor response induced by peptides derived 
from Salmonella-treated-B16 cells (Vax) combined with two different adjuvant 
formulations: ODN1826 (CpG) and Incomplete Freud’s Adjuvant (IFA) + Aldara. 
ODN1826 is a TLR9 agonist while IFA is an oily solution that allows gradual release of 
antigens and Aldara (Imiquimod) is a TLR7 agonist. The immunogenicity of peptides 
derived from untreated cells was also assessed as control (GpG-NONE/IFA Aldara 
Control). The dose of peptides was the same used for the first experiment thus equivalent 
to the peptides derived from 2x106 tumor cells (Vax/dose2). In order to evaluate whether 
peptides’ concentration could influence the immune response we also tested a lower and a 
higher dose of peptides but only combined with IFA and Aldara; respectively peptides 
derived from 1x106 (Vax/dose1) and 5x106 (Vax/dose3) Salmonella-treated B16 cells. The 
schedule adopted was equivalent to the schedule followed for the first in vivo experiment 
(Figure 4-5A). 
Mice vaccinated with peptides released by Salmonella-treated tumor cells conjugated with 
CpG (CpG Vax) and with the higher dose of peptides combined with IFA Aldara (IFA-
Aldara Vax/dose3) had a significant prolonged survival compared with their control group 
(respectively CpG and IFA-Aldara) (Figure 4-7C, F). The administered doses of peptides 
positively correlated with the amplitude of the antitumor response both in terms of overall 
survival (Figure 4-7D-F) and tumor growth delay (Figure 4-8B). Peptides derived from 
untreated cells (Control), either conjugated with CpG or IFA-Aldara, had no effect on 
tumor growth  (Figure 4-8-A,B) suggesting once more that the antitumor response induced 
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by IFA-Aldara Vax/dose3 and CpG Vax rely on the peptides specifically release by tumor 
cells following Salmonella infection. 
 
Figure 4-7. Peptides released by Salmonella-treated B16 cells in combination with 
either IFA-Aldara or CpG induce an antitumor response in vivo. Kaplan–Meier 
survival curves of C57J/BL6 mice vaccinated with peptides derived from untreated cells 
(Control) in combination with IFA-Aldara (A) and CpG (B). Survival curve of mice 
vaccinated with peptides derived from 2x106 B16 cells infected with Salmonella and 
combined with CpG (C). Survival curves of mice vaccinated with increasing doses of 
peptides derived from Salmonella infected B16 cells, 1x106 cells (D), 2x106 (E), 5x106 (F), 
combined with IFA-Aldara. (Log-rank Mantel-Cox test was performed to assess 
differences among tumor growth curves). 
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Figure 4-8. Peptides released by Salmonella-treated B16 cells in combination with 
either IFA Aldara or CpG induce an antitumor response in vivo. C57J/BL6 mice were 
vaccinated subcutaneously 3 times (at day 0, 4 and 11) and then at day 40, 105 B16 cells 
were injected at the flank opposite to the vaccination. Tumor growth was assessed every 
two days measuring the x and the y dimension. (A) Tumor growth curves of C57J/BL6 
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mice (n =8+) vaccinated with peptides combined with CpG. Mice vaccinated with peptides 
derived from untreated cells (CpG Control), with peptides derived from 2x106 B16 cells 
infected with Salmonella (CpG VAX), with CpG alone (CpG). Tumor growth of not 
vaccinated mice is represented as black dashed line. (B). Tumor growth curves of 
C57J/BL6 mice vaccinated with peptides combined with IFA-Aldara. Mice vaccinated 
with increasing doses of peptides derived from Salmonella infected B16 cells, 1x106 cells 
(Vax/dose1), 2x106 (Vax/dose2), 5x106 (Vax/dose3), vaccinated with supernatant of 
untreated cells (IFA-Aldara Control), vaccinated with IFA-Aldara alone (IFA-Aldara). 
Tumor growth of not vaccinated mice is represented as black dashed line. (Two way 
ANOVA followed by Bonferroni post-test *p<0,05 **p<0,01 ***p<0,001) 
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4.2 Human melanoma cell lines infected with Salmonella release 
peptides that induce the expansion of CD8-T cell from peripheral blood 
mononuclear cells that specifically kill human melanoma cells in vitro.  
4.2.1 Salmonella infection of tumor cells induces a hemichannel-mediated peptide 
release 
Salmonella induces mouse tumor cells to release immunogenic peptides that stimulate an 
antitumor immune response in vivo. We asked whether Salmonella could exert the same 
effect on human tumor cells. To address this question, we took advantage of the T2 cell in 
vitro system, suitable to assess peptide-enrichment inside the Salmonella-conditioned 
media (Hosken & Bevan 1990). T2 cells are HLA-A0201 restricted lymphoblastic cells 
that are deficient for the transporter associated with antigen processing (TAP) (Leone et al. 
2013; Durgeau et al. 2011). Without TAP-mediated transport of cytosolic peptides into the 
endoplasmic reticulum (ER), assembled class I complexes are structurally unstable and 
retained only transiently at the cell surface. However once T2 cells are exposed to a 
solution containing peptides capable to bind HLA-A0201 molecule, surface HLA are 
stabilized (Hosken & Bevan 1990). The expression of HLA-A0201 molecules detected the 
surface of T2 cells is proportional to the number of antigens inside the solution in which 
are cultured. 
To evaluate whether Salmonella-treated tumor cells released HLA-A0201-binding 
peptides, we treated both the human colon cancer cell line HT29 and the human melanoma 
cell line SkMel24, with the vaccine strain of Salmonella enterica serovar Typhi (Ty21a); 
then, the conditioned-medium was added to T2 cells (Figure 4-9A). T2 cells cultured with 
the supernatant from Salmonella-infected SkMel24 cells showed a significantly higher 
expression of HLA-A0201 compared to T2 cells cultured with conditioned media of 
untreated cells (Figure 4-9B). Interestingly, peptide enrichment was completely lost once 
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the hemichannel blocker heptanol was added to the system, suggesting that peptide release 
was mainly hemichannel-mediated. We hypothesize that the Salmonella-induced peptide 
release might be a shared mechanism among tumour cells since it also occurred in human 
adenocarcinoma HT29 cells infected with Salmonella Ty21a (Fig.4-9B). To confirm that 
the higher HLA-A0201 expression on T2 cells correlated with the higher antigen 
concentration inside the supernatants, we loaded T2 cells with two different concentrations 
of the HLA-A0201-resctricted peptide Mart-1 (Kawakami et al. 1994); also in this case the 
higher amount of Mart-1 lead to a higher HLA-A0201 signal (Fig.4-9B). 
 
Figure 4-9. Salmonella-treated tumor cells release peptides through hemichannels. 
Functional hemichannels opening was assessed performing a T2 binding assay. A Scheme 
of the performed T2 assay. B Human melanoma cells (Skmel24) and adenocarcinoma cell 
line (HT29) were treated with Salmonella enterica serovar Typhi (Ty21a) and the derived 
supernatants were added to T2 cells. As a positive control, an increasing amount of Mart-1 
peptide was added to T2 cells. HLA-A0201 expression was detected after 24 hours of 
incubation. (The Student's t-test was used for statistical analysis*p<0.05,**p<0.01, 
***p<0.001, (n=4)). 
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4.2.2  Peptides released by 62438 human melanoma cell line upon Salmonella 
infection induce the expansion of CD8-T cell from PBMCs  
We showed that both human and mouse tumor cells can release peptides once stimulated 
with Salmonella; in order to verify whether among the peptides released by human tumor 
cells some are immunogenic, we tested their capability to activate antigen-specific-CD8+ T 
cells starting from peripheral blood mononuclear cells (PBMCs) of healthy donors. Indeed, 
in the blood of healthy people there are circulating CD8+ T-lymphocytes whose TCR 
recognize tumor antigens; since the frequency is estimated to be very low (Gros et al. 
2016), usually several stimulations with a known tumor antigen are required to expand a 
specific CD8+ T cell population. We infected the HLA-A2-restricted human melanoma cell 
line 62438 with Salmonella enterica serovar Typhi (Ty21a) and we used the derived 
supernatant to stimulate PBMCs isolated (Chapter 3.9) from blood of an HLA-A2+ 
healthy donor. In parallel, we stimulated PBMCs with the known HLA-A2 restricted 
melanoma antigen Mart-1. Every 10 days CD8+ lymphocytes were enriched by magnetic 
column separation and further stimulated with HLA-A2-matched irradiated PBMCs loaded 
either with Mart-1 or with peptides released by Ty21-infected 62438 cells. At every 
stimulation, we tested the capacity of the CD8+ lymphocytes stimulated by peptides 
released by 62438 cells (CTL2_SUP) to recognize antigens presented by 62438 (the tumor 
cells from where peptides-were derived). Increasing frequencies of IFN-ɣ expressing CD8+ 
lymphocytes were detected over time in response to their co-culture with 62438 cells 
(Figure 4-10). Moreover after 4 stimulations, CTL2_SUP had a mild cytotoxic response 
against 62438 cells (Figure 4-11) further proved by the augmented expression of the 
degranulation marker CD107a (Figure 4-10-3rd stimulation). For the Delfia-cytotoxicity 
test (Figure 4-11) two different ratios of effector cells (CTLs) and target cells (62438) 
were assessed; respectively 25:1 and 12.5:1. The observed killing activity correlated with 
the number of effector cells used in the test. Importantly, the activation of CD8+ 
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lymphocytes against 62438 was specifically mediated by the recognition of HLA-antigen 
complex as the same lymphocytes did not get activated once incubated with 62428, a 
melanoma 62438 cell-derivative lacking HLA-A2 molecule. Clusters formed by the 
activated CD8+ T cells were clearly visible; Mart-1-induced clusters were usually larger 
and expanded more rapidly than the clusters stimulated by peptides released by tumor cells 
following Salmonella infection (Figure 4-12).  
 
Figure 4-10.  Peptides released by human melanoma cells following Salmonella 
infection induce the expansion of CD8+ T cells from healthy donor’s PBMCs. Peptides 
released by Salmonella infected human melanoma 62438 cells were used to stimulate 
PBMCs isolated by the blood of healthy donors (SUP). In parallel the melanoma antigen 
Mart-1 was used to stimulate the expansion of CD8+ T cells as positive control (Mart-1). 
At every stimulation aliquots of expanded CD8+ lymphocytes were co-cultured with 62438 
tumor cells at 1:1 ratio (from where peptides-were derived) and their activation was 
assessed measuring IFN-ɣ and CD107 expression. HLA-negative human melanoma cells 
line 62428 were used to verify the specificity of the activation. Each graph referrers to one 
independent experiment. 
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Figure 4-11.  Peptides released by human melanoma cells following Salmonella 
infection induce the expansion of CD8+ T cells that kill tumor cells from where 
peptides were derived. Peptides released by Salmonella infected human melanoma 62438 
cells were used to stimulate PBMCs isolated by the blood of healthy donors (SUP). In 
parallel, the melanoma antigen Mart-1 was used to stimulate the expansion of CD8+ T cells 
as positive control (Mart-1). After three stimulations, expanded CD8+ lymphocytes were 
co-cultured with 62438 tumor cells and their killing ability was assessed by Delfia assay 
using two different ratios of effector:target cells (1:25 and 1:12.5). Samples were tested in 
duplicates. HLA-negative human melanoma cells line 62428 were used to verify the 
specificity of the killing. Graph referrers to one independent experiment. 
 
Figure 4-12. Peptides released by human melanoma cells following Salmonella 
infection induce the expansion of CD8+ T. Pictures of representative clusters formed 
stimulating healthy donor’s PBMCs with peptides derived from Salmonella infected 62438 
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human melanoma cell line (CTL-SUP) and with the known melanoma antigen Mart-1 
(CTL-Mart-1). 
4.3 From bench to patients: translating our vaccine strategy into clinical practice 
4.3.1 Salmonella-derived peptides-based vaccine prolongs survival of osteo/sarcoma 
affected dogs 
To translate our immunotherapy vaccine strategy into a patient anticancer treatment, we 
started to collaborate with a veterinary clinic. Dogs with osteosarcoma and high-grade 
sarcoma are being treated with an autologous vaccine formulation with the purpose of 
promoting a specific antitumor response, that can prevent tumor relapse and increase 
survival. Osteosarcoma (OSA) is the most common bone primary tumor in dogs, 
comprising up to 85% of all reported bone neoplasia (Mirabello et al. 2009). Median 
survival times approach 4–5 months with amputation alone (Mirabello et al. 2009), and 
adjuvant chemotherapy improves median survival times to 8–12 months (Selmic et al. 
2014). Despite the use of various chemotherapy protocols and novel treatment approaches, 
clinically meaningful improvements in survival have not been achieved and 90% of dogs 
die of metastatic disease within 2 years from treatment (Wycislo & Fan 2015). Differently 
high grade sarcoma (SA) dog patient’s life expectancy is between 3 and 6 months from 
diagnosis (Dennis et al. 2011; Frezza et al. 2017). The clinical trial protocol is explained in 
details in the method section (Chapter 3.15.2) and schematically represented in Figure 4-
13. Briefly, patients diagnosed with OSA or high-grade SA were surgically operated for 
tumor resection; we derived SA/OSA cells from patient’s tumor biopsy, kept them in 
culture and infected them with Salmonella. Cell supernatants were filtered and lyophilized 
to be combined with a veterinary adjuvant (Leptospirosis vaccine) and a topically delivered 
TLR9-agonist Imiquimod (Aldara) for the first 2 immunizations while they were 
solubilized in water for the following 4 immunizations. In total 6 intramuscular 
vaccinations were performed after 4 cycles of chemotherapy. As tumor cell-isolation was 
not successful in two patients (OSA0 and OSA42), these were treated with a heterologous 
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vaccine formulation. Our choice is supported by data from literature that show how 
heterologous vaccines can induce a higher immune response than autologous once 
(Schadendorf et al. 2000; Selvaraj 2014).  
 
Figure 4-13. Pipeline of the clinical trial. Dog patients diagnosed with OSA or high-
grade SA were surgically operated for tumor resection (1); SA/OSA cells from patient’s 
tumor biopsy were derived (2) and kept in culture to infect them with Salmonella(3). Cell 
supernatants were filtered and lyophilized to be either combined with Leptospirosis 
vaccine and a topically delivered Imiquimod or solved in water; vaccinations were 
performed either in autologous setting (4a) or in heterologous setting (4b). 
Since our collaboration started, eleven patients have been treated, eight with osteosarcoma 
and three with high grade sarcoma (Figure 4-14). Of the osteosarcoma patients, one is still 
under vaccination, four died before completing the vaccination, two out of three patients 
that completed the vaccination died within the life expectancy period (367 and 390 days 
after diagnosis) and one patient had a long overall survival, dying after 653 days for 
reasons not related to the tumor. With regard to the sarcoma affected dogs, one patient is 
alive and still within life expectancy period while one patient died without improvement of 
the overall survival; the third patient is alive after more than 1400 days and survived also 
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to a recurrence of disease that was again treated with vaccination, showing that a marked 
antitumor response had been promoted.  
 
Figure 4-14. List of the patients involved in the clinical trial. In a clinical setting, dogs 
affected by spontaneous high-grade sarcoma or osteosarcoma have been treated with 
vaccines obtained following our strategy. Primary ostosarcoma/sarcoma cells were 
obtained from the dissociation of patient’s tumor specimen and were treated with S. 
thyphimurium. Dogs were administered with the derived vaccine following four 
carboplatin cycles (Chapter 3.15.2). 
4.3.2 Dog patients’ overall survival correlates with the presence of circulating tumor 
specific lymphocytes. 
Dog patients were constantly monitored during the clinical trial. Blood (from where 
PBMCs were derived) and sera samples were taken at different time points in order to 
perform an adequate immune-monitoring. In details, blood withdraws were done during 
the first three vaccinations and at the end of the vaccination protocol (4 months since the 
beginning). SA5 can be considered the patient that better responded to the therapy; two 
years after the vaccination protocol, a sarcoma relapse occurred but following a second 
 
77 
 
cycle of vaccination the prognosis is stable and the patient is healthy. The level of 
circulating lymphocytes able to respond to tumor cells was assessed performing a CD107a 
assay in which IFN-ɣ staining was included. Total PBMCs isolated before Sa5 was 
included in the clinical trial (Sa5 T0) and at the end of the first vaccination protocol (Sa5 
T3) were co-cultured for 5 hours with Sa5 tumor cells in a ratio 5:1 in presence of the golgi 
stop monensine. Frequency of circulating anti-tumor lymphocytes was induced by the 
vaccines (Figure 4-15). Indeed, at the end of the vaccination protocol a higher percentage 
of CD8+ T cells were activated in response to the co-culture with Sa5-tumor cells (Figure 
4-15A,B) expressing both IFN-ɣ and CD107a (marker of cytotoxicity). Similar levels of 
circulating antitumor CD8+ lymphocytes were detected when a sarcoma relapse was 
diagnosed (Sa5 Tmet0, Figure 4-15A,B) and at the end of the second vaccination protocol 
(Tmet2). Interestingly, also an antitumor specific response mediated by CD4 lymphocytes 
was boosted by the vaccine (Figure 4-15C,D). The percentage of CD4+IFN-ɣ+ cells was 
higher at the end of the immunization protocol (Sa5 Tmet2) than at the beginning (Sa5 T0). 
Contrarily to what we observed in terms of CD8+ lymphocytes response, a low level of 
antitumor CD4+ T cells was detected at the moment of sarcoma relapse diagnosis; 
positively the second immunization protocol increased the circulating anti-tumor CD4+ T 
cells (Figure 4-15C,D).  
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Figure 4-15. Vaccination of sarcoma patient with peptides derived from Salmonella 
treated patient’s derived tumor cells boosted the expansion of specific antitumor 
lymphocytes. The ability of circulating lymphocytes that recognize patient’s tumor cells 
was assessed for the duration of the clinical trial. Total PBMCs were co-cultured with 
tumor cells at a ratio (PBMCs:tumor) cells of 5:1 for 5 hours. CD107a antibody was added 
for the duration of the protocol while intracellular staining for IFN-ɣ expression together 
with the staining to distinguish CD4+ CD8+ subpopulation was performed at the end of the 
protocol.  
Moreover, we observed that circulating lymphocytes of Sa5 at the end of the immunization 
protocol had acquired also the ability to kill tumor cells (Figure 4-16A). Total PBMCs 
were co-cultured for 1h30min with Batda-labelled-tumor cells and their killing ability was 
assessed by Delfia assay (Chapter 3.13.2) using different ratio of effector:target cells 
(1:50 1:25 1:12,5 and 1:6,125). Lymphocytes’ cytotoxic effect was also observed after 
sarcoma relapse (Figure 4-16B) but the percentage of specific release didn’t increase over 
the time of the second immunization protocol. 
 
Figure 4-16. Vaccination of sarcoma patient with peptides derived from Salmonella 
treated patient’s derived tumor cells boosted the expansion of lymphocytes able to kill 
tumor cells. The ability of circulating lymphocytes to recognize and kill patient’s tumor 
cells was assessed for the duration of the clinical trial. Total PBMCs were co-cultured for 
90 min with tumor cells and their killing ability was assessed by Delfia assay (Chapter 
3.13.2) using different ratio of effector:target cells (1:50 1:25 1:12.5 and 1:6.125). 
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While CD8+ T lymphocytes are the principal mediator of an antitumor cytotoxic response, 
CD4+ T cells are responsible for B cell activation that leads to immunoglobulin production. 
Consistent with the finding that the vaccination leads Sa5 to boost an antitumor CD4+ T 
cell response (Figure 4-15C,D), a specific antitumor humoral response was equally 
induced by the vaccination (Figure 4-17).  
 
Figure 4-17. Vaccination of sarcoma patient with peptides derived from Salmonella 
treated patient’s derived tumor cells induced a humoral response against tumor cells. 
The content of tumor cell-specific IgG in the serum of Sa5 was assessed for the duration of 
the clinical trial. T0=before entering the clinical trial; T1=after one vaccination; T2=after 
two vaccinations; T3=after four vaccinations. *p<0.05 ***p<0.001 2-way-ANOVA 
Bonferroni post-test to compare T3vsT0. 
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4.4 Unravelling vaccine composition by mass spectrometry-based 
approach 
4.4.1 Identification of the peptides released by Salmonella treated tumor cells: 
samples preparation for mass spectrometry analysis. 
Salmonella induces the release of immunogenic peptides from tumor cells. Their 
identification will allow the development of a vaccine formulation of antigens with a 
strong antitumor immunity. To achieve this goal, we compared peptides released by 
Salmonella-treated tumor cells with those released by untreated tumor cells and developed 
a list of immunogenic peptide candidates. Due to the complexity of supernatant 
composition low and high molecular weight peptides were separated with a 10KDa 
centrifugation filter (filter aided sample preparation, FASP) and differently analysed. Low 
molecular weight fraction was concentrated in a centrifuge vacuum concentrator and soon 
acquired by nLC-MS, while high molecular weight fraction, containing mainly proteins, 
underwent enzymatic treatment before acquisition (see pipeline Figure 4-18). The MS-
based peptidomic approach we developed and the strategy that we propose to identify both 
tumor antigens and neoantigens are explained in the next chapter. Even though we believe 
that antigens and neoantigens (included in the low molecular weight fraction) are 
responsible for the induction of the antitumor response, a role of the proteins included in 
the high molecular weight fraction cannot be excluded. Indeed, proteins might exert an 
adjuvant function in vivo or might be taken up and processed by DCs thus contributing to 
the antitumor specific immune response. 
4.4.2 Strategy to identify tumor antigens and neoantigens released by tumor cells 
following Salmonella infection 
Aiming to identify tumor antigens among the peptides released after Salmonella infection 
we performed a mass-spectrometry based proteomic study via a Data Dependent Analysis 
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(DDA) methodology coupled with direct database search. Briefly, the 15 most abundant 
precursor ions detected by the mass spectrometer in a survey scan per millisecond (MS1) 
are selected for fragmentation (MS2). The resulting fragmented ions recorded are searched 
against Uniprot databases to have sequences identified, using two independent Database 
search engine. MaxQuant was used as platform to detect proteins and peptides significantly 
different in supernatant derived from Salmonella treated and untreated cells imposing a 
supervised analysis and a Student-T test statistical analysis. Proteome Discoverer coupled 
with Mascot were applied only to the low molecular weight fractions of samples derived 
from Salmonella treatment to identify peptides and to access the MS2 scan list of all 
annotated and non-annotated peptides. Theoretically, with this DDA-approach, we can 
identify all the tumor antigens whose sequence is derived from normally expressed 
proteins. Both tumor associated antigens (TAA), that are peptides normally encoded by the 
normal genome but aberrantly expressed by tumor cells (i.e. overexpressed) and cancer 
testis antigens (CTAs), that are peptides belonging to developmental protein whose 
expression is re-stored by cancer cells, can hence be identified. On the contrary, 
neoantigens, that are mutated peptides generated by non-synonymous mutations or other 
genetic alterations, and the recently identified spliced antigens that arise from post 
translational splicing (Hanada et al. 2004; Vigneron 2004; Warren et al. 2006), cannot be 
easily identified by this approach due to the fact that their sequence differs from normally 
expressed peptides (Mishto & Liepe 2017). These antigens have been so far identified 
tailoring the phase of database searching on customized databases of peptides usually 
derived from exome sequencing data but this approach is time consuming and suffers of 
false sequence assignment. With the aim to overcome drawbacks associated to this 
strategy, we followed a different pipeline (Figure 4-18); after DDA-analysis we focused 
on the MS1 scan. All detected signals were considered as features, meaning a combination 
of mass-charge ratio (m/q) and retention time (RT). Then we used XCMS software 
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(Tautenhahn et al. 2012) to determine the features whose levels were significantly higher 
in the supernatant derived from Salmonella-treated tumor cells compared with supernatant 
of untreated tumor cells. We identified features belonging to three different categories:  
1) Category1 (Cat1): Peptides that underwent MS2 fragmentation and that were identified 
as true PSM (Peptides Sequence Match) by the data base searching engine Proteome 
Discoverer coupled with Mascot.  
2) Category 2 (Cat2): Peptides that underwent fragmentation but were not annotated by 
Proteome Discoverer due to the parameters imposed in the search, suggesting that they 
might be either PTM-modified peptides or mutated peptides. A further ranking of these 
features was done on the basis of the comparison between the retention time (RT) 
associated to the matched m/z value in order to exclude false positive features. If the 
difference between the RT attributed by XCMS and the RT showed by PD was less than 2 
minutes, features were ranked as ClassA; if the same difference was in-between 2 and 4 
minutes features were included in ClassB; eventually, if the difference was higher than 4 
minutes features were excluded from the analysis. 
3) Category 3 (cat3): MS1 features that, although highlighted as specific for Salmonella-
treatment by XCMS, were not fragmented. This might be due either to a poor ionization of 
the peptide that leads to its exclusion from the fragmentation step (intrinsic drawback of 
short peptides that lack basic amino acids residues) or simply to an exclusion driven by the 
DDA mode where the selection of precursor ions is stochastic since it follows an intensity 
dependent heuristics (Caron et al. 2015). These features included exclusively in the MS1 
scan and described as over-represented in Salmonella-derived supernatant might be still 
promising for the identification of modified or mutated tumor antigens and thus might be 
targeted by further MS analysis tailored for their identification. This category includes also 
instrumental ‘noise’, namely features that have an MS trace although they are not analytes. 
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Figure 4-18. Pipeline of the peptidomic analysis 
4.4.2.1 Feasibility of the proposed pipeline 
In order to evaluate the feasibility of our strategy we analyzed by XCMS features derived 
from a standard protein analysis. We chose tryptic digestion of bovine serum albumin 
(BSA), and compared features detected by XCMS to a blank sample (features derived from 
a buffer run). Before proceeding with the categorization of the features detected by XCMS 
as BSA-specific we assessed the overlap between all the features detected by XCMS (MS1 
scan) and all the PSM revealed by Proteome Discoverer/Mascot. 15% of the overall 
features overlapped at the m/z level (Figure 4-19) but the majority of the features appeared 
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to be software specific. These can be considered as ‘noise’ intrinsic of both softwares. In 
most of DDA studies only a small portion of PSMs (20% - 40%) represents plausible 
matches and is annotated while the remaining are considered as ‘noise’ (Jeong et al. 2012). 
This percentage can be lower if a pure protein is analyzed. Taking into account that XCMS 
applies to a specific algorithm to filter and identify peaks from the MS1 scan and to match 
peaks across samples, its noise is reasonably different from the noise of classical data base 
searching engine as Mascot, MaxQuant or SEQUEST. The overlap at m/z level was scored 
for all the peptidomic studies performed to characterize supernatants derived from 
melanoma cells that are discussed below. Similarly to what we observed for BSA-analysis, 
the overlap between all the features detected by XCMS (MS1 scan) and all the PSM 
revealed by Proteome Discoverer/Mascot was around 15% (ranging in between 18%-28%, 
data not shown). 
 
Figure 4-19. Overlap between analysis based on MS1 scan and MS2 scan is 15%. 
Venny diagram representing the overlap at m/z level between MS2 scan list (all PSM 
showed by PD) and the list of features revealed by XCMS (based on MS1 scan). 
We then proceeded investigating the 496 features (pvalue<0.01 fold change>3 Intensity 
precursor>2x106) detected by XCMS as overrepresented inside the BSA sample compared 
to the blank. Comparing at m/z level these 496 significant features with the MS2 scan 
revealed by Proteome Discoverer we observed a 30% of overlap (149 on 496 total 
significant features, Figure 4-20). The analysis of the true PSM of BSA detected by PD 
was in line with that expected for a pure protein (13%, 234 on 1240 total PSM). 14,8% of 
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these true PSM were in common with XCMS (36 annotated features on 234 total PSM). 
This percentage represents 24% of the significant features detected by XCMS (36 out of 
149 total significant and overlapping features). The remaining 85% of the true PSM is 
scored in our proposed pipeline by MaxQuant/PD while the remaining 76% of the 
significant features revealed by XCMS could be potential neoantigens and PTM-modified 
antigens and will be further investigated. In conclusion, following our proposed pipeline 
for two-group comparison that combines the analysis of classical database searching 
engine with the analysis of the features at MS1-level, we are not losing information but, on 
the opposite, we are gaining knowledge of features that otherwise would not be accessible. 
 
Figure 4-20. 30% of the features selected as overrepresented in BSA sample overlap 
with the MS2 scan list. 496 BSA-features were selected by XCMS imposing pvalue<0.01, 
fold change>3 Intensity precursor>2x106. 149 out of 496 (30%) were overlapping with the 
MS2 scan list revealed by PD.  
4.4.2.2 Identification of peptides released by murine melanoma B16 cell line  
Vaccination of mice with peptides released by murine melanoma B16 cells upon 
Salmonella infection boosted a strong antitumor response that significantly delayed the 
growth of B16  tumor cells injected in the flank of the mice (Figure 4-7). Three sets of 
supernatants tested in vivo were analyzed by mass spectrometry. Briefly, low molecular 
weight peptides inside cell’s supernatants were separated by proteins using a 10KDa 
centrifugation filter and analyzed by nLC-ESI-MS2 (see pipeline, Figure 4-18).  
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23 peptides were identified as specifically released following Salmonella infection (Figure 
4-21). A Gene Ontology (GO) Cellular Component analysis showed that several proteins, 
to which the selected peptides belonged to, are found in the focal adhesion or as 
components of ribosomes (Figure 4-22) and we observed an enrichment of proteins 
dedicated to mRNA transport, mRNA stability regulation and protein translation (Table 4-
1). Our attention focused on a peptide belonging to Cofilin, a protein already described to 
be a source of human tumor antigen. This same peptide was found to be expressed also by 
3 different human melanoma cell lines and primary human melanoma cells (Gloger et al. 
2016)  and to be identified by proteomic analysis in the MHC-binding peptidome of human 
breast and pancreatic cancer cell lines (Antwi et al. 2009). NetMHC4.0 predicted this 
Cofilin peptide to be a good binder of murine MHC class I molecules H2Kk and H2Kd 
(IC50<3000nM). 
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Figure 4-21. Profiling peptides specifically released by murine B16 melanoma cells 
upon Salmonella infection: results from data base searching engine. Three B16-
supernatants that were tested in vivo were analyzed through nLC-MS: control supernatants 
(None) and the ones derived from Salmonella treated B16 cells (Vax). Each supernatant 
was analyzed in duplicate, shown as -bis. A. HeatMap that shows 23 identified peptides 
significantly more abundant in Vax supernatants; analyses were performed with MaxQuant 
software on the identified peptides. *P <0.05. Red color: up-regulated. Green color: down-
regulated B. Graph representing the distribution of the intensity of the 23 Vax-specific 
peptides 
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Figure 4-22. Peptides released by murine B16 melanoma cells upon Salmonella 
infection belong to proteins mainly found at the level of focal adhesion and as 
components of ribosomes. Gene Ontology (GO) Cellular Component analysis applied to 
the 23 peptides identified as released specifically following Salmonella infection. 
Combined score calculated by EnrichR tool is plotted for each GO-Cellular component 
category. 
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Table 4-1. Peptides released by murine B16 melanoma cells upon Salmonella infection 
belong to proteins mainly involved in protein translation. Pathway knowledge analysis 
with KEGG2016 and Reactome2016 databases was applied to the 23 peptides identified as 
released specifically following Salmonella infection. Tabs show the statistically significant 
enriched pathways and the associated scores calculated by EnrichR tool. 
  
In order to evaluate the presence of peptide candidates as neoantigens or posttranslational 
modified tumor antigens we analyzed the differences at the level of MS1 scan between 
samples derived from Salmonella treated or untreated B16 cells (following the pipeline 
shown in Figure 4-18). 79 features were found to be over represented in samples derived 
from Salmonella treatment of tumor cells (Figure 4-23). 39 of them overlapped with the 
list of total PSM (Figure 4-23); among them 2 were already annotated spectra with the 
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search parameter imposed (Cat1) and 6 features belonging to Cat2 were candidates positive 
to undergo de-novo sequencing (Cat2). The non-overlapping fraction, is composed of 40 
features that will be further investigated with a target data acquisition (TDA) mode to force 
the Mass Spectrometer to fragment them. As additional control, we verified by Proteome 
Discoverer if some of the peptides released by B16 cells following Salmonella infection 
were belonging to Salmonella itself. The few peptides found to belong to Salmonella were 
not present in these lists as they were neither erroneously assigned by MaxQuant nor 
included among the selected significant features by XCMS. 
 
Figure 4-23. 50% of the features selected as overrepresented by XCMS in Salmonella-
derived sample overlap with the MS2 scan list. 79 features specific for Salmonella-
treatment were selected by XCMS imposing pvalue<0.01, fold change>3 Intensity 
precursor>2x106. 39 out of 79 (50%) were overlapping with the MS2 scan list revealed by 
PD.  
 
4.4.2.3 Identification of peptides released by human melanoma 62438 cell line  
Supernatant derived from the infection of human melanoma 62438 cell line with 
Salmonella allowed the expansion of CD8+ T cells from healthy donor’s PBMCs (Figure 
4-10). Moreover expanded lymphocytes were able to activate a cytotoxic response against 
62438 cells that was mediated by the recognition of  HLA-peptide complex (Figure 4-11). 
Peptide candidates to be responsible for CD8+T cells expansion were identified by mass 
spectrometry analyzing cell supernatants derived from three biological replicates.  
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Figure 4-24. Profiling peptides specifically released by human 62438 melanoma cells 
upon Salmonella infection: results from data base searching engine. Three 62438-
supernatants that were tested for expansion of CD8+ T cells from healthy donor PBMCs 
(Chapter 4.2) were analyzed through nLC-MS both control supernatants (None) and the 
ones derived from Salmonella treated 62438 cells (Ty21a). Each supernatant was analyzed 
in duplicate, identified as -r. A. HeatMap that shows 24 identified peptides significantly 
more abundant in Ty21a-supernatants; analysis were performed with MaxQuant software 
on the identified peptides. *P <0.05. Red color: up-regulated. Green color: down-regulated 
B. Graph representing the distribution of the intensity of the 24 Ty21a-specific peptides. 
 
Comparing peptides detected inside the supernatant of untreated 62438 cells with 
supernatant derived from Salmonella infected 62438 cells, 24 peptides were found to be 
over-represented in this second condition (Figure 4-24). Cellular-Component Gene 
Ontology analysis (Figure 4-25) showed that proteins to which peptides belonged to are 
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mainly localized at the focal adhesion; some are instead either nuclear or cytoplasmic 
ribosomal subunit, other belong to supraspliceosomal complexes. Interestingly Reactome 
and KEGG databases highlighted the enrichment of proteins involved either in pathways 
triggered by infection or in peptide chain elongation and splicing processes (Table 4-2). 
 
Figure 4-25. Peptides released by 62438 cells upon Salmonella infection belong to 
proteins mainly found at the level of focal adhesion, as components of ribosomes or 
spliceosomal complex. Gene Ontology (GO) Cellular Component analysis applied to the 
24 peptides identified as specifically released following Salmonella infection. Combined 
score calculated by EnrichR tool is plotted for each GO-Cellular component category. 
 
Table 4-2. Peptides released by 62438 cells upon Salmonella infection belong to 
proteins mainly involved in protein translation. Pathway knowledge analysis with 
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KEGG and Reactome databases was applied on the 24 peptides identified as specifically 
released following Salmonella infection. Tabs show the statistically significant enriched 
pathways and the associated scores calculated by EnrichR tool. 
 
XCMS showed that 159 features were over-represented inside the supernatant derived 
from Salmonella infection of 62438. 49 out of 159 overlapped with features also present 
inside the MS2 scan (Figure 4-26). 5 features were found to be fragmented and already 
associated to a sequence (Cat1) while 21 features have been fragmented but not assigned to 
any sequence (Cat2). Importantly these 21 features could be further characterized by a de-
novo sequencing. The 110 features whose m/z did not overlap with any PSMs will be 
further investigated following a target data acquisition (TDA) mode to define their identity. 
To conclude this analysis we verified by proteome discoverer if some of the peptides 
released by 62438 following Salmonella infection were belonging to Salmonella. The few 
peptides found to belong to Salmonella even in this case were neither erroneously assigned 
by MaxQuant nor included among the selected significant features by XCMS. 
 
Figure 4-26. 32% of the features selected as overrepresented by XCMS in Salmonella-
derived sample overlap with the MS2 scan list. 159 features specific of Salmonella-
treatment were selected by XCMS imposing pvalue<0.01, fold change>3 Intensity 
precursor>2x106. 49 out of 159 (32%) were overlapping with the MS2 scan list revealed by 
PD.  
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4.4.2.4 Identification of peptides released by patients-derived human 
melanoma cells.  
We demonstrated that Salmonella induces the release of immunogenic peptides by both 
murine and human tumor cell lines. Peptide candidates to be responsible of the 
immunogenicity were identified by mass spectrometry approach combining two different 
strategies in order to identify both non mutated tumor antigens and PTM-tumor 
antigen/neoantigens/spliced antigens (see pipeline Figure 4-18). The same pipeline could 
be used on cells directly derived from patient’s tumor cells with the aim to identify novel 
tumor antigens and neoantigens to be included in vaccine formulation to be administered to 
patients to boost an antitumor response. To verify the feasibility of this strategy we derived 
primary tumor cells from melanoma biopsies, we infected them with Salmonella and we 
went through a MS-based peptidomic analysis of the released peptides. Peptides over-
represented in supernatants derived from Salmonella-infected tumor cells clustered 
together and separately from peptides released by untreated tumor cells (Figure 4-27) 
although they were derived from melanoma cells of three different patients. This suggests 
that Salmonella induces the release of peptides that are shared among patients affected by 
the same tumor type. 115 peptides were selected to be specific of Salmonella treatment. 
Proteins to which these selected-peptides belonged to are mainly located at focal adhesion 
or belong to cytosolic ribosomal protein (Figure 4-28). They participate to several steps of 
the translational processes impacting on the mRNA splicing, on its subsequent transport 
from nuclei to ribosomal protein, protein translation and protein transport. KEGG and 
Reactome analysis highlighted also the enrichment of proteins that are involved in 
pathways activated in response to bacterial infection (Table 4-3). Since we have 
previously performed an MS-based peptidomic study on peptides released by the human 
melanoma cell line 62438, we wondered whether some of the selected peptides were found 
to be released also by primary patients-derived melanoma cells. We found 3 peptides 
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commonly released after Salmonella infection (Figure 4-4). They belonged to 
Nucleophosmin (NM1) protein and to the high mobility group protein (HMG-I/HMG-Y), 
both involved in pathways activated in response to a pathogen, while the third peptide is 
involved in the translation process and belongs to the translation machinery-associated 
protein 7 (TMA7). Interestingly peptides derived from NM1 and TMA7 were predicted to 
be strong binders of the HLA-A0301; IC50 lower than 500nM were calculated by 
NetMHC4.0 (Figure 4-4) either for the entire sequence or for shorter portions of the 
sequenced peptides. HMG-I-peptide was predicted to be a mild binder of HLA-B4001 
(IC50<1000nM). Moreover, we found NM1-peptide to be described as an HLA-binder in 
two different studies (Bassani-Sternberg et al. 2015; Pearson et al. 2016). Furthermore, 
TMA7 protein is already known as a source of tumor antigens but the peptide-sequence we 
found has not been described yet. This finding further proves that infection of tumor cells 
with Salmonella promote cancer cells to release immunogenic peptides. 
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Figure 4-27. Profile of peptides specifically released by human patients-derived 
melanoma cells upon Salmonella infection: results from data base searching engine. 
Supernatants of three different patients-derived melanoma cells (Mel1, Mel4, Mel7) were 
analyzed through nLC-MS both control supernatants (None) and the ones derived from 
Salmonella treated melanoma cells (Ty21a). Each supernatant was analyzed in duplicate, 
identified as -r. A. HeatMap that shows 115 identified peptides significantly more 
abundant in Ty21a-supernatants; analysis were performed with MaxQuant software on the 
identified peptides. *P <0.05. Red color: up-regulated. Green color: down-regulated B. 
Graph representing the distribution of the intensity of the 115 Ty21a-specific peptides. 
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Figure 4-28. Peptides released by patients-derived melanoma cells upon Salmonella 
infection belong to proteins mainly found at the level of focal adhesion, as component 
of ribosomes or spliceosomal complex. Gene Ontology (GO) Cellular Component 
analysis applied on the 115 peptides identified as specifically released following 
Salmonella infection. Combined score calculated by EnrichR tool is plotted for each GO-
Cellular component category. 
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Table 4-3. Peptides released by patients-derived melanoma upon Salmonella infection 
belong to proteins mainly involved in protein translation and in pathway activated in 
response to infection. Pathway knowledge analysis with KEGG and Reactome databases 
was applied to the 115 peptides identified as specifically released following Salmonella 
infection. Tabs show the statistically significant enriched pathway and the associated 
scores calculated by EnrichR tool. 
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Table 4-4. Human 62438 melanoma cell line and patients-derived melanoma cells 
release identical peptides upon Salmonella infection. Three peptides were found to be 
equally released by human melanoma 62438 cells and patients-derived melanoma cells 
upon Salmonella infection. Of each peptide, sequence, gene name, protein name and the 
predicted HLA binding are described. 
 
By the analysis of the features we observed 269 signals that specifically correlated with 
Salmonella treatment (Figure 4-29); 177 of these features overlapped with the list of PSM 
and among these 11 were already annotated while 76 (44 ranked as ClassA and 30 as 
ClassB) were selected for further de novo sequencing approach. The 92 features whose m/z 
did not overlap with the m/z of the total PSMs were selected to be further added to an 
inclusion list for a TDA mass spectrometry analysis aimed to identify them. 
	
Figure 4-29. 60% of the features selected as overrepresented by XCMS in Salmonella-
derived sample overlap with the MS2 scan list. 269 features specific of Salmonella-
treatment were selected by XCMS imposing pvalue<0.01, fold change>3 Intensity 
precursor>2x106. 177 out of 269 (60%) were overlapping with the MS2 scan list revealed 
by PD.  
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4.4.2.5 Identification of peptides released by dog patient-derived melanoma 
cells treated with Salmonella. 
In collaboration with a veterinarian clinic we had the opportunity to receive one dog-
patient melanoma biopsy. As we did for osteosarcoma and high-grade sarcoma patients, we 
isolated tumor cells from the melanoma biopsy, we kept them in culture and infected them 
with Salmonella Ty21a. An MS-based peptidomic analysis was performed to identify 
peptide composition of the conditioned-supernatants. The same pipeline described to 
analyze peptides released by murine and human melanoma cells treated with Salmonella 
was applied also in this case. Peptides derived from untreated or Salmonella-treated tumor 
cells clustered separately and 243 peptides were selected as specific of Salmonella 
treatment (Figure 4-30). These selected peptides belonged to proteins mainly located at the 
cell focal adhesion or at the level of proteasome structure or inside stress-associated 
granules (Figure 4-31). This GO-Cell Component observation was in accordance to what 
we stated analyzing peptides released by both murine and human melanoma cells upon 
Salmonella infection. In agreement with the previous analysis, proteins were described to 
be involved in mRNA to protein-translation process, mRNA splicing, protein transport and 
in pathways activated following bacterial infection (Table 4-5). In addition to what we 
previously found, KEGG tool stated a significant enrichment for proteins associated to gap 
junction pathway (Table 4-5). 
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Figure 4-30. Profile of peptides specifically released by dog patients-derived 
melanoma cells upon Salmonella infection: results from data base searching engine. 
Supernatants of dog patient-derived melanoma cells were analyzed through nLC-MS both 
control supernatants (None) and the ones derived from Salmonella treated melanoma cells 
(Ty21a). Each supernatant was analyzed in duplicate, identified as -r. A. HeatMap that 
shows 243 identified peptides significantly more abundant in Ty21a-supernatants; analysis 
was performed with MaxQuant software on the identified peptides. *P <0.05. Red color: 
up-regulated. Green color: down-regulated B. Graph representing the distribution of the 
intensity of the 243 Ty21a-specific peptides. 
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Figure 4-31. Peptides released by dog patients-derived melanoma cells upon 
Salmonella infection belong to proteins mainly found at the level of focal adhesion, as 
component of ribosomes or in the ER-lumen. Gene Ontology (GO) Cellular Component 
analysis applied on the 243 peptides identified as specifically released following 
Salmonella infection. Combined score calculated by EnrichR tool is plotted for each GO-
Cellular component category. 
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Table 4-5. Peptides released by dog patients-derived melanoma cells upon Salmonella 
infection belong to proteins mainly involved in protein translation and in pathway 
activated in response to infection. Pathway knowledge analysis with KEGG and 
Reactome databases was applied to the 243 peptides identified as specifically released 
following Salmonella infection. Tabs show the statistically significant enriched pathways 
and the associated scores calculated by EnrichR tool. 
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Feature analysis by XCMS showed that 1313 were overrepresented in supernatant derived 
from Salmonella treated tumor cells (Figure 4-32). 322 of them were overlapping with the 
list of features detected by Proteome Discoverer software; among them, 24 were 
unambiguously annotated (Cat1) while 175 (119 were ranked as ClassA and 56 as ClassB) 
belong to Cat2. 10 out of 175 of the significant features were found to be peptides 
belonging to Salmonella; hence they were excluded from the selection-list and 151 were 
eventually taken under consideration for de-novo sequencing analysis. The 991 non 
overlapping features (Cat3) could be targeted by future MS-based peptidomic analysis to 
get their MS2 spectrum. 
 
Figure 4-32. 40% of the features selected as overrepresented by XCMS in Salmonella-
derived sample overlap with the MS2 scan list. 1313 features specific of Salmonella-
treatment were selected by XCMS imposing pvalue<0.01, fold change>3 Intensity 
precursor>2x106. 322 out of 1313 (40%) were overlapping with the MS2 scan list revealed 
by PD.  
4.4.3 Identification of proteins inside Salmonella-derived supernatants 
Aiming to properly characterize the cell supernatant derived in response to cell infection 
with Salmonella the MS-based peptidomic analysis described above was done in parallel 
with a proteomic analysis (see pipeline Figure 4-18). The high molecular weight fraction 
deriving from FASP procedure was digested with trypsin and analyzed by nLC-MS. For 
technical reasons the analysis of the proteins derived from 62438 human melanoma cell 
line couldn’t be performed. The analysis of proteins derived from melanoma cells, both 
mouse B16, human-patient and dog-patient-derived cells are described below. 
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4.4.3.1 Murine melanoma B16 cells: protein analysis 
Three sets of supernatants derived from murine melanoma B16 cells that were tested in 
vivo were analyzed by mass spectrometry. The proteomic analysis revealed that two out of 
three supernatants derived from cells treated with Salmonella clusterd together (Figure 4-
21). The third Salmonella-derived sample resulted overall poor of signals; the lack of most 
of the proteins that well profile the other two Salmonella-derived samples weights more 
than the shared proteins.  
 
Figure 4-33. Profile of proteins overrepresented in supernatants derived from 
Salmonella-infected B16 melanoma cells. Protein content of supernatants of murine B16 
melanoma cells were analyzed through nLC-ESI-MS2 both control supernatants (None) 
and the ones derived from Salmonella treated melanoma cells (AT). Each supernatant was 
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analyzed in duplicate, identified as -r. A. HeatMap that shows 30 identified proteins 
significantly more abundant in AT-supernatants; analysis was performed with MaxQuant 
software on the identified proteins. *P <0.05. Red color: up-regulated. Green color: down-
regulated B. Graph representing the distribution of the intensity of the 30 AT-specific 
proteins. 
 
The proteins selected as specific of Salmonella stimuli are mainly associated to stress 
response (Table 4-6). Some proteins are involved in pathways activated by infection; the 
overrepresentation of pathways like Huntingon disease and Rheumatoid arthritis suggest 
that some proteins are involved in disfunctional intracellular acitvity: endocytosis, 
accumulation of unfolded proteins. Interestingly there is an enrichment of proteins 
involved in lysosome and the lysosomal degradation of glycoprotein. None of the proteins 
representative of Salmonella treatment was found by the peptidomic analysis done on the 
low molecular fraction discussed in Chapter 4.4.2.2. This suggests that peptides selected 
by the peptidomic study do not derive from the degradation of proteins inside cells 
supernatant. 
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Table 4-6. Proteins overrepresented in supernatants of B16 cells treated with 
Salmonella are mainly involved in pathways activated in response to stress. Pathway 
knowledge analysis with KEGG and Reactome databases was done on the 30 proteins 
found specifically in Salmonella-derived cells’ supernatants. Tab shows the statistically 
significant enriched pathways and the associated scores calculated by EnrichR tool. 
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4.4.3.2 Human patients-derived melanoma cells: protein analysis 
Protein content of supernatants derived from primary patients-derived melanoma cells 
treated with Salmonella was analyzed and resulted clustering separately from proteins 
derived from untreated cells (Figure  4-34). The selected proteins are mainly involved in 
stress-response to infection, in metabolic dysfunctional pathway and in transcriptional 
misregulation (Table 4-7). Similar observations were done for the proteins analysis of 
mouse melanoma cells (Table 4-6), while at peptidomic level (Chapter 4.4.2.3), the 
significant peptides arising from the analysis were not overlapping with the proteins found 
in the high molecular weight fraction. 
 
Figure 4-34. Profile of proteins overrepresented in supernatants derived from 
patients-melanoma cells infected with Salmonella. Protein content of supernatants of 
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human patient-derived melanoma cells were analyzed through nLC-ESI-MS2 both control 
supernatants (None) and the ones derived from Salmonella treated melanoma cells 
(Ty21a). Each supernatant was analyzed in duplicate, identified as -r. A. HeatMap that 
shows 43 identified proteins significantly more abundant in Ty21a-supernatants; analysis 
was performed with MaxQuant software on the identified proteins. *P <0.05. Red color: 
up-regulated. Green color: down-regulated B. Graph representing the distribution of the 
intensity of the 43 Ty21a-specific proteins. 
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Table 4-7. Proteins overrepresented in supernatant of patients-derived melanoma 
cells treated with Salmonella are mainly involved in pathways activated in response to 
stress. Pathway knowledge analysis with KEGG and Reactome databases was done on the 
43 proteins found specifically in Salmonella-derived cells’ supernatants. Tabs show the 
statistically significant enriched pathways and the associated scores calculated by EnrichR 
tool. 
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4.4.3.3 Dog-patient derived melanoma cells: protein analysis 
Proteins overrepresented in supernatant derived from Dog-patient melanoma cells treated 
with Salmonella clustered well and separately from proteins found in supernatant of 
untreated cells (Figure 4-35). 467 proteins were defined specific of samples derived from 
Salmonella treatment and, as we observed analyzing proteins derived from mouse and 
human samples, proteins were enriched for pathways associated to stress-response to 
infection and metabolic dysfunctional pathways. In addition to what we observed with the 
analysis of mouse and human samples, some proteins found in dog samples are involved in 
protein translation (spliceosome and ribosome) and protein processing inside the 
endoplasmic reticulum (Table 4-8). 5 proteins were found to overlap with the peptidomic 
analysis: Semaphorin3G, HistonH3, Tubulin-α-chain, Ribosomal protein P0, Serum 
amyloid A protein. The peptides belonging to these five proteins that have been found by 
the peptidomic analysis, might be the results of protein degradation. 
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Figure 4-35. Profile of proteins overrepresented in supernatants derived from dog 
patient-derived melanoma cells infected with Salmonella. Protein content of 
supernatants of dog patient-derived melanoma cells were analyzed through nLC-MS both 
control supernatants (None) and the ones derived from Salmonella treated melanoma cells 
(Ty21a). Each supernatant was analyzed in duplicate, identified as -r. A. HeatMap that 
shows 467 identified proteins significantly more abundant in Ty21a-supernatants; analysis 
were performed with MaxQuant software on the identified proteins. *P <0.05. Red color: 
up-regulated. Green color: down-regulated B. Graph representing the distribution of the 
intensity of the 467 Ty21a-specific proteins. 
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Table 4-8. Proteins overrepresented in supernatant of dog melanoma cells treated 
with Salmonella are mainly involved in pathways activated in response to stress. 
Pathway knowledge analysis with KEGG and Reactome databases was done on the 467 
proteins found specifically in Salmonella-derived cells’ supernantants. Tabs show the 
statistically significant enriched pathways and the associated scores calculated by EnrichR 
tool. 
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4.5 Annex 
4.5.1 Assessment of OVA-peptides inside supernatants derived from Salmonella 
treatment of B16-OVA cells: samples preparation optimization.  
In order to analyze by mass spectrometry the supernata nts derived from Salmonella 
treated B16-OVA cells to detect OVA peptides we had to find a suitable protocol. 
Importantly we had to find the way to remove salts that could interfere with mass 
spectrometry analysis and to concentrate peptides instead of proteins in order to increase 
the probability to detect OVA257-264 among all the released peptides. For these purposes, we 
loaded a precise volume of medium derived from untreated cells with 20ug OVA257-264 and 
tested two different peptide-enrichment protocols (Figure 4-36). The first strategy was 
based on chemical precipitation of protein (TCA-mediated), while the second was based on 
protein exclusion by size (using Centricon device). Following this step of peptide-
enrichment, desalting and fractionation procedures were performed through the use of Sep-
Pak C18, a silica-based bonded phase with strong hydrophobicity. Fractions were obtained 
by eluting peptides with an increasing percentage of Acetonitrile solution (5% 10% 20% 
50% 80%) and peptides-enrichment efficiency was evaluated by MS. As shown by 
MALDI spectra of two of the derived Acetonitrile-fractions (Figure 4-37), samples 
obtained by TCA-mediated procedure were characterized by a higher number of signals. 
Moreover, the MS signal associated to OVA257-264 (m/z=963,5) obtained by the TCA-
mediated protocol was more intense than the one obtained by Centricon-based procedure 
(Figure 4-37). In agreement with these observations, DCs loaded with TCA-derived 
fractions induced a stronger activation of CD8+-OTI lymphocytes (Figure 4-38), leading 
them to produce IFN-ɣ. On the basis of all these results we selected the TCA-mediated 
protocol to proceed with the analysis. 
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Figure 4-36. Pipeline of the strategy followed to optimize the analysis of B16-OVA-
derived supernatant. Two different protocol for peptides enrichment were assessed: 
either a Centricon-mediated or a TCA-mediated. Following peptides’ concentration step, 
required to favour OVA-peptides detection, salts removal and fractionation of the peptides 
based on different percentages of acetonitrile were performed using Sep-Pak C18 device. 
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Figure 4-374. A TCA-based protocol performed to enrich peptides is more efficient 
than a Centricon-based protocol. With the aim to concentrate peptides starting from the 
supernatant of cells-treated with Salmonella, two different strategies were assessed. 
Peptides were enriched either by a TCA-based protocol, through which protein were 
precipitated incubating sample over night with a 13% of cold TCA, or by size exclusion 
with a Centicon cut-off 10KDa. The two differently obtained samples were then loaded on 
SepPakC18 to be desalted and fractionated with different percentages of Acetonitrile. 
TCA 
CENTRICON		-		TCA			 	20%	AcetoNitrile 
CENTRICON		-		TCA												50%	AcetoNitrile 
 
 CENTRICON 
TCA 
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Fractions derived from elution with 20% and 50% acetonitrile solution were crystallized on 
alpha-ciano-hydroxycinnamic acid matrix and analyzed by MALDI. OVA257-264 
(m/z=963,5) peptide is marked with a red circle. 
 
Figure 4-38 A TCA-based protocol performed to enrich peptides is more efficient 
than a Centricon-based protocol. With the aim to concentrate peptides starting from the 
supernatant of cells-treated with Salmonella, two different strategies were assessed. The 
first strategy is based on chemical precipitation of protein (TCA-mediated) while the 
second is based on protein exclusion by size (Centricon device). Following peptide-
enrichment, both desalting and fractionation procedures were performed by the use of Sep-
Pak C18. All the derived fractions were loaded on murine DCs for 4 hours and then cells 
were co-cultured with CD8+lymphocytes isolated by the spleen of OTI mice. Following 72 
hours lymphocytes activation was assessed measuring IFN-ɣ release by ELISA. 
 
4.5.2 Assessment of Salmonella-derived supernatant composition by mass 
spectrometry approaches: samples overview by MALDI and SACI-ESI-MS.  
The MS-based peptidomic study to identify antigens released by Salmonella treated tumor 
cells (Chapter 4.4) was preceded by an overall characterization of the samples’ 
composition. An aliquot of them was dedicated to a SACI/ESI-MS analysis (Albini et al. 
2015) (Chapter 3.14.3). Since sample ionization is obtained at a low voltage, the observed 
chemical noise was low (gaining in sensitivity) and we could detect a wide m/z range (low, 
medium, and high molecular weight compounds). As shown in Figure 4-39, the profile of 
the supernatant derived from Salmonella-treated tumor cells (B16 Vax) was largely 
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different from the profile of the supernatant of untreated cells (B16 NONE). B16 Vax 
samples are enriched in signals associated to multi-polimers and peptides, approximately 
90% of the detectable. The remaining 10% is associated to lipids suggesting that lipids 
might contribute to the antitumoral effect of the vaccine either being a source of lipid-
antigens or exerting an adjuvant effect. B16 NONE samples are instead characterized by 
signals of low intensity distributed all along the m/z.   
 
Figure 4-39 Supernatant derived from Salmonella-treated B16 cells have a unique 
profile in term of Lipid-polimer and peptide composition detected by SACI-ESI-MS. 
Supernatants derived from Salmonella-treated B16 cells (B16 Vax), by untreated cells 
(B16 NONE) and by B16 Vax after FASP procedure were analysed by SACI-ESI-MS. 
 
With the perspective to perform a peptidomic analysis (Chapter 4.4), being aware of the 
complex composition of the Salmonella derived supernatants, we decided to process 
samples by a 10KDa centrifugation filter (Filter aided sample preparation, FASP) in order 
to separate high from low molecular weight peptides to then proceed by nLC-ESI-MS2 of 
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both fractions (as explained in the pipeline Figure 4-18). MALDI spectra show the 
complexity of the samples along the applied procedure (Figure 4-40). Sinapinic acid 
matrix, that favours proteins crystallization instead of peptides crystallization, highlighted 
the efficiency of protein removal exerted by FASP device since nearly to zero proteins 
were detected inside B16 Vax FASP sample compared to both B16 NONE and B16 VAX 
samples (Figure 4-40A). At the opposite, alpha-ciano-hydroxycinnamic acid matrix that 
favors the crystallization of low molecular weight proteins showed that peptides inside 
FASP-derived samples were abundant and possibly detected even at higher resolution if 
compared with peptides acquired on the same matrix from the initial and unprocessed 
supernatant (either B16 Vax and B16 NONE samples) (Figure 4-40B). FASP-derived 
samples were also analysed by SACI-ESI-MS. FASP allow to have multipolimeres 
removed in favour of peptides signals (Figure 4-40). 
 
Figure 4-40 Supernatant derived from Salmonella treated B16 cells are enriched in 
peptides. Protein composition of supernatant derived from Salmonella treated or untreated 
B16 cells was assessed before and after being processed on FASP devices (cut-off 10KDa). 
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Samples were crystalized either on sinapinic acid matrix (A) or on alpha-ciano-
hydroxycinnamic acid matrix (B) and then acquired by MALDI-TOF.  
4.5.3 Lipids released by murine melanoma B16 cells upon Salmonella infection can 
activate iNKT cells 
Mass spectrometry analysis of supernatants derived from Salmonella infected B16 cells 
revealed the presence of lipids (Figure 4-39). Sep-pak C18 device used to concentrate 
peptides before proceeding with mice immunization enables to remove salts but is 
conservative with lipids. Invariant NK-T cells activation is based on the recognition of 
specific lipids by the CD1d invariant receptor (Brennan et al. 2013). Upon activation iNKT 
cells produce IL2 and can mediate a cytotoxic response. Taking advantage of a murine 
hybridoma (generated by the fusion of a iNKT cell with a thymoma (Schümann et al. 
2007)), we tested whether the supernatants derived from Salmonella infected tumor cells 
were able to stimulate iNKT activation. We generated dendritic cells from the bone 
marrow of wild type C57J/BL6 mice (BMDCs), we loaded them with cell’s supernatant 
either derived following Salmonella infection (B16 VAX) or by untreated cells (B16 
NONE), and we then added iNKT-hybridoma to the culture. B16 NONE supernatant didn’t 
have any effect on iNKT hybridoma cells since the IL2 production was the same as the one 
associated to the negative control (consisting of iNKT incubated with BMDCs without 
stimuli). VAX samples instead were able to stimulate a mild but significant IL2 production 
by iNKT hybridoma cells (Figure 4-41) indicating that iNKT activation might be also 
induced in vivo and iNKT cells might be involved in the antitumor response. IL2 release 
following αGal stimulation was monitored as a positive control. 
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Figure 4-41. Supernatants-derived from murine melanoma cells treated with 
Salmonella can activate iNKT cells. iNKT hybridoma cells were cocultured with bone 
marrow derived dendritic cells (BMDCs) in presence of different stimuli: supernatant 
derived from untreated cells (B16 NONE), supernatant derived from Salmonella treated 
B16 cells (B16 Vax), αGal, or left un-stimulated (BMDCs+iNKT). After 48hours IL-2 
production was assessed by ELISA. (The Student's t-test was used for statistical analysis 
p=0,0285).  
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5. DISCUSSION 
In this work we provide evidence that Salmonella infection of tumor cells promotes the 
release of antigens that, once administered with selected adjuvant following a prophylactic 
schedule, induced an antitumor response either in a mouse model of non-immunogenic 
melanoma B16, or in dog patients suffering from spontaneous osteosarcoma or high grade 
sarcoma. We also proposed a novel mass-spectrometry based approach that enables to 
identify the sequence of neoantigens and spliced tumor antigens that otherwise wouldn’t be 
accessible. 
Starting from a previous finding of the laboratory by Saccheri and colleagues (Saccheri et 
al. 2010) that showed that Salmonella infection of mouse melanoma cells promoted a gap 
junction mediated transfer of immunogenic peptides from tumor cells toward dendritic 
cells, we proved that the same Salmonella stimulus induced both murine and human cell 
lines to release peptides in the extracellular space through plasma membrane 
hemichannels. If the ATP assay allowed us to verify that Salmonella promoted the opening 
of hemichannels of murine cells, by the T2 binding assay, frequently used to validate the 
antigenicity of peptides, we demonstrated that peptides released by Salmonella-infected 
human melanoma cells are of the correct size to be loaded on HLA molecules and hence 
are potential antigens. Moreover, peptide release is hemichannel-dependent as it is 
completely blocked by heptanol, a hemichannel blocker.  
Furthermore, taking advantage of a well-established murine cell model to monitor antigen 
processing, B16OVA, we showed that among the peptides released by tumor cells upon 
Salmonella infection some were well-described antigens. Indeed B16OVA cells released 
the most immunogenic ovalbumine-derived class I peptide, OVA257-264.  
All these compelling evidence about the presence of antigens inside the supernatant of 
tumor cells treated with Salmonella lead us to assess their immunogenicity in a preclinical 
model of melanoma. Mice vaccinated three times with LPS-activated DCs loaded with 
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peptides released by B16 cells treated with Salmonella had a longer overall survival than 
mice vaccinated with unloaded DCs. Furthermore DCs loaded with the mixture of peptides 
released by B16 cells upon Salmonella stimulus had a stronger effect than DCs loaded with 
two B16-tumor antigens Trp2180-188 gp10025-33 showing that our vaccine formulation 
possibly contains antigens more immunogenic than Trp2180-188 and gp10025-33. Our results 
are promising considering that B16 cells are poorly immunogenic; although 180 druggable 
mutations have been estimated by the B16-mutanome study of Castle and colleagues 
(Castle et al. 2012), mice immunized with irradiated tumor cells are not protected from a 
subsequent challenge with B16 cells (Dranoff et al. 1993); this is mainly due to the fact 
that this melanoma cell line expresses MHC class I very poorly and do not express MHC 
class II (Seliger et al. 2001; Overwijk & Restifo 2001). Of notice, Schreus and colleagues 
were instead able to obtain a partial but consistent mice survival vaccinating them with DC 
loaded with Trp2 (Schreurs et al. 2000); the shorter schedule adopted, meaning the time in 
between immunization and B16 challenge, together with the higher number of DC used for 
the immunization procedures may have favored the induction of a protective immune 
response. From an immunologic standpoint, DC-based immunotherapy carries the highest 
potential of inducing effective anticancer immune responses as it provides cytokines and 
co-stimulatory molecules necessary to activate naïve-T cell in an antigen specific manner. 
Nevertheless, one major drawback of DC-based approaches is that, once applied in the 
clinics for therapeutic purposes, they require leukapheresis, processing and culturing of 
peripheral PBMCs, therefore allowing a limited number of vaccinations and long 
preparation time. Improvement for patients has been achieved through the use of 
therapeutic DC-based vaccines as recently reported by Gross and colleagues (Gross et al. 
2017) but, since they rely on patient-derived DCs they imply high costs for a not shareable 
procedure. To set us as close as possible to a feasible and less demanding clinical setting 
and aiming to provide a vaccine with neoantigens shared among patients, we conjugated 
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peptides released by Salmonella treated B16 cells with adjuvants and assessed them as DC-
free vaccines.  
Incomplete Freud Adjuvant (IFA)-based vaccines are water-in-oil emulsions of antigen in 
mineral oil and mannide monooleate as a surfactant; IFA is thought to induce local 
inflammation and forms a depot that protects antigen from degradation and slowly releases 
it to antigen presenting cells  (Aucouturier et al. 2002). Its safety has been early clarified 
by Rosenberg studies (Rosenberg et al. 1998) while its adjuvant efficacy has been debated. 
Haileilmichaeil and colleagues showed that IFA-based vaccination turns the vaccination 
site into a persistent source of T cell priming thus preventing their tumor localization while 
causing their dysfunction and deletion  (Hailemichael et al. 2013). On the contrary Kenter 
and colleagues showed that synthetic long peptides combined with IFA, specifically 
Montanide 51, gave clinical benefits to patients affected by Vulvar Intraepithelial 
Neoplasia (VIN) (Kenter et al. 2009). To overcome any possible drawback related to IFA it 
has been proposed to administer the emulsion of peptides together with a TLR-agonist as 
CpG (TLR-9 agonist, (Speiser et al. 2005) ) or poly (I:C) (TLR-3 agonist, (Sabbatini et al. 
2012) or with CpG and Imiquimod (TLR-9 and TLR-7 agonists, (Goldinger et al. 2012)). 
We chose to administer peptides in emulsion with IFA together with the Imiquimod and, 
separately, to assess peptides immunogenicity in solution with CpG ODN 1826 alone. 
Peptides in emulsion with the IFA and a subsequent stimulation with Aldara cream 
(Imiquimod) induced an ample antitumor response and mice showed a peptide-dose 
dependent benefit in terms of overall survival. A significant retardation of tumor growth 
together with an ameliorated overall survival was also observed immunizing mice with 
peptides released by Salmonella-treated B16 cells combined with CpG ODN 1826, a TLR-
9 agonist. The two chosen adjuvants were able to induce an immune response of similar 
amplitude in terms of both tumor growth retardation and overall survival. Moreover they 
were as efficient as DCs in boosting the antitumor response thus indicating that DCs as 
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adjuvants are not an advantage. We obtained following both procedures significant positive 
results but further investigations are needed to decipher whether different immune cell 
populations were activated by the two adjuvant formulations. Possibly, we could further 
enhance vaccine effect combining peptides with all the three adjuvants together; indeed the 
percentage of central memory T cells responsible of a long term immune response 
(Hendriks et al. 2000) have been shown to be further augmented in patients, combing IFA 
with CpG and Imiquimod (Goldinger et al. 2012). 
All of the therapeutic vaccinations we performed, either DC-dependent or DC-free, 
although increasing the survival time against B16 melanoma, did not guarantee a complete 
tumor rejection and all animals ultimately succumbed to the disease. As discussed earlier, 
this could be due to the low immunogenicity of B16 cells but also to the rapid growth of 
this tumor cell line which possibly did not allow for a time sufficient to generate an 
effective immune response; moreover the induction of anergy or other immune 
escape/suppressor mechanisms cannot be excluded. As it happens during melanoma 
progression in humans, PDL-1 is overexpressed by B16 cells during tumor growth (Kleffel 
et al. 2015) leading to anergic tumor infiltrating lymphocytes; on the contrary, differently 
from human melanoma, B16 cells however, do not respond to checkpoint blockade 
(Twyman-Saint Victor et al. 2015), either to a single antibody treatment (CTLA-4, PD-1, 
PDL-1) or to a combinatorial use of these antibodies. It has been shown instead that 
coupling radiotherapy to CTLA-4 and PD-1 monoclonal antibodies lead to 80% of mice 
survival (Twyman-Saint Victor et al. 2015) proving that MHC-class I down regulation, 
reverted by radiotherapy, is the other tumor-escape mechanism, not less relevant than T 
cell effectors anergy, that needs to be considered once designing a novel immunotherapy 
approach. In light of the above considerations, the B16 tumor retardation we observed by 
vaccinating mice with only one type of adjuvant, is significant and might be further 
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augmented adding both checkpoint blockade to unleash T cells responses and radiotherapy 
to induce MHC class I expression.  
The immunogenicity of peptides released by tumor cells upon Salmonella infection was 
further demonstrated in the human system, by their ability to induce the expansion of 
tumor specific CD8+ T cells from healthy donor peripheral blood mononuclear cells 
(PBMCs). Peptides extracellularly released by the human melanoma cell line 62438 
induced CD8+ lymphocytes that responded to the tumor of origin, in an HLA-dependent 
manner both producing IFN-γ and recruiting the degranulation marker CD107a at the cell 
membrane; in addition, the expanded lymphocyte population killed 62438 cells in an HLA-
dependent manner. These results showed not only that peptides released by 62438 cells 
upon Salmonella infection are antigenic but also that healthy patients have circulating 
lymphocytes that recognize them and expand upon few rounds of stimulation. One among 
all of the antigens expressed by 62438 melanoma cell line in association with the HLA-
class I molecules is Mart-1, also known as Melan-A. Mart-1 is one of the first melanoma 
tumor antigens described (Kawakami et al. 1994) and is a melanocyte specific 
melanosomal protein. As high frequency of Mart-1 specific CD8+ circulating T 
lymphocytes have been described in healthy donors (Pittet et al. 1999) we used this 
melanoma antigen as positive control for CD8+ lymphocyte expansion. Mart-1 stimulus 
gave rise to expansion of tumor-specific lymphocytes that were much more activated in 
response to tumor cells than lymphocytes expanded by tumor-released peptides, following 
our approach. This might be due to the heterogeneity of lymphocyte clones stimulated by 
the multiplicity of peptides derived from the treatment of 62438 cells with Salmonella. We 
possibly expanded several antigens-specific lymphocytes that in response to tumor cells 
competed between each other resulting in an HLA-dependent activation of lower 
amplitude than the activation of Mart-1 specific lymphocytes. To ultimately assess the 
tumor-specific-killing ability of the expanded lymphocytes it would be informative to test 
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them in vivo. A possibility is to challenge immune-reconstituted NSG mice (by healthy 
human PBMCs) with 62438 cells and to test the capacity of adoptively transferred ex vivo 
peptides-expanded-T lymphocytes to counteract tumor growth. As we had the opportunity 
to receive tumor biopsies of three different melanoma patients from which melanoma cell 
lines were derived we could perform the same flow of experiments with patients-derived 
melanoma cells. The results that would be obtained with these primary cells could be 
relevant to further sustain the translational potential of our immunotherapy strategy. 
The collaboration with a veterinary hospital allowed us to verify the feasibility of the 
immunotherapy approach we are proposing. Osteosarcoma (OSA) and high grade sarcoma 
(SA) are a two unmet medical needs in veterinary medicine and the same is true for the 
human tumor counterpart (Mirabello et al. 2009; Bray 2016). As both tumors similarly 
develop in human and dogs we were further encouraged to assess vaccine effect on dog 
patients. The main cause of death is tumor metastases in secondary organs; in particular, 
for osteosarcoma patients, metastases occur mostly in the lung and it has been shown that 
micrometastasic disease is likely present in approximately 80% of the patients at diagnosis 
(V.Griend et al, 1996). Cancer vaccine administration soon after surgical intervention was 
curative for 2 out of 13 patients enrolled; OSA0 affected by osteosarcoma was immunized 
with an heterologous vaccine and lived more than 600 days after diagnosis while SA5, a 
high grade sarcoma patient was immunized with an autologous vaccine and is still alive 
after more than 1400 days from diagnosis. OSA0 was vaccinated with peptides released by 
the tumor cell line of a second OSA patient due to the non-availability of its own primary 
tumor cells; the benefit that OSA0 had in terms of overall survival, suggests the presence 
of shared tumor antigens inside the heterologous administered vaccine and the possibility 
to develop a universal OSA vaccine. Unfortunately, we did not succeed to stably grow 
OSA-donor’s cells in vitro thus the immune-monitoring was possible only for SA5. T-
lymphocytes able to produce IFN-γ and CD107 upon tumor stimulation were detected in 
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peripheral blood of SA5 demonstrating that the vaccine formulation boosted an immune 
response which was both CD8 and CD4  T cell-mediated. Accordingly, a tumor specific 
humoral response was detected in SA5 sera and it increased along the immunization 
schedule. Three patients are still under vaccination, six died before completing the 
vaccination because of a highly aggressive disease progression, while other four patients 
completed the vaccination but died without improvement of the overall survival. We have 
not yet clarified whether the latter four patients developed an antitumor response although 
they did not benefit of a longer overall survival. The assessment of tumor specific-
antibodies in the sera of patients or the responsiveness of PB-lymphocytes upon tumor 
stimulation will indicate if vaccine was immunogenic but other factors, such as immune 
escape strategies, interfered with an effective antitumor response. The results of the clinical 
trial showed a high variability in individual responses to treatments. The choice of not 
restricting to a narrow, homogenous sample of patients might have contributed to the 
observed variability. However, we had the striking indication that at least in two cases an 
antitumor response was induced by the vaccine and that both autologous and heterologous 
settings are feasible and can be successful. 
Reports of successful cancer vaccine therapies have been recently published. Gross and 
colleagues reported that 19% of nonresectable metastatic melanoma patients that 
underwent intradermal autologous vaccination with DCs loaded with 4 HLA class I and 6 
class II-restricted tumor peptides over two years (Gross et al. 2017) were still alive after 11 
years; a result similar to what was observed treating patients with Ipilimumab. A second 
report, although it dealt with only six high risk melanoma patients, conveyed that 
vaccination with clinical grade long peptides (SLP) targeting up to 20 neoantigens per 
patient was feasible, safe and a successful strategy (Ott et al. 2017). Ott and colleagues 
reported that four out of six patients were disease-free after 25 months while two patients 
with recurrent disease that were subsequently treated with anti PD-1 experienced complete 
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tumor protection. This evidence, together with the results of preclinical studies (Yadav et 
al. 2014; Kreiter et al. 2015), renovated the interest toward cancer vaccines whose potential 
was underestimated following the discovery of immunocheckpoint blockade and the 
failures of clinical trials involving vaccines. Together with what we are proposing with our 
immunotherapy strategy, the novelty of these successful approaches is that they rely on the 
induction of an antitumor response directed against neoantigens.  
Neoantigens, due to a different sequence from self-peptides, minimize immune tolerance 
thus becoming the best-choice target for an effective antitumor response. Importantly, we 
set up a mass-spectrometry (MS) method that will enable us the identification not only of 
neoantigens but also of tumor specific spliced-peptides. Spliced peptides are a recently 
discovered category of antigens generated by the post translational ligation of two non-
adjacent peptides of a parental protein, mediated by the proteasome. Proteasome catalyzed-
peptides splicing occurs more frequently than expected (Liepe et al. 2016) and nowadays 
compelling evidence showed that spliced peptides are often targeted by T lymphocytes 
both in response to bacterial infection (Platteel et al. 2017) and to mediate an antitumor 
response being recognized as tumor antigens (Vigneron et al. 2004; Ebstein et al. 2016). 
Although they have been identified for the first time in 2004 as target of patients-derived 
tumor infiltrating lymphocytes, their subsequent discovery has been limited by the lack of 
tools. Their identification was possible only tailoring the phase of database searching of 
MS analysis on customized databases of peptides in which all the possible spliced peptides 
(predicted in silico following criteria that limited the number of all the theoretically 
possible spliced-peptides) were included (Liepe et al. 2016). Reasonably the efficacy of 
these pioneering methods are limited both to the size and to the accuracy of customized 
databases; for example trans-spliced peptides cannot be identified. By our proposed MS-
approach, combining the analysis by classical database searching engine with the analysis 
of the features at MS1-level, we gained knowledge of peptides that otherwise would not be 
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accessible. We used XCMS software (Tautenhahn et al. 2012) to determine the MS1-
features whose levels were significantly higher in supernatants derived from Salmonella-
treated tumor cells compared with supernatants of untreated tumor cells. Then, overlapping 
the selected MS1 features with the MS2 scan we obtained a list of features that were not 
identified by common available databases and thus were likely to be enriched of 
neoantigens, spliced tumor antigens and PTM peptides. De novo sequencing procedures 
will allow us to identify their sequence.  
Although the results of the novo sequencing data are not available yet, the classical 
database searching engine analysis highlighted that Salmonella-treated tumor cells release 
non-mutated potentially immunogenic peptides. The analysis of the peptides released by 
B16 cells showed the presence of Cofilin, described to be an antigen potentially shared by 
different tumor types. It has indeed been found expressed both on three different human 
melanoma cell lines and on primary human melanoma cells (Gloger et al. 2016), and 
furthermore, it has been identified as HLA-binder of both human breast and pancreatic 
tumor cell lines (Antwi et al. 2009). The analysis of the peptides released by patient-
derived melanoma cells and human melanoma cell lines unraveled three peptides that 
although deriving from different melanoma cells were equally released specifically upon 
Salmonella infection. NM1 and TMA7 are strong HLA binders while HMG-I is a good 
HLA binder suggesting that they can potentially be immunogenic. Furthermore NM1 has 
been already described as expressed on HLA molecules of a lymphoblast cell line 
(Bassani-Sternberg et al. 2015; Pearson et al. 2016). Both the non-mutated peptides 
selected by canonical database searching engine and the peptides that will be deciphered 
by the novo sequencing procedure will be prioritized on the basis of the predicted-HLA-
binding affinity. Only the good binders will be synthesized and their immunogenicity will 
be assessed either ex vivo or in vivo: we will be testing the ability of the peptides to expand 
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T-lymphocytes from healthy donor PBMCs able to recognize and kill tumor cells in vitro 
and in vivo, similarly to what I previously discussed. 
A Gene Ontology (GO) Cellular Component analysis applied to the peptides found to be 
overrepresented in the supernatant of both murine, human and dog tumor cells treated with 
Salmonella showed that several of them belonged to proteins found at the level of focal 
adhesion and as components of ribosomes; we observed an enrichment of proteins 
dedicated to mRNA transport, mRNA stability regulation and protein translation. These 
findings are a further indication that peptides released by tumor cells upon Salmonella 
infection are prone to bind to HLA molecules; indeed previous studies highlighted that 
ribosomes-derived peptides but also proteins involved in translational processes and 
nucleosomal proteins are particularly well presented on HLA molecules (Bassani-
Sternberg et al. 2015). A possibility that we still need to address is whether among the 
released peptides upon Salmonella infection, non-common antigens as tumor epitopes 
associated with impaired peptide processing (TEIPPs) are found (Seidel et al. 2012). These 
peptides although derive from housekeeping proteins are not presented by normal cells and 
can evade both central and peripheral immune tolerance; thus they could be efficiently 
targeted by a cancer vaccine immunotherapy (Oliveira et al. 2011; Lampen et al. 2010). 
An issue to consider once proposing a peptide-based anticancer vaccine strategy is the 
autoimmunity that might be induced following immunization. Peptides might indeed boost 
an aberrant immune response against endogenously HLA-associated peptides instead of 
inducing an antitumor-specific immune response. None of the mice vaccinated with 
peptides released by B16 cells upon Salmonella infection developed vitiligo (white skin 
patches that are due to the disappearance of melanocytes). Moreover the clinical trial that 
involves dogs affected by both high grade sarcoma and osteosarcoma demonstrated the 
safety of the vaccination. Of note, none of the enrolled patients had a positive reaction to 
Delayed Type Hypersensitivity (DTH) test. Erythema or induration after 48-72 hours was 
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never revealed thus indicating that none of the peptides included in the vaccine formulation 
induced a strong and immediate immune response but also that autoimmunity reactions can 
be excluded.  
The mechanism by which Salmonella induces tumor antigen release still remains elusive. 
Using a hemichannels blocker we demonstrated that peptides-release upon Salmonella 
infection was mostly but not exclusively hemichannel-dependent. From previous studies it 
is known that Salmonella infection induces hemichannel overexpression (Saccheri et al. 
2010) but how, and why preferentially proteasome-produced tumor antigens are conveyed 
toward hemichannels for their release requires further investigation. However, it is evident  
that the treatment of tumor cells with Salmonella is a strategy to unravel novel T cell 
epitopes that are expressed by tumor cells. We validated this approach on three different 
tumor types, melanoma, osteosarcoma and sarcoma, but it might potentially be applied to 
other solid tumors. Importantly, the peptides provided by our approach are pre-processed 
by tumor proteasome and in vivo, once taken up by DCs, could not require further 
trimming by the immune-proteasome of DC-proteasome. This is an advantage considering 
that antigens presented by tumor cells often do not correspond to the ones presented by 
DCs due to the diverse proteasomes expressed by the two cell types (Vigneron & Van den 
Eynde 2014). DCs express constitutively the immunoproteasome and very little of the 
standard proteasome that is instead expressed by tumor cells. One of the first evidence of 
this discrepancy was shown in melanoma patients. The immunodominant HLA-A2-
resctricted MelanA antigen (Melan-A26-35), highly expressed by tumor cells was not 
produced by DC’s immunoproteasome (Chapatte et al. 2006). Significantly, the inhibition 
of DCs-immunoproteasome to favor the standard proteasome, enabled DCs to induce a 
strong anti Melan-A specific T cell response in vitro and in vivo (Dannull et al. 2009; 
Chapatte et al. 2006). A way to overcome this DC-proteasome processing  is to 
exogenously provide tumor-processed antigens of the right size and affinity for MHC-I 
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molecules, as proposed in our strategy. Another advantage of our approach is that several 
antigens are simultaneously provided to the immune system thus leading to a multi-target 
and specific tumor-directed T cell response that addresses tumor heterogeneity as well as 
minimizes the chance of tumor escape by loss of antigens.  
In conclusion, we demonstrated that infection of tumor cells with Salmonella induced the 
extracellular release of immunogenic tumor antigens that could be successfully exploited 
as cancer vaccines for the prevention or treatment of tumors. By a novel MS-based 
approach we identified the non-mutated tumor antigens and we will soon derive the 
sequence of neoantigens and likely spliced-tumor antigens. By the implementation of the 
vaccine in veterinarian clinical practice for the treatment of dogs affected by spontaneous 
osteosarcoma and high grade sarcoma we assessed the safety, feasibility and efficacy of the 
protocol.  
Neoantigens, non-common antigens (as TEIPP peptides) or spliced peptides released by 
tumor cells following Salmonella infection could be applied in a clinical setting as a 
prophylactic cancer vaccine in the adjuvant setting for the therapeutic treatment of solid 
cancer to avoid recurrence. Initially, we envisage an autologous personalized cancer 
vaccine and cancer biopsies would be necessary in the first phase of clinical development, 
for the enrichment of patient-specific tumor-antigens. We will then evaluate whether there 
is a ‘signature’ of these antigens (including neoantigens) commonly released by patients-
derived tumor cells upon Salmonella infection and whether this correlates with vaccine 
efficacy with the aim of identifying a ‘universal’ vaccine treatment. A ‘universal’ vaccine 
formulation would pave the way to a robust mass vaccination schedule treatment as it 
could be administered to patients soon after tumor resection, boosting rapidly an antitumor 
response directed against micro-metastases that are often not clinically visible at the 
moment of primary tumor diagnosis. To enhance cancer vaccine effect it will be pivotal to 
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monitor the expression of both immunocheckpoint and HLA molecules at tumor level. A 
personalized combinatorial therapy would be instrumental for patients clinical benefits. 
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7. Appendix 
7.1 Peptides released by Salmonella infected tumor cells. 
In this study, MS analysis have been conducted to identify peptides specifically released 
from tumor cells upon Salmonella infection (described in Chapter 4.4). The results are 
additionally shown below in descriptive tables. 
7.1.1  Peptides specifically released by B16 murine melanoma cell line treated with 
Salmonella 
Sequence Proteins 
Gene 
names 
Protein names id Charges 
ADKVPKTAENFR Q5SVY2 Ppia Peptidyl-prolyl cis-trans isomerase 85 3 
APEEKASVGP Q9Z1W5 Serp1 Stress-associated endoplasmic reticulum protein 1 238 2 
AQASAPAQAPK Q5M8M8 Rpl29 60S ribosomal protein L29 283 2 
AQASAPAQAPKGAQAPK Q5M8M8 Rpl29 60S ribosomal protein L29 285 3 
DVSKPDITA Q5FWJ3 Vim Vimentin 523 2 
EIEGGSASEGAARP Q3U4F9 Csf1 Macrophage colony-stimulating factor 1 609 2 
GGGGGGGRYYGGGNEG Q3UMT7 Hnrnpl Heterogeneous nuclear ribonucleoprotein L 899 2 
GQTPKVAKQEK Q642K5 Fau 40S ribosomal protein S30 1148 2;3 
GVIKAVDK Q58E64 Eef1a1 Elongation factor 1-alpha 1255 2 
HIDKAQQNNVE F6SVV1 Gm9493 40S ribosomal protein S7 1284 2;3 
KKEKVIATVTK Q3UFI4 Rpl6 60S ribosomal protein L6 1751 3 
KVPAVPETIKK Q5M9N8 Rpl7 60S ribosomal protein L7 1852 3 
NETNEIANANS A2A547 Rpl19 Ribosomal protein L19 1960 2 
NQGGYGGSSSSSSYGSGR Q3TIK8 Hnrnpa1 Heterogeneous nuclear ribonucleoprotein A1 2053 2 
PGVTVKDVN Q5M9P3 Rps19 40S ribosomal protein S19 2205 2 
PTPQDAGKPSGPG Q3TQF7 Adamts1 
A disintegrin and metalloproteinase with 
thrombospondin motifs 1 
2321 2 
PVVQPSVVDRVA Q2XSQ4 Plin3 Perilipin 2334 2 
SGGGGGGGGSWGGRSNS Q9CX86 Hnrnpa0 Heterogeneous nuclear ribonucleoprotein A0 2863 2 
TEEEKNFK P47963 Rpl13 60S ribosomal protein L13 3231 2 
TVTKTVGGDKNGGTR Q3UFI4 Rpl6 60S ribosomal protein L6 3378 2;3 
VDKKAAGAGKVT Q58E64 Eef1a1 Elongation factor 1-alpha 3410 2;3 
YDATYETKESKKEDI Q544Y7 Cfl1 Cofilin-1 3627 3 
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YQSHADTATKSGSTTK A0A0G2JFB4 Eif4e Eukaryotic translation initiation factor 4E 3713 2;3 
Table 7-1. Peptides released by B16 cells upon Salmonella infection. Supernatants of 
murine melanoma B16 cells were analyzed through nLC-MS both control supernatants and 
the ones derived from Salmonella treated melanoma cells (Chapter 4.4.2.2). 23 identified 
peptides were significantly more abundant in Salmonella-derived supernatants; analysis 
was performed with MaxQuant software on the identified peptides. *P <0.05. 
 
7.1.2 Peptides specifically released by 624.38 human melanoma cell line treated with 
Salmonella 
Sequence Proteins Gene names Protein names id Charges 
AAGKGPIATGGIKKSGKK A0A024R306 TMA7 
Translation machinery-
associated protein 7 
3 3;4 
AQGPKGGSGSGPTIEE B4E1T6 HEL-S-103 
 
23 2 
DDWDIITR H0YLV1 MORF4L1 
Mortality factor 4-like 
protein 1 
41 2 
DYPSSRDTRD B3KRG5 RBMX 
RNA binding motif protein, 
X-linked-like-1 
65 2 
EAPRPYSK C9J6H5 ADAM9 
Disintegrin and 
metalloproteinase domain-
containing protein 9 
67 2 
ESKTAVEMIQNQI P49454 CENPF Centromere protein F 88 2 
FGGPGTASRPS V9HWE1 HEL113 Vimentin 107 2 
GGGNYGPGGSGGSGGYGGR A0A024RA28 HNRPA2B1 
Heterogeneous nuclear 
ribonucleoproteins A2/B1 
123 2 
IRPAVSSSDQQS C9JVB2 KIAA0319L 
Dyslexia-associated protein 
KIAA0319-like protein 
186 2 
ISHEIDSASSE F2YQ21 SPP1 Osteopontin 187 2 
KANDESNEHSDVIDSQEISK F2YQ21 SPP1 Osteopontin 209 3 
KIEKEEEEGISQESSEEEQ P17096 HMGA1 
High mobility group 
protein HMG-I/HMG-Y 
214 2;3 
MGESDDSIIR Q6FGH5 RPS21 40S ribosomal protein S21 227 2 
RKSPENTEGKDGSKVTKQEPTR A0A087WZE9 HMGN3 
High mobility group 
nucleosome-binding 
domain-containing protein 
295 4 
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3 
RSAPGGGSKVPQK Q9NX34 NPM1 Nucleophosmin 304 3 
RSGPTDDGEEEMEEDTVTNGS Q53G61 SNRPA1 
U2 small nuclear 
ribonucleoprotein A 
306 2 
SPEEATPSSRPNR H3BMM8 HN1L 
Hematological and 
neurological expressed 1-
like protein 
322 2 
TVAGGAWTYNTTSAVTVK C9J4Z3 RPL37A 60S ribosomal protein L37a 357 2 
VGGEGGAGGRSP Q6UW78 C11orf83 UPF0723 protein C11orf83 372 2 
VIYTRNTKGGDAPAAGEDA P62851 RPS25 40S ribosomal protein S25 378 2;3 
VPDRDPASP B4DZS5 GPNMB 
Transmembrane 
glycoprotein NMB 
380 2 
YGGGNYGPGGSGGSGGYG A0A024RA28 HNRPA2B1 
Heterogeneous nuclear 
ribonucleoproteins A2/B1 
406 2 
YGGGNYGPGGSGGSGGYGGR A0A024RA28 HNRPA2B1 
Heterogeneous nuclear 
ribonucleoproteins A2/B1 
407 2 
YGGGSEGGRAPK B2R959 HNRNPL 
Heterogeneous nuclear 
ribonucleoprotein L 
410 2 
 
Table 7-2. Peptides released by human melanoma 62438 cell line upon Salmonella 
infection. Supernatants of human melanoma 624.38 cells were analyzed through nLC-MS 
both control supernatants and the ones derived from Salmonella-treated melanoma cells 
(Chapter 4.4.2.3). 24 identified peptides were significantly more abundant in Salmonella-
derived supernatants; analysis was performed with MaxQuant software on the identified 
peptides. *P <0.05. 
 
7.1.3  Peptides specifically released by patients-derived melanoma cells treated with 
Salmonella 
Sequence Proteins 
Gene 
names 
Protein names id Charges 
AAGKGPIATGGIKKSGKK A0A024R306 CCDC72 
Translation machinery-associated 
protein 7 
27 3;4 
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ADGYNQPDSKR B4DMD1 HNRNPR 
Heterogeneous nuclear 
ribonucleoprotein R 
105 2 
ADKVPKTAENFR V9HWF5 HEL-S-69p 
Peptidyl-prolyl cis-trans 
isomerase 
112 2;3 
AEINANRADAEEEAATRIPA Q9H5W7 DYNC1I2 
Cytoplasmic dynein 1 
intermediate chain 2 
135 2;3 
AKDQTKAQAAAPASVPAQAPK A0A024R326 RPL29 60S ribosomal protein L29 229 2;3 
ANPNSAIFGGARPREEVVQKEQE Q75MT8 WBSCR1 
Eukaryotic translation initiation 
factor 4H 
268 3;4 
APVPPVNEPETIKQQNQ G3V153 CAPRIN1 Caprin-1 329 2 
AQASSTPISPTR P02545 LMNA Prelamin-A/C 336 2 
AQVIYTRNTKGGDAPAAGEDA P62851 RPS25 40S ribosomal protein S25 351 2;3 
ASSPGGVYATRSSA V9HWE1 HEL113 Vimentin 370 2 
ATGGNRTKTPGPGAQ P62263 RPS14 40S ribosomal protein S14 378 2;3 
ATSAKKVVVSPTK A0A024R4A0 NCL Nucleolin 390 2;3 
AVDKKAAGAGKVT Q6IPT9 EEF1A1 Elongation factor 1-alpha 402 2 
AVDKKAAGAGKVTKSAQKAQ Q6IPT9 EEF1A1 Elongation factor 1-alpha 409 3;4;5 
AVRAIKNNSNDIVN H0YHX9 NACA 
Nascent polypeptide-associated 
complex subunit alpha 
432 2 
DDVKEQIYKIAK J3KMX5 RPS13 40S ribosomal protein S13 526 2;3 
DESGPSIVHR P63261 ACTG1 Actin, cytoplasmic 2 551 2;3 
DKVPKTAENFR V9HWF5 HEL-S-69p 
Peptidyl-prolyl cis-trans 
isomerase 
640 2;3 
DMRQTVAVGVIK Q6IPT9 EEF1A1 Elongation factor 1-alpha 642 2 
DSIIRIAKADGIVSKNF Q6FGH5 RPS21 40S ribosomal protein S21 692 2;3 
DSVKPGAHITVK P51991 HNRNPA3 
Heterogeneous nuclear 
ribonucleoprotein A3 
706 2;3 
DVTPIPSDSTRR P62263 RPS14 40S ribosomal protein S14 734 2;3 
EADRDTYR P46783 RPS10 40S ribosomal protein S10 759 2 
EEEMREIR V9HWE1 HEL113 Vimentin 851 2 
EGHDPKEPEQIR P51991 HNRNPA3 
Heterogeneous nuclear 
ribonucleoprotein A3 
918 2;3;4 
EIFADKVPKTAEN V9HWF5 HEL-S-69p 
Peptidyl-prolyl cis-trans 
isomerase 
954 2 
ESDDSIIRIAKADGIVSKNF Q6FGH5 RPS21 40S ribosomal protein S21 1076 2;3 
EVDKVTGRFNGQ Q6FGH5 RPS21 40S ribosomal protein S21 1109 2 
FEEYGKIDTIEIITDRQSGKK P22626 
HNRNPA2B
1 
Heterogeneous nuclear 
ribonucleoproteins A2/B1 
1199 3;4;5 
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FEIFADKVPK V9HWF5 HEL-S-69p 
Peptidyl-prolyl cis-trans 
isomerase 
1202 2 
GAIAPIAIPSAAAAAAAAGR A6NLN1 PTBP1 
Polypyrimidine tract-binding 
protein 1 
1277 2 
GDSRGGGGNFGPGPGSNF P22626 
HNRNPA2B
1 
Heterogeneous nuclear 
ribonucleoproteins A2/B1 
1309 2 
GGDQQSGYGKVSR A0A024RDF4 HNRPD 
 
1344 2;3 
GGPGTASRPSSSRSYVTT V9HWE1 HEL113 Vimentin 1397 2;3 
GGPGTASRPSSSRSYVTTST V9HWE1 HEL113 Vimentin 1399 2;3 
GHDPKEPEQIR P51991 HNRNPA3 
Heterogeneous nuclear 
ribonucleoprotein A3 
1422 2;3 
GSAIRPSTSR V9HWE1 HEL113 Vimentin 1566 2 
HGIQPDGQMPSDK A8JZY9 TUBA1A Tubulin alpha-1A chain 1661 2 
HKEVDPGTKTA J3QL69 LIMD2 LIM domain-containing protein 2 1673 2 
IDAEPPAKR Q9NUW4 BRIX 
Ribosome biogenesis protein 
BRX1 homolog 
1728 2 
IDEVRTGTYR A8JZY9 TUBA1A Tubulin alpha-1A chain 1736 2;3 
IDPNETNEIANANSR J3QR09 RPL19 Ribosomal protein L19 1748 2 
IEEQFQQGK Q5JR95 RPS8 40S ribosomal protein S8 1790 2 
IGGIGTVPVGRVETGVIKPGMVVT Q6IPT9 EEF1A1 Elongation factor 1-alpha 1836 2;3 
IGGISFETTDDSIR P51991 HNRNPA3 
Heterogeneous nuclear 
ribonucleoprotein A3 
1838 2 
IIEEQKIVVK A0A024RDH8 RPL34 60S ribosomal protein L34 1863 2;3 
IIKTISKEEETKK J3QR09 RPL19 Ribosomal protein L19 1876 2;3 
IISKIENHEGVR V9HWB8 HEL-S-30 Pyruvate kinase 1889 2;3 
IKEQISDIDDAVRKI Q6IBA2 PC4 
Activated RNA polymerase II 
transcriptional coactivator p15 
1897 2;3;4 
IREAGEQGDIEPR B7Z8K4 G3BP 
Ras GTPase-activating protein-
binding protein 1 
1970 2;3 
IVSKGTIVQTKGTGASG B2R984 HIST1H1E Histone H1.4 2062 2 
IYTRNTKGGDAPAAGEDA P62851 RPS25 40S ribosomal protein S25 2079 2;3 
KAAATPAKKTVTPAK A0A024R4A0 NCL Nucleolin 2081 2;3;4 
KAAVTPGKKAAATPAK A0A024R4A0 NCL Nucleolin 2090 2;3 
KAEGDAKGDKAKVKDEPQR P05204 HMGN2 
Non-histone chromosomal 
protein HMG-17 
2095 3;4 
KAPRGDVTAEEAAGASPA P49006 MARCKSL1 MARCKS-related protein 2111 2 
KASGPPVSEIITK B2R984 HIST1H1E Histone H1.4 2113 2;3 
KDSYVGDEAQSK P63261 ACTG1 Actin, cytoplasmic 2 2124 2 
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KGPIATGGIKKSGKK A0A024R306 CCDC72 
Translation machinery-associated 
protein 7 
2165 2;3;4 
KIEKEEEEGISQESSEEEQ P17096 HMGA1 
High mobility group protein 
HMG-I/HMG-Y 
2174 2;3 
KKAPAQKVPAQKATGQK Q6IPH7 RPL14 60S ribosomal protein L14 2193 3;4 
KKIEKEEEEGISQESSEEEQ P17096 HMGA1 
High mobility group protein 
HMG-I/HMG-Y 
2197 2;3 
KQPPVSPGTA P17096 HMGA1 
High mobility group protein 
HMG-I/HMG-Y 
2224 2 
KSPENTEGKDGSKVTKQEPTR Q15651 HMGN3 
High mobility group nucleosome-
binding domain-containing 
protein 3 
2243 3;4 
KTETQEKNTIPTKETIEQEKRSEIS D6W5K2 TMSB10 Thymosin beta-10 2253 3;4;5 
KTGGADQSIQQGEGSKKGKG 
A0A087WYR
0 
SRP19 
Signal recognition particle 19 
kDa protein 
2254 3;4 
KVAPAPAVVKKQEAK P62424 RPL7A 60S ribosomal protein L7a 2269 2;3;4 
KVSSAEGAAKEEPKR P05114 HMGN1 
Non-histone chromosomal 
protein HMG-14 
2292 2;3 
KVSSAEGAAKEEPKRR P05114 HMGN1 
Non-histone chromosomal 
protein HMG-14 
2293 3;4 
MKETIMNQEKIAKIQAQVR P20290 BTF3 Transcription factor BTF3 2335 3 
NQQPSNYGPMKSGNFGGSR P22626 
HNRNPA2B
1 
Heterogeneous nuclear 
ribonucleoproteins A2/B1 
2444 2;3 
NVAEVDKVTGR Q6FGH5 RPS21 40S ribosomal protein S21 2475 2 
PEPVKSAPVPK I6L9F7 HIST1H2BM Histone H2B 2531 2;3 
PGPTPSGTNVGSSGRSPSK Q53FA5 SEC61B 
Protein transport protein Sec61 
subunit beta 
2552 2;3 
PGPTPSGTNVGSSGRSPSKAVAAR Q53FA5 SEC61B 
Protein transport protein Sec61 
subunit beta 
2556 3;4 
PKRKAEGDAKGDKAKVKDEPQR P05204 HMGN2 
Non-histone chromosomal 
protein HMG-17 
2589 3;4;5;6 
PKRKAEGDAKGDKAKVKDEPQR
R 
P05204 HMGN2 
Non-histone chromosomal 
protein HMG-17 
2590 5;6 
PKRKVSSAEGAAKEEPKRR P05114 HMGN1 
Non-histone chromosomal 
protein  
2594 5 
RARPPSGSSKATDIGGTSQAGTSQ A8K9U6 ZC3HAV1 
Zinc finger CCCH-type antiviral 
protein 1 
2687 3 
RATRSGAQASSTPISPTR P02545 LMNA Prelamin-A/C 2688 3;4 
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RDSYGGPPRREPIPSR B4E352 RBMX 
RNA-binding motif protein, X 
chromosome 
2699 4 
REPTEEERAQRPR Q75MT8 WBSCR1 
Eukaryotic translation initiation 
factor 4H 
2711 3;4 
RGPAETEATTD Q12792 TWF1 Twinfilin-1 2733 2 
RIAPITSDPTEATAVGAVE V9HWB8 HEL-S-30 Pyruvate kinase 2738 2 
RQTVAVGVIKAVDK Q6IPT9 EEF1A1 Elongation factor 1-alpha 2800 2;3 
RSAPGGGSKVPQK Q9NX34 NPM1 Nucleophosmin 2813 2;3 
RSAVPPGADKKAEAGAGSATE P46783 RPS10 40S ribosomal protein S10 2820 2;3 
RVIQAIEGIKMVE B0ZBD0 RPS19 40S ribosomal protein S19 2858 2 
RVPPPPPIAR G3V2D6 HNRNPC 
Heterogeneous nuclear 
ribonucleoproteins C1/C2 
2860 2 
SAAEMYGSVTEHPSPSPIIS G3V555 HNRNPC 
Heterogeneous nuclear 
ribonucleoproteins C1/C2 
2869 2 
SAAPSTIDSSSTAPAQIGK H7C4H2 SRPRB 
Signal recognition particle 
receptor subunit beta 
2870 2 
SAPGGGSKVPQK Q9NX34 NPM1 Nucleophosmin 2903 2 
SAPSGPVRSSSGMGGRAP B4E352 RBMX 
RNA-binding motif protein, X 
chromosome 
2911 3 
SDIDDAVRKI Q6IBA2 PC4 
Activated RNA polymerase II 
transcriptional coactivator p15 
2932 2 
SEEVTASQVAATK Q15149 PLEC Plectin 2945 2 
SGGTTMYPGIADR P63261 ACTG1 Actin, cytoplasmic 2 2990 2 
SGKGKVQFQGK Q14730 SSB Lupus La protein 2991 2;3 
SGRPVTPPRTANPPKKR B4DJ75 HEL-S-80p 
Serine/threonine-protein 
phosphatase 
3010 4 
SIPIVDTHSKR V9HWE1 HEL113 Vimentin 3043 2;3 
SRPETGRPRPKGIEGERPA P46783 RPS10 40S ribosomal protein S10 3138 4;5 
STTPGGTIFSTTPGGTR Q13541 EIF4EBP1 
Eukaryotic translation initiation 
factor 4E-binding protein 1 
3217 2 
SVIISIKQAPIVH C9J8P9 CLTA Clathrin light chain A 3231 2 
SYVTTSTR V9HWE1 HEL113 Vimentin 3271 1;2 
TAGPIASAQKQPAGKVQIVSK E7EVA0 MAP4 Microtubule-associated protein 3287 2;3 
TGPPVSEIITK P16401 HIST1H1B Histone H1.5 3386 2 
TGSPGSPGAGGVQSTAK J3KRI4 DYNC1LI2 
Cytoplasmic dynein 1 light 
intermediate chain 2 
3388 2 
TIVTRTQGTK H0Y9Y4 RPS3A 40S ribosomal protein S3a 3427 2 
TQEKNTIPTKETIEQEKRSEIS D6W5K2 TMSB10 Thymosin beta-10 3467 3;4 
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VAVGVIKAVDK Q6IPT9 EEF1A1 Elongation factor 1-alpha 3606 2 
VFKEDGQEYAQVIK A6NJH9 EIF1AY 
Eukaryotic translation initiation 
factor 1A, X-chromosomal 
3705 2;3 
VGVIKAVDK Q6IPT9 EEF1A1 Elongation factor 1-alpha 3744 2 
VKIAKAGKNQGDPK A0A024R4A0 NCL Nucleolin 3798 2 
VMVGMGQKDSYVGDEAQSK P63261 ACTG1 Actin, cytoplasmic 2 3804 2;3 
VNEPETIKQQNQYQA G3V153 CAPRIN1 Caprin-1 3810 2 
YGGGNYGPGGSGGSGGYGGR P22626 
HNRNPA2B
1 
Heterogeneous nuclear 
ribonucleoproteins A2/B1 
4012 2 
 
Table 7-3. Peptides released by patient-derived melanoma cells upon Salmonella 
infection. Supernatants of human patient-derived melanoma cells were analyzed through 
nLC-MS both control supernatants and the ones derived from Salmonella-treated 
melanoma cells (Chapter 4.4.2.4). 115 identified peptides were significantly more 
abundant in Salmonella-derived supernatants; analysis was performed with MaxQuant 
software on the identified peptides. *P <0.05. 
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7.1.4  Peptides specifically released by dog melanoma cells treated with Salmonella 
Sequence Proteins 
Gene 
names 
Protein names id Charges 
FPEPRPGGAPAP A0A140T8E2 ADM ADM 174 2 
FTDKDKDGVAPRS A0A140T8E2 ADM ADM 179 2;3 
IAEVKAGPAQT A0A140T8E2 ADM ADM 228 2 
IRTQDVKGASRNPQTSGPDAA A0A140T8E2 ADM ADM 271 3 
PEPRPGGAPAPR A0A140T8E2 ADM ADM 358 3 
RQSMNNFQ A0A140T8E2 ADM ADM 391 2 
RQSMNNFQGPR A0A140T8E2 ADM ADM 392 2 
VKGASRNPQTSGPDAA A0A140T8E2 ADM ADM 554 2;3 
VSSSYPTGIAEVKAGPAQT A0A140T8E2 ADM ADM 565 2 
YRQSMNNFQ A0A140T8E2 ADM ADM 596 2 
YRQSMNNFQGPR A0A140T8E2 ADM ADM 597 3 
TPEPGEDPR B8ZXI2 gnas1 
Guanine nucleotide binding 
protein alpha subunit (Fragment) 
502 2 
ANAESASNRQPR D5IGF6 Smoc2 
SPARC-like modular calcium 
binding 2 protein (Fragment) 
40 2 
SVYYNEATGGKYVPR E2QSF4 TUBB Tubulin beta chain 476 2;3 
YNEATGGKYVPR E2QSF4 TUBB Tubulin beta chain 593 2 
SQPVAVRGGGGKQV E2QTN0 KIF5B Kinesin-like protein 438 2 
VSGQIDDATR E2QW82 MMP19 Matrix metallopeptidase 19 561 2 
APVNVTTEVKS E2QW85 
 
Elongation factor 1-alpha 57 2 
AVDKKAAGAGKVT E2QW85 
 
Elongation factor 1-alpha 79 2 
AVDKKAAGAGKVTK E2QW85 
 
Elongation factor 1-alpha 80 2 
KAAGAGKVTKSAQKAQKA E2QW85 
 
Elongation factor 1-alpha 302 2;4;5 
KAAGAGKVTKSAQKAQKAK E2QW85 
 
Elongation factor 1-alpha 303 2;3;4;5 
VGVIKAVDK E2QW85 
 
Elongation factor 1-alpha 536 2 
VIKAVDKKAAGAGKVT E2QW85 
 
Elongation factor 1-alpha 543 2 
DEQKNDVAGSQPQVETEA E2QWF5 FKBP4 
Peptidylprolyl isomerase (EC 
5.2.1.8) 
97 2 
GPGPGSNF E2QXH4 
HNRNPA2
B1 
Heterogeneous nuclear 
ribonucleoprotein A2/B1 
201 1 
TINGHNAEVRKA E2QXH4 
HNRNPA2
B1 
Heterogeneous nuclear 
ribonucleoprotein A2/B1 
498 2;3 
IVYDQEIIGPSDKSQA E2QZA1 C19orf70 MICOS complex subunit MIC13 295 2 
AAAGYDVEKNN E2R494 HIST1H1T Histone cluster 1 H1 family 0 2 
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member t 
TKGTGASGSFK E2R494 HIST1H1T 
Histone cluster 1 H1 family 
member t 
499 2 
AYSDMREANYK E2RBD0 
LOC47687
9 
Serum amyloid A protein 84 2 
FIKEAGQGTRD E2RBD0 
LOC47687
9 
Serum amyloid A protein 171 2 
IKEAGQGTRD E2RBD0 
LOC47687
9 
Serum amyloid A protein 255 2 
RIKNWKKQS E2RBF0 
LOC47687
9 
Serum amyloid A protein 384 2 
GEEGHDPKEPEQIR E2RFV7 HNRNPA3 
Heterogeneous nuclear 
ribonucleoprotein A3 
188 3 
TETKTITYESSQVD E2RHR2 EPB41L3 
Erythrocyte membrane protein 
band 4.1 like 3 
489 2 
ARPVKEPRG E2RIQ3 PCSK1N 
Proprotein convertase 
subtilisin/kexin type 1 inhibitor 
65 2;3 
SVGTSIATDKS E2RK67 TMX1 
Thioredoxin related 
transmembrane protein 1 
471 2 
RTPREVEAT E2RK68 SEMA3G Semaphorin 3G 396 2 
APQQEAIPDETEVVEETVAE E2RMA3 SPARC 
Secreted protein acidic and 
cysteine rich 
55 2 
VITVINQTQKE E2RPE5 RPL35 Ribosomal protein L35 550 2 
VITVINQTQKEN E2RPE5 RPL35 Ribosomal protein L35 551 2 
VITVINQTQKENIR E2RPE5 RPL35 Ribosomal protein L35 552 2;3 
EAPAPAKTNVAVGESKAKE E2RPY8 C2orf40 
Chromosome 2 open reading 
frame 40 
128 2;3 
EIADAIKKQSMSE E2RQU1 
 
Uncharacterized protein 133 2 
AAIQEIISK E2RS49 RPS25 Uncharacterized protein 5 2 
IYTRNTKGGDAPAAGEDA E2RS49 RPS25 Uncharacterized protein 301 2;3 
NTKGGDAPAAGEDA E2RS49 RPS25 Uncharacterized protein 347 2 
RNTKGGDAPAAGEDA E2RS49 RPS25 Uncharacterized protein 389 2 
VIYTRNTKGGDAPAAGEDA E2RS49 RPS25 Uncharacterized protein 553 2;3 
AEQNDSVSPR E2RST6 STC1 Stanniocalcin 1 19 2 
NIRGEAASPSHIK E2RST6 RPL5 Ribosomal protein L5 341 2 
RTSEPQKIK E2RST6 RPL5 Ribosomal protein L5 398 2;3 
THEAEQNDSVSPR E2RST6 RPL5 Ribosomal protein L5 493 2;3 
IRAQERAAES F1P7B0 RPL5 Ribosomal protein L5 270 2 
150 
 
ISDRDYEKNG F1P7G8 GFRA1 GDNF family receptor alpha 1 273 2 
SPAQPEGGQASEGAAGAI F1P7H1 CSF1 Colony stimulating factor 1 428 2 
SPAQPEGGQASEGAAGAIAHSN
AIP 
F1P7H1 CSF1 Colony stimulating factor 1 430 2 
FGDSIVTRSY F1PBJ3 LMNA Uncharacterized protein 159 2 
GGSGGGSFGDSIVTRSY F1PBJ3 LMNA Uncharacterized protein 197 2 
GSISSGSSASSVTVTR F1PBJ3 LMNA Uncharacterized protein 211 2 
ISVQQQATQPTR F1PCG5 YTHDF2 
YTH N6-methyladenosine RNA 
binding protein 2 
277 2 
FVGGAENTAHPR F1PEQ5 IGFBP5 
Insulin like growth factor binding 
protein 5 
182 2;3 
AITGASIADIMAK F1PGD7 RPL24 Uncharacterized protein 35 2 
AATESFASDPIIYR F1PHR2 PKM Pyruvate kinase (EC 2.7.1.40) 10 2 
APVPASEI F1PHS5 PLEC Plectin 59 1 
RYASGPVSSIGGPESAAA F1PHS5 PLEC Plectin 399 2 
SSSSYSSSGYGR F1PHS5 PLEC Plectin 451 2 
DEIAPAGTGVSREAVSG F1PKW5 APLP1 
Amyloid beta precursor like 
protein 1 
96 2 
AINTEFKNTRTN F1PLS4 VIM Uncharacterized protein 32 2 
AINTEFKNTRTNEK F1PLS4 VIM Uncharacterized protein 33 4 
AIRPSTSRS F1PLS4 VIM Uncharacterized protein 34 2 
AQIQDQHVQ F1PLS4 VIM Uncharacterized protein 61 2 
ASSPGGAYATR F1PLS4 VIM Uncharacterized protein 71 2 
ASSPGGAYATRSS F1PLS4 VIM Uncharacterized protein 72 2 
ASSPGGAYATRSSA F1PLS4 VIM Uncharacterized protein 73 2 
ASSPGGAYATRSSAVR F1PLS4 VIM Uncharacterized protein 74 3 
ASSPGGAYATRSSAVRIR F1PLS4 VIM Uncharacterized protein 75 3 
DAIRQAKQESNE F1PLS4 VIM Uncharacterized protein 87 2 
EAANRNNDAIRQ F1PLS4 VIM Uncharacterized protein 125 2 
ETRDGQVINETSQ F1PLS4 VIM Uncharacterized protein 143 2 
FGGPGTGSRP F1PLS4 VIM Uncharacterized protein 160 2 
FGGPGTGSRPS F1PLS4 VIM Uncharacterized protein 161 2 
FGGPGTGSRPSS F1PLS4 VIM Uncharacterized protein 162 2 
FGGPGTGSRPSST F1PLS4 VIM Uncharacterized protein 163 2 
FGGPGTGSRPSSTR F1PLS4 VIM Uncharacterized protein 164 3 
FGGPGTGSRPSSTRS F1PLS4 VIM Uncharacterized protein 165 3 
GAYATRSSAVR F1PLS4 VIM Uncharacterized protein 185 2 
GGPGTGSRPS F1PLS4 VIM Uncharacterized protein 191 2 
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GGPGTGSRPSS F1PLS4 VIM Uncharacterized protein 192 2 
GGPGTGSRPSST F1PLS4 VIM Uncharacterized protein 193 2 
GGPGTGSRPSSTR F1PLS4 VIM Uncharacterized protein 194 2;3 
GGPGTGSRPSSTRS F1PLS4 VIM Uncharacterized protein 195 2;3 
GGPGTGSRPSSTRSY F1PLS4 VIM Uncharacterized protein 196 2 
GQVINETSQHHDDIE F1PLS4 VIM Uncharacterized protein 208 2;3 
GSAIRPSTSR F1PLS4 VIM Uncharacterized protein 209 2 
GSAIRPSTSRS F1PLS4 VIM Uncharacterized protein 210 2 
IGSAIRPSTS F1PLS4 VIM Uncharacterized protein 241 2 
IGSAIRPSTSR F1PLS4 VIM Uncharacterized protein 242 2 
IIKTVETRDGQ F1PLS4 VIM Uncharacterized protein 246 2 
IIKTVETRDGQVINETSQHHDDI
E 
F1PLS4 VIM Uncharacterized protein 249 2;3;4 
INETSQHHDDIE F1PLS4 VIM Uncharacterized protein 262 2 
IQDSVDFSIA F1PLS4 VIM Uncharacterized protein 267 2 
IQEAEEWYKSK F1PLS4 VIM Uncharacterized protein 268 2 
IVDTHSKRTI F1PLS4 VIM Uncharacterized protein 285 2;3 
IYASSPGGAYATR F1PLS4 VIM Uncharacterized protein 296 2 
IYASSPGGAYATRS F1PLS4 VIM Uncharacterized protein 297 2 
KTVETRDGQVINETSQ F1PLS4 VIM Uncharacterized protein 316 2 
MFGGPGTG F1PLS4 VIM Uncharacterized protein 320 1 
MFGGPGTGSRP F1PLS4 VIM Uncharacterized protein 322 2 
MFGGPGTGSRPS F1PLS4 VIM Uncharacterized protein 323 2 
MFGGPGTGSRPSS F1PLS4 VIM Uncharacterized protein 324 2 
MFGGPGTGSRPSST F1PLS4 VIM Uncharacterized protein 325 2 
MFGGPGTGSRPSSTR F1PLS4 VIM Uncharacterized protein 326 2;3 
MFGGPGTGSRPSSTRS F1PLS4 VIM Uncharacterized protein 327 3 
NDAIRQAKQESNE F1PLS4 VIM Uncharacterized protein 333 2 
NDKARVEVERDN F1PLS4 VIM Uncharacterized protein 334 3 
NIQEAEEWYKSK F1PLS4 VIM Uncharacterized protein 339 2 
RDGQVINETSQ F1PLS4 VIM Uncharacterized protein 379 2 
RDVRQQYES F1PLS4 VIM Uncharacterized protein 381 2 
RMFGGPGTGSRPSSTR F1PLS4 VIM Uncharacterized protein 387 4 
RMFGGPGTGSRPSSTRS F1PLS4 VIM Uncharacterized protein 388 3 
RSYVTTSTR F1PLS4 VIM Uncharacterized protein 395 2 
SAIRPSTSR F1PLS4 VIM Uncharacterized protein 404 2;3 
SAIRPSTSRSI F1PLS4 VIM Uncharacterized protein 406 2 
SIGSAIRPSTS F1PLS4 VIM Uncharacterized protein 417 2 
152 
 
SIYASSPGGAYATRS F1PLS4 VIM Uncharacterized protein 422 2 
SIYASSPGGAYATRSS F1PLS4 VIM Uncharacterized protein 423 2 
SIYASSPGGAYATRSSAVR F1PLS4 VIM Uncharacterized protein 425 2;3 
SPGGAYATR F1PLS4 VIM Uncharacterized protein 431 2 
SPGGAYATRSSA F1PLS4 VIM Uncharacterized protein 434 2 
SPGGAYATRSSAV F1PLS4 VIM Uncharacterized protein 435 2 
SSINIRETN F1PLS4 VIM Uncharacterized protein 442 2 
SSPGGAYATRSS F1PLS4 VIM Uncharacterized protein 446 2 
SSPGGAYATRSSA F1PLS4 VIM Uncharacterized protein 447 2 
SSPGGAYATRSSAVR F1PLS4 VIM Uncharacterized protein 448 3 
SSVPGVRIIQ F1PLS4 VIM Uncharacterized protein 455 2 
SVAAKNIQEAEE F1PLS4 VIM Uncharacterized protein 464 2 
SVSSSSYRR F1PLS4 VIM Uncharacterized protein 474 2 
SYVTTSTRT F1PLS4 VIM Uncharacterized protein 477 2 
TEFKNTRTNEK F1PLS4 VIM Uncharacterized protein 488 2;3 
TRDGQVINETSQ F1PLS4 VIM Uncharacterized protein 503 2 
TVETRDGQVINET F1PLS4 VIM Uncharacterized protein 510 2 
TVETRDGQVINETS F1PLS4 VIM Uncharacterized protein 511 2 
TVETRDGQVINETSQ F1PLS4 VIM Uncharacterized protein 512 2 
TVETRDGQVINETSQHHDD F1PLS4 VIM Uncharacterized protein 513 3 
TVETRDGQVINETSQHHDDIE F1PLS4 VIM Uncharacterized protein 514 2;3;4 
TYSIGSAIRPST F1PLS4 VIM Uncharacterized protein 518 2 
TYSIGSAIRPSTS F1PLS4 VIM Uncharacterized protein 519 2 
VETRDGQVINE F1PLS4 VIM Uncharacterized protein 528 2 
VETRDGQVINETSQ F1PLS4 VIM Uncharacterized protein 530 2 
YASSPGGAY F1PLS4 VIM Uncharacterized protein 581 1 
YASSPGGAYATR F1PLS4 VIM Uncharacterized protein 582 2 
YASSPGGAYATRS F1PLS4 VIM Uncharacterized protein 583 2 
YASSPGGAYATRSS F1PLS4 VIM Uncharacterized protein 584 2 
YASSPGGAYATRSSAVR F1PLS4 VIM Uncharacterized protein 586 3 
YESVAAKNIQ F1PLS4 VIM Uncharacterized protein 588 2 
YSIGSAIRPSTS F1PLS4 VIM Uncharacterized protein 598 2 
YVTTSTRTY F1PLS4 VIM Uncharacterized protein 600 2 
YVTTSTRTYS F1PLS4 VIM Uncharacterized protein 601 2 
YVTTSTRTYSIG F1PLS4 VIM Uncharacterized protein 602 2 
FIAEKNIPRNPSE F1PLT8 QSOX1 Sulfhydryl oxidase (EC 1.8.3.2) 169 2;3 
FPQEPPSQPSSTYSIVN F1PNV7 SCIMP Uncharacterized protein 176 2 
APITSRGSQQ F1PQ68 TUBB2A Tubulin beta chain 48 2 
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ISDEHGIDPT F1PQ68 TUBB2A Tubulin beta chain 272 2 
NEAAGNKYVPR F1PQ68 TUBB2A Tubulin beta chain 335 2 
THSIGGGTGSGMGT F1PQ68 TUBB2A Tubulin beta chain 495 2 
TSRGSQQYR F1PQ68 TUBB2A Tubulin beta chain 506 2 
APAAAAAPAKVE F1PUX4 RPLP0 60S acidic ribosomal protein P0 41 2 
APAAAAAPAKVEA F1PUX4 RPLP0 60S acidic ribosomal protein P0 42 2 
TAAPAAAAAPAKVE F1PUX4 RPLP0 60S acidic ribosomal protein P0 479 2 
AVNPDASSSQDPQTNSPR F1PVS7 PVR Poliovirus receptor 81 2 
SQDPQTNSPR F1PVS7 PVR Poliovirus receptor 437 2 
SSQDPQTNSPR F1PVS7 PVR Poliovirus receptor 449 2 
PATEKDIAE F1PWW0 FLNA Filamin A 351 2 
HGRPGIGATHS F1Q1T5 RPS15 Ribosomal protein S15 216 2 
DEAQSKRGIIT F2Z4N8 ACTG2 
Actin, gamma 2, smooth muscle, 
enteric 
91 2 
GDEAQSKRGIIT F2Z4N8 ACTG2 
Actin, gamma 2, smooth muscle, 
enteric 
186 2 
GMGQKDSYVGDEA F2Z4N8 ACTG2 
Actin, gamma 2, smooth muscle, 
enteric 
199 2 
TEAPINPKANR F2Z4N8 ACTG2 
Actin, gamma 2, smooth muscle, 
enteric 
487 2;3 
VGDEAQSKRGIIT F2Z4N8 ACTG2 
Actin, gamma 2, smooth muscle, 
enteric 
532 2 
VGMGQKDSYVG F2Z4N8 ACTG2 
Actin, gamma 2, smooth muscle, 
enteric 
535 2 
VMVGMGQKDS F2Z4N8 ACTG2 
Actin, gamma 2, smooth muscle, 
enteric 
555 2 
RTPSASNDDQQE F6XMP7 SGTA 
Small glutamine rich 
tetratricopeptide repeat 
containing alpha 
397 2 
PEPAKSAPAPKK H9GWB1 
HIST1H2B
G 
Histone H2B 355 2 
PEPAKSAPAPKKGSK H9GWB1 
HIST1H2B
G 
Histone H2B 356 4 
PEPAKSAPAPKKGSKKA H9GWB1 
HIST1H2B
G 
Histone H2B 357 3 
ISSWVSSSS J9JHY2 TBX20 T-box 20 276 2 
KIEISQHAK J9NUU3 
 
Uncharacterized protein 309 2 
YNTTSAVTVK J9NVE6 LOC10655 Uncharacterized protein 594 2 
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9486 
RSAVPPGADKKAEAGAGSATE J9NVU2 RPS10 Ribosomal protein S10 393 3 
IVTADRAATGN J9NVZ6 QKI Protein quaking 292 2 
FATPSFAAGTA J9NX04 AAK1 AP2 associated kinase 1 154 2 
PVTVTRTTITTTT J9NYK7 
LOC10085
5913 
Uncharacterized protein 369 2 
PVTVTRTTITTTTSSSSG J9NYK7 
LOC10085
5913 
Uncharacterized protein 371 2 
HGKYVKEQEQ J9NYN5 MINOS1 MICOS complex subunit MIC10 215 2 
FKNIQTVNVDEN J9NZ04 
 
Uncharacterized protein 172 2 
KNIQTVNVDEN J9NZ04 
 
Uncharacterized protein 311 2 
NIQTVNVDEN J9NZ04 
 
Uncharacterized protein 340 2 
SAINEVVTREY J9NZ04 
 
Uncharacterized protein 403 2 
FEGDEDVSNKVS J9NZ79 SDC4 Syndecan 4 157 2 
SSTAQGGNIFERTEVIAA J9NZ79 SDC4 Syndecan 4 454 2 
STAQGGNIFERTEVIAA J9NZ79 SDC4 Syndecan 4 460 2 
TSPQGMPQHPPAPQGQ J9P014 FUBP1 
Far upstream element binding 
protein 1 
505 2 
PIPSKETIEQEKQAGES J9P127 TMSB4X Thymosin beta 4, X-linked 365 2;3 
AEQENEKDPFH J9P1V9 FXYD6 
FXYD domain containing ion 
transport regulator 6 
18 2 
SAAEQENEKDPFH J9P1V9 FXYD6 
FXYD domain containing ion 
transport regulator 6 
401 2;3 
SAAEQENEKDPFHYD J9P1V9 FXYD6 
FXYD domain containing ion 
transport regulator 6 
402 2;3 
DTPENIRIKQQSEIQ J9P3M1 LASP1 LIM and SH3 protein 1 116 2 
IAGQVAAANKKH J9P425 RPS19 Uncharacterized protein 230 2 
PGVTVKDVNQQE J9P425 RPS19 Uncharacterized protein 363 2 
PGPPPPPPP J9P7U7 
 
Uncharacterized protein 359 1 
QESQAQAIIQQAR J9P8F7 COL5A1 Collagen type V alpha 1 chain 372 2 
RPPPPPPPP J9P8I5 
 
XK-related protein 390 2 
DETQGQQPPQR J9P9A0 
 
Uncharacterized protein 98 2 
IHSDSGISVDSQS J9PAM0 NGFR Nerve growth factor receptor 243 2 
VVTRGTADN J9PAM0 NGFR Nerve growth factor receptor 578 2 
STGGKAPRKQIA J9PB22 
LOC10655
8266 
Histone H3 462 2 
DIEPTVIDEVRTGTYR L7N0B2 TUBA1B Tubulin alpha chain 107 2 
ETGAGKHVPR L7N0B2 TUBA1B Tubulin alpha chain 140 2 
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FHSFGGGTGSG L7N0B2 TUBA1B Tubulin alpha chain 167 2 
FSETGAGKHVPR L7N0B2 TUBA1B Tubulin alpha chain 177 2 
NAAIATIKTK L7N0B2 TUBA1B Tubulin alpha chain 330 2 
SVDYGKKSKIE L7N0B2 TUBA1B Tubulin alpha chain 466 2 
TYAPVISAEKA L7N0B2 TUBA1B Tubulin alpha chain 517 2 
VDIEPTVIDEVR L7N0B2 TUBA1B Tubulin alpha chain 524 2 
VSSITASIR L7N0B2 TUBA1B Tubulin alpha chain 563 2 
VVEPYNSIITTHT L7N0B2 TUBA1B Tubulin alpha chain 575 2 
ISKQEYDESGPS O18840 ACTB Actin, cytoplasmic 1 274 2 
IVMDSGDGV O18840 ACTB Actin, cytoplasmic 1 290 1 
NPGPAGPAGPRG O46392 COL1A2 Collagen alpha-2(I) chain 343 2 
IDVMQDSFNRA P25473 CLU Clusterin (Glycoprotein 80) 233 2 
GPIASQVRR P34962 NMU 
Neuromedin-U-25 (NmU-25) 
[Cleaved into: Neuromedin-U-8 
(NmU-8)] 
204 2 
IDEEFQGPIASQVR P34962 NMU 
Neuromedin-U-25 (NmU-25) 
[Cleaved into: Neuromedin-U-8 
(NmU-8)] 
232 2 
PGPTPSGTNVGSSGRSPS P60467 SEC61B 
Protein transport protein Sec61 
subunit beta 
360 2 
PGPTPSGTNVGSSGRSPSK P60467 SEC61B 
Protein transport protein Sec61 
subunit beta 
361 3 
IIEPSIRQIAQK P63050 UBA52 
Ubiquitin-60S ribosomal protein 
L40 
244 2 
FAEDVGSNKG Q28280 APP Amyloid-beta A4 protein 146 2 
IVFFAEDVGSNK Q28280 APP Amyloid-beta A4 protein 286 2 
IVNKEPSETPDQ Q28284 CD44 CD44 antigen 291 2 
VQPSTFSSYSRR Q30DN6 KDM5D Lysine-specific demethylase 5D 558 3 
RAGEITEDEVER Q5TJE9 RPS18 40S ribosomal protein S18 377 2 
VINTNIDGRRK Q5TJE9 RPS18 40S ribosomal protein S18 547 2 
NEEQEYIETVK Q6JDN3 ANXA1 Annexin I (Fragment) 336 2 
KIEKEEEEGISQESSEEEQ Q6URC2-2 HMGA1 
High mobility group protein 
HMG-I/HMG-Y (HMG-I(Y)) 
310 2;3 
ITGSPGSPGPDGKTGPPGPAG Q9XSJ7 COL1A1 
Collagen alpha-1(I) chain (Alpha-
1 type I collagen) 
282 2 
SIADIQNDEVAFR Q9XST7 rpS3A Ribosomal protein (Fragment) 414 2 
ATGGNRTKTPGPGAQSAIR Q9XSU9 rpS14 Ribosomal protein S14  77 3 
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Table 7-4. Peptides released by dog patient-derived melanoma cells upon Salmonella 
infection. Supernatants of dog patient-derived melanoma cells were analyzed through 
nLC-MS both control supernatants and the ones derived from Salmonella-treated 
melanoma cells (Chapter 4.4.2.4). 243 identified peptides were significantly more 
abundant in Salmonella-derived supernatants; analysis was performed with MaxQuant 
software on the identified peptides. *P <0.05. 
	
